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Abstract 
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly. In 
countries with aging populations, such as Australia, the prevalence of AD is 
projected to increase substantially. AD is characterised by two distinctive 
pathological lesions in the brain, amyloid plaques and neurofibrillary tangles. The 
major component of amyloid plaques is an aggregating protein termed the beta-
amyloid protein (Aβ). Aβ is formed normally from a larger precursor protein, 
known as the beta-amyloid precursor protein (APP). Although APP is centrally 
involved in the pathogenesis of Alzheimer’s disease and the production of Aβ, 
relatively little is known about its normal function. Deciphering the function of 
APP in the brain may be essential for the development of effective AD 
therapeutics.  
APP is a type I transmembrane glycoprotein that can be proteolytically processed 
by α, β- and γ-secretases to produce a number of secreted ectodomain fragments 
termed sAPPβ, sAPPα, Aβ and p3. Many studies have suggested that sAPPα may 
act in the maintenance and development of the central nervous system, by acting 
as a paracrine factor. In vitro, sAPPα has been reported to modulate the 
proliferation and differentiation of a variety of cell types. However, the 
mechanistic basis for these effects is unclear. In part, this uncertainty has arisen 
because the cell-surface receptor molecules that interact with sAPPα are not 
known. 
Previous studies have reported that sAPPα may interact with a novel lipid-raft 
type membrane domain in the cell. Furthermore, sAPPα has been reported to bind 
to the lipid GM1-ganglioside. On the basis of these reports, the work in this thesis 
explored the hypothesis that an interaction of APP with cell surface lipids could 
facilitate binding and/or signalling by sAPPα.  
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To determine if sAPPα is able to interact with a sub-group of lipids. The relative 
ability of sAPPα to bind to 27 physiological lipids was examined using a protein-
lipid overlay assay. This assay identified that sAPPα could bind selectively to 
phosphoinositide lipids (PIPs). Further, a recombinant fragment of APP 
corresponding to the E1 N-terminal domain (APP-E1) also bound selectively to 
PIPs, suggesting there is a PIP-binding region within the E1 domain of APP.  
To investigate whether APP and PIP could interact on the cell surface, it was first 
necessary to demonstrate that PIPs are present on the cell surface. A live cell 
immunolabelling method was used to examine the location of cell surface PIPs. 
Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) immunoreactivity was found to 
be present on the surface of cells in primary murine hippocampal cultures in 
discrete puncta <1 µm in size. This observation was also confirmed using a 
recombinant PI(4,5)P2 biosensor protein.  
To examine whether APP could interact with cell-surface PIP, studies were 
performed to examine the degree of colocalisation of exogenous APP-E1 and cell-
surface PI(4,5)P2. APP-E1 that was added to primary hippocampal cultures bound 
to the surface of neurons in discrete puncta <1 µm in size. The cell-bound APP-
E1 and the cell-surface PI(4,5)P2 were highly co-localised on the surface of 
neurons. However, cell-surface PI(4,5)P2 was also present on glial cells in culture 
where APP-E1 did not bind. Furthermore the binding of APP-E1 to cells could 
not be inhibited using a water soluble analogue of PI(4,5)P2. Therefore, these data 
suggested that APP-E1 interacts with cell-surface PI(4,5)P2, but the interaction 
was not sufficient to explain why APP-E1 binds to the cell surface.  
As the APP E1 domain contains a heparin-binding site, the role of this region was 
investigated in the binding of APP-E1 to PIP and also the binding of APP-E1 to 
cells. Heparin did not block the binding of APP-E1 to PIP in vitro, suggesting the 
heparin-binding region and the PIP-binding region in the APP E1 domain are 
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distinct. However, heparin did inhibit the binding of APP-E1 to cells, suggesting 
that the heparin-binding region of APP is required for binding to cells. 
Furthermore, heparitinase treatment of cells significantly reduced cell surface 
heparan sulfate immunoreactivity, but did not affect the binding of APP-E1 to 
cells. These results suggest that APP may interact with PIP on the cell surface 
along with another cell surface component that binds to the heparin-binding site, 
which is not heparan sulfate. 
As PIPs are involved in many aspects of cellular physiology, it was hypothesized 
that APP may signal through modulation of levels of PIPs. To address this 
hypothesis, levels of PIPs were measured in primary cortical cultures by two 
methods. Firstly, a mass-spectroscopy based method was developed to measure 
total levels of cellular PIP. No change in total PIP levels upon sAPPα treatment 
could be detected using this method. Secondly, levels of cell-surface PIPs were 
determined using an array of anti-PIP biosensors and antibodies. Under resting 
conditions, only PI(4,5)P2 was present on the surface of cells. However, in the 
presence of APP-E1, there was an increase in the level of cell surface PI(3,4,5)P3 
and an increase in the level of PI(4,5)P2, indicating that APP binding to cells may 
result in an increase level of cell surface PIPs. 
The data presented in this thesis demonstrate that APP has a novel N-terminal 
PIP-binding domain. This domain may play a role in the normal function of APP, 
by facilitating PIP-dependent signalling.  
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Alzheimer’s disease (AD) is a progressive neurodegenerative condition and the 
leading cause of dementia in the elderly. Alois Alzheimer first described the 
symptoms and pathology of AD in a 51-year-old female dementia patient to a 
meeting of psychiatrists in Tübingen, Germany (Alzheimer, 1907). Using the 
newly developed Bielschowsky’s silver-staining technique, Alzheimer was able to 
examine the post-mortem brain of the patient to identify characteristic 
pathological lesions. Alzheimer’s colleague and mentor, Emil Kraepelin later 
named the condition Alzheimer’s disease (Kraepelin, 1910). It was not until many 
decades later that it became accepted that pre-senile AD and late-onset dementia 
were indistinguishable and the definition of AD was expanded to include senile 
dementia (Blessed et al., 1968). Today, there are considered to be two forms of 
AD, early onset AD (EOAD), also known as familial AD (FAD), which has a 
clear genetic heritability and late-onset AD (LOAD), which is often referred to as 
sporadic AD (sAD). Both EOAD and LOAD have a similar clinical manifestation, 
but differ in the age of onset (Reitz et al., 2011).  
1.1.1 Clinical features of AD 
AD is the leading cause of dementia (Reitz et al., 2011). Dementia can be defined 
as an acquired syndrome of impaired cognitive function (Tarawneh and 
Holtzman, 2012). Dementia can present clinically as a combination of memory 
impairment, language disturbance, impaired motor activity, agnosia (impaired 
recognition) and disturbed executive function (Tarawneh and Holtzman, 2012). 
Currently, AD can only be confirmed as the cause of dementia by post-mortem 
pathological analysis, so the diagnosis of probable AD is used based on clinical 
criteria (Tarawneh and Holtzman, 2012). 
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The early stages of dementia are challenging to distinguish from the decline in 
cognitive function associated with normal ageing (Tarawneh and Holtzman, 
2012). Mild cognitive impairment (MCI) can often be detected in AD patients 5 
years before clinical diagnosis of probable AD (Linn et al., 1995). However, MCI 
cannot be used as an accurate predictor of AD or dementia, as MCI can often be 
caused by a short-term fluctuation in cognitive performance. The annual 
conversion rate of individuals with MCI to dementia is approximately 10% 
(Bruscoli and Lovestone, 2004; Ward et. al., 2013; Mitchell and Shiri-Feshki, 
2009). 
Clinical diagnosis of dementia usually occurs in the mild to moderate stages of 
dementia progression. In the mild stage, patients display a significant impairment 
of learning and memory, especially recent declarative memory. This memory 
impairment affects the ability to perform complex tasks, although patients with 
mild dementia are able to live independently (Forstl and Kurz, 1999). As the 
disease progresses into moderate dementia, the symptoms increase in severity, 
impacting many cognitive functions. Reasoning, organisation, planning, literacy, 
communication and facial recognition deteriorate to the extent that the patient 
requires close supervision (Forstl and Kurz, 1999). Patients with severe dementia 
are reliant on caregivers and usually require institutionalisation. Death usually 
occurs over a period of 5 – 8 years after diagnosis (Forstl and Kurz, 1999). 
Mortality in dementia patients is most often caused by bronchopneumonia or 
myocardial infarction (Brunnstrom and Englund, 2009; Burns et al., 1990).  
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1.1.2 Impact and prevalence of AD 
Alzheimer’s disease presents a major-challenge to global healthcare systems. In 
Australia, the number of people with dementia in 2012 was estimated to be over 
300,000 (Australian Institute of Health and Welfare, 2012). Globally in 2010, 
dementia was estimated to affect 35.6 million people (Prince et al., 2013). Age is 
the biggest risk factor for LOAD (Reitz et al., 2011). In developed countries with 
an aging population, the prevalence of AD is projected to increase significantly, 
resulting in an increased social and economic demand for care provision 
(Alzheimer’s Australia, 2010, Prince et al., 2013). If current dementia care health 
policy is not altered, there will be a significant shortfall of care provision to meet 
the increase in people with dementia (Alzheimer’s Australia, 2010). Therefore, 
dementia represents an emerging health care priority for the health care system in 
Australia (Alzheimer’s Australia, 2010). 
1.2 Pathological features of AD 
Pathologically, AD is characterised by a number of lesions. The original 
description of AD described the presence of neuritic plaques, neurofibrillary 
tangles, and adipose inclusions in glia (Alzheimer, 1907; Alzheimer et al., 1995). 
In AD, there is gross brain atrophy in the late stages of the disease, degradation of 
synapses, and deposition of amyloid in brain blood vessels (cerebral amyloid 
angiopathy; Braak and Braak, 1991; Thal et al., 2008; Terry et al., 1991). Much of 
the basis of our understanding for the processes that underlie Alzheimer’s disease 
has come from careful investigation of these pathological lesions. 
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1.2.1 Amyloid plaques 
Amyloid plaques are focal pathological lesions that are characteristic of AD 
(Braak and Braak, 1991). Amyloid plaques are generally found in the six layers of 
the isocortex, and are most abundant in layers II-V (Braak and Braak, 1991). At 
the centre of the amyloid plaque, there is a dense core of amyloid, which is an 
insoluble fibrous protein aggregate that can be identified by its ability to retain 
amyloid stains such thioflavin or Congo red (Sipe et al., 2010). The main 
proteinaceous component of the amyloid core was initially identified in 
cerebrovascular amyloid in both Down syndrome and AD patients (Glenner and 
Wong, 1984b). Shortly afterward, Glenner and Wong (1984a) identified the same 
protein as the amyloid forming protein in AD plaques. This observation was 
quickly replicated by a number of studies and the protein is now known as β-
amyloid (Aβ; Selkoe et al., 1986; Masters et al., 1985). Aβ is now known to be 
produced from a larger precursor protein, the β-amyloid precursor protein 
(discussed in Section 1.3.1).  
Studies of AD brain using monoclonal antibodies directed against Aβ revealed 
that there are dense-core thioflavin positive plaques present in AD, but also 
immunoreactive accumulations of Aβ that are not stained by thioflavin. These are 
termed diffuse plaques (Joachim et al., 1989; Tagliavini et al., 1989; Yamaguchi 
et al., 1988). Diffuse plaques may represent an early stage of neuritic plaque 
development (Gowing et al., 1994; Iwatsubo et al., 1994; Iwatsubo et al., 1995; 
Lemere et al., 1996). However, diffuse plaques have also been detected in non-
demented elderly individuals and in young individuals after brain injury (Roberts 
et al., 1994; Armstrong et al., 1996; Tagliavini et al., 1989; Yamaguchi et al., 
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1998). As the presence of diffuse plaques is not restricted to patients with AD, the 
conversion of diffuse plaques to dense-core plaques may be a distinguishing 
factor in the development of AD. Aged subjects with diffuse plaques may 
therefore have a pre-clinical AD phenotype (Morris et al., 1996; Villemagne et al., 
2008). 
The spatial deposition of amyloid plaques in AD appears to follow a temporal 
progression. Studies by Braak and Braak (1991) were influential in characterising 
this process, which were grouped into three stages. In stage A, amyloid deposits 
are found in the isocortex, particularly in the basal portions of the frontal, 
temporal and occipital lobes. In stage B, a medium density of Aβ deposits is 
present in all isocortical association areas except the primary sensory areas and 
the primary motor areas. In stage C, all isocortical areas have dense deposits of 
amyloid, including the hippocampus. Deposits are also present in subcortical 
structures, the striatum, thalamus, hypothalamus and sub-thalamic and red nucleus 
in this stage (Braak and Braak, 1991). More recently, a progression of plaque 
deposition with five stages has been proposed, based on immunohistochemical 
detection of plaques, as well as silver staining (Thal et al., 2002). It is important to 
note however, that although amyloid deposition does progress in a staged manner 
throughout particular regions of the brain, this does not correlate with the severity 
of symptoms of AD nor the duration of illness (Terry et al., 1991; Hyman et al., 
1993).  
Although Aβ is the main component of amyloid plaques, a number of other 
plaque components have also been identified in amyloid plaques by biochemical 
and histological techniques. These include α1-antichymotrypsin, cystatin C, 
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proteoglycans, apolipoprotein E, collagen XXV, clusterin and complement 
inhibitor (Abraham et al., 1988; Atwood et al., 2002; Hashimoto et al., 2002; 
Levy et al., 2001; May et al., 1990; Namba et al., 1991; Snow et al., 1988; DeWitt 
et al., 1994; Vinters et al., 1990; Young et al., 1989). A more recent proteomic 
study using laser-capture microdissection to isolate plaques identified 480 
different proteins that were present in amyloid plaques (Liao et al., 2004). 
However, a study with a similar approach, but with a formic acid extraction step 
only identified Aβ, suggesting that formic acid extraction may obscure the 
detection of some plaque proteins (Soderberg et al., 2006). Both studies showed 
that Aβ was the major component of plaques.  
1.2.2 Neurofibrillary tangles 
Neurofibrillary tangles (NFTs) are intracellular accumulations of protein that 
result in dystrophic, swollen tangle-bearing neurons, often found surrounding 
plaques. Importantly, NFTs are a feature of many neurodegenerative diseases, not 
only AD (Morris et al., 2011). In AD, the distribution of NFTs is less variable 
than that of amyloid plaques, and follows a temporal progression that has been 
characterised into six stages (Braak and Braak, 1991). Progression of NFT 
pathology is a better correlate of clinical symptoms of dementia than Aβ 
deposition (Bierer et al., 1995). In stages I-II, most of the NFTs are confined to a 
single layer of the transentorhinal region (Braak and Braak, 1991). Stages I-II 
represent nonclinical pathology and can be present in individuals as young as 20 
(Braak et al., 2011). In stage III-IV (the limbic stages), the transentorhinal layer 
and entorhinal layer become severely affected with NFT pathology. In addition, 
there is modest pathology in regions of the hippocampus (Braak and Braak, 
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1991). Stages III-IV are thought to represent incipient AD, and are present in 10% 
of adults aged 50, and in 50% of adults aged 80 (Braak et al., 2011). In stages V-
VI (the isocortical stage), severe NFT pathology is found in the hippocampus and 
isocortex and destruction of the isocortex is apparent (Braak and Braak, 1991). 
Stages V-VI represent full-blown AD and are present in 10% of adults aged 80 
and 20% of adults aged 90 (Braak and Braak, 1995). 
1.2.2.1 Biochemical characterisation of NFTs. 
Electron microscopy studies of NFTs reveal that dystrophic neurons contain 
accumulations of 10 nm diameter fibres that form helical pairs (Kidd, 1963; 
Wisniewski et al., 1976). These structures are termed paired helical filaments 
(PHFs). Immunohistochemical and biochemical studies show that a component of 
these PHFs is the microtubule-associated tau protein (Delacourte and Defossez, 
1986; Grundke-Iqbal et al., 1986; Kosik et al., 1986; Nukina and Ihara, 1986; 
Wischik et al., 1988; Wood et al., 1986). In PHFs, tau is abnormally 
phosphorylated (Biernat et al., 1992). In vitro phosphorylation of recombinant tau 
can induce assembly of tau into PHFs (Biernat et al., 1992; Hanger et al., 1992). 
The tau in PHFs is unable to bind to microtubules and is biologically inert (Iqbal 
et al., 1994). However, hyperphosphorylated tau that is not accumulated into 
PHFs has been suggested to actively inhibit microtubule polymerization by 
binding to normal tau and other microtubule-binding proteins (Alonso et al., 1994; 
Alonso et al., 1997). Understanding the biology of tau protein in disease remains a 
subject of intense investigation and is too extensive to be discussed here in further 
detail, however this topic has been reviewed recently elsewhere (Iqbal et al., 
2009; Morris et al., 2011). 
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1.2.3 Cerebral amyloid angiopathy 
Approximately 80% of patients with AD have amyloid accumulation in the 
cerebral and leptomeningeal vessels (Ellis et al., 1996). This type of deposit is 
termed cerebral amyloid angiopathy (CAA; Glenner and Wong, 1984; Ellis et al., 
1996). CAA is characterised in arteries and veins by deposits of Aβ in the outer 
basement membrane and between smooth muscle cells (Thal et al., 2008). CAA is 
also present in capillaries of some individuals, where Aβ accumulates on the 
capillary basement membrane (Thal et al., 2008).  
CAA is present in normal aged individuals and there is a strong increase in 
prevalence of CAA with age (Attems et al., 2008; Greenberg and Vonsattel, 1997; 
Thal et al., 2008; Sillus et al., 1993). However, CAA is distributed more widely in 
the brain in patients with AD, and is also more severe (Thal et al., 2003). CAA is 
the cause of a number of vascular complications, such as cerebral haemorrhage 
and ‘microbleeds’ that may contribute to the cognitive decline seen in AD 
(Kalyan-Raman and Kalyan-Raman, 1984; Mandybur, 1986; Benedictus et al., 
2013; Thal et al., 2008). CAA pathology has been associated with the severity of 
dementia in AD, although further research is needed to establish whether this 
represents a causal or a concurrent relationship (Attems et al., 2007; Thal et al., 
2003). 
1.3 Aβ  hypothesis of AD 
The predominant hypothesis to explain the molecular pathogenesis of AD is the 
amyloid hypothesis (reviewed by Hardy and Higgins, 1992). The amyloid 
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hypothesis places Aβ as the primary effector of the biochemical and cellular 
changes that underlie AD. This hypothesis is based on a number of lines of 
evidence that will be discussed in this section. Firstly, Aβ is the primary 
component of amyloid plaques, the pathological lesion that characterises AD. 
Secondly, mutations that cause familial forms of Alzheimer’s disease have been 
mapped to the β-amyloid precursor protein and also to enzymes that produce Aβ 
from the β-amyloid precursor protein (Section 1.5.1). Thirdly, transgenic animal 
models carrying these mutations have phenotypes that recapitulate some of the 
neurological and pathological lesions of AD (Section 1.5.2). Finally, Aβ in 
various aggregation states has a capacity to act in a neurotoxic manner (Section 
1.3.2). This section will discuss the cellular and biochemical changes that underlie 
the production of Aβ, and also discuss evidence for a central role of Aβ in AD 
pathogenesis.  
1.3.1 Aβ production  
The biochemical process that results in the production of Aβ has been well 
studied. A major breakthrough came from the observation that Aβ is derived from 
a larger precursor protein (Kang et al., 1987). The sequence of Aβ was used to 
identify a precursor gene on chromosome 21, which was termed the β-amyloid 
precursor protein (APP; Kang et al., 1987; Tanzi et al., 1987; Robakis et al., 1987; 
Goldgaber et al., 1987). APP is a 100 – 130 kilodalton (kDa) type 1 
transmembrane glycoprotein (Kang et al., 1987; Goldgaber et al., 1987). 
Alternative mRNA splicing produces three major isoforms of APP, which consist 
of 695, 751 and 770 amino-acid residues (discussed in section 1.4). The 751 and 
770 isoforms are widely expressed throughout the body, but neurons express 
higher levels of the 695 isoform (Goedert, 1987; Goldgaber et al., 1987; Tanzi et 
 11 
al., 1987). Aβ is produced by the action of proteolytic enzymes known as 
secretases on APP, which can produce Aβ isoforms ranging from 37 – 48 amino 
acids in length (Qi-Takahara et al., 2005). There are three major proteolytic 
activities identified in the processing of APP that form two distinct pathways: the 
amyloidogenic pathway and the non-amyloidogenic pathway (Fig.1.1). Under 
normal conditions, the majority of APP is processed via the non-amyloidogenic 
pathway (Sisodia et al., 1990).  
In the non-amyloidogenic pathway, α-secretase cleavage occurs at lysine 687 of 
APP (amino-acid numbering relative to the 770 amino-acid APP isoform). This 
cleavage produces two fragments, an 83-residue C-terminal fragment of APP 
(C83), which remains in the membrane, and a large soluble ectodomain fragment 
(sAPPα). 
Alternatively, in the amyloidogenic pathway, APP undergoes cleavage by β-
secretase, which cleaves APP at methionine 671. This cleavage produces a 99-
residue C-terminal fragment of APP, which also remains associated with 
membrane (C99), and a smaller ectodomain fragment (sAPPβ) that is secreted.  
Both C99 and C83, produced by α-secretase and β-secretase cleavage 
respectively, can then be sequentially cleaved by a third protease, γ-secretase. 
Cleavage of APP by γ-secretase occurs in the centre of the trans-membrane 
domain, and either leads to the production of Aβ from the C99 fragment, or a 
fragment termed p3 from the C83 fragment. Differential γ-secretase cleavage can 
occur in the processing of APP resulting in production of different isoforms of Aβ 
ranging from 37 - 48 residues in length (discussed in more detail in Section 
1.4.1.3). However, the major isoforms of Aβ in amyloid plaques are Aβ40 and 
Aβ42 (Iwatsubo et al., 1994). The predominant Aβ isoform that accumulates in 
CAA is Aβ40 (Roher et al., 1993). 
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Figure 1.1. Diagrammatic representation of the amyloidogenic and non-amyloidogenic 
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1.3.1 Aβ aggregation  
Aβ has a high propensity to form tightly packed cross β-sheet fibrils known as 
amyloid (Eisenberg and Jucker, 2012; Toyama and Weissman, 2011). Amyloid 
fibres are typically 5 – 15 nanometres in diameter and can be micrometres in 
length (Toyama and Weissman, 2011). Amyloid formation is a feature of various 
neurodegenerative conditions and a number of amyloid-forming proteins have 
been implicated in disease. Other examples of amyloid forming proteins that have 
been associated with disease include islet amyloid polypeptide (type 2 diabetes) 
and prion protein (Creutzfeldt-Jacob disease; Eisenberg and Jucker, 2012). 
Therefore, there is great interest in understanding the formation and biological 
activity of amyloids. The exact structural processes that result in the formation of 
Aβ amyloid are unresolved and current theories have been discussed in detail by a 
number of recent reviews (Eisenberg and Jucker, 2012; Masters and Selkoe, 2012; 
Toyama and Weissman, 2011).  
The aggregation state of Aβ is strongly influenced by a number of factors. Aβ is 
partially hydrophobic and probably forms an α-helix in hydrophobic 
environments such as the cell membrane or organic solvents (Burdick et al., 
1992). In aqueous environments, Aβ transitions to β-sheet structures and 
aggregates (Burdick et al., 1992; Kirschner et al., 1987). A low pH also promotes 
insolubility of Aβ (Burdick et al., 1992). The longer chain isoforms of Aβ (e.g. 
Aβ42, Aβ43) are more prone to aggregation due to additional hydrophobic 
residues (Jarrett et al., 1993; Burdick et al., 1992). Evidence also exists that Aβ42 
can “seed” the aggregation of Aβ40 (Jarrett et al., 1993; Jan et al., 2008). 
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Consequently, the ratio of Aβ40/Aβ42 is thought to be a critical factor in plaque 
formation that may be perturbed in AD (Scheuner et al., 1996).  
It is thought that a number of intermediate size aggregated Aβ species exist that 
may represent transition states between soluble Aβ and fibrillar Aβ. These include 
globular oligomeric species, which are water-soluble, and protofibrillar species, 
which are fibrillar, but shorter than amyloid fibrils. Oligomeric species have been 
reported to exist in various natural and synthetic preparations of Aβ, appearing as 
dimers, trimers, 12-mers and other forms (Lambert et al., 1998; Lesne et al., 2006; 
Townsend et al., 2006; Shankar et al., 2008; Hepler et al., 2006). Protofibrillar Aβ 
may represent a transition state between oligomeric Aβ and fibrillar Aβ (Walsh et 
al., 1997; Harper et al., 1997). Atomic force microscopy (AFM) studies of 
protofibrils suggest that the fibres are composed of a repeating structure of 100 
nm in length, which is consistent with the idea that short protofibrils can combine 
to form longer fibres (Arimon et al., 2005). The significance placed on the 
different aggregation states of Aβ is largely due to observed differences in the 
biological interactions between various forms. The next section will discuss the 
relationship between the aggregation of Aβ and its ability to cause neurotoxicity. 
1.3.2 Aβ toxicity 
Aβ is thought to be a neurotoxic protein. This capacity has been postulated to be a 
primary cause of AD (Hardy and Higgins, 1992). However, current understanding 
of the toxicity of Aβ is complicated by its propensity to form a variety of 
aggregation states. Therefore, a consensus mechanism explaining the reported 
toxic effects of Aβ has not been reached, but there have been a number of 
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suggestions. The effects of the different reported aggregation states of Aβ will not 
be discussed here in complete detail, as this topic has been discussed 
comprehensively in several recent reviews (Shankar and Walsh, 2009; Benilova et 
al., 2012; Kayed and Lasagna-Reeves, 2013; Masters and Selkoe, 2012).  
Early studies of Aβ toxicity found that an APP fragment containing the Aβ 
domain was toxic to primary hippocampal neurons (Yankner et al., 1989). Further 
experiments demonstrated that synthetic Aβ is neurotoxic for differentiated 
primary hippocampal neurons, but not undifferentiated cells (Yankner et al., 
1990). This toxic effect was attributed to a region within Aβ between residues 25 
and 35 (Yankner et al., 1990). Interestingly, at lower concentrations the Aβ 25 – 
35 fragment was reported to have trophic effects (Yankner et al., 1990). 
Subsequent studies have indicated that the aggregation state of Aβ is a key factor 
in determining its toxicity to cells. In vitro aging of Aβ, which increases the 
proportion of aggregated species, has been demonstrated to increase the toxicity 
of Aβ when compared to monomeric Aβ (Pike et al., 1991). However, it has also 
emerged that fibrillar Aβ is probably not the most toxic species of Aβ (Dahlgren 
et al., 2002). In recent years, lower molecular weight oligomeric forms of Aβ 
have been suggested to be the most toxic Aβ species (Walsh et al., 2002; 
Barghorn et al., 2005; Lambert et al., 1998).  
A number of in vitro studies report that oligomeric Aβ is toxic to neurons. 
Lambert et al. (1998) found that a preparation of synthetic Aβ termed ADDLs 
(Abeta-derived diffusible ligands) was toxic to neurons at nanomolar 
concentrations. Further, they reported that oligomeric Aβ binds neurons close to 
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synaptic sites on dendrites, which has led many investigators to question if Aβ can 
affect synaptic function (Lacor et al., 2004; Barghorn et al., 2005). A number of 
studies have now reported effects of oligomeric Aβ preparations on synaptic 
function (Mucke and Selkoe, 2012; Shankar and Walsh, 2009). Oligomeric Aβ 
has been suggested to alter the behaviour of a number of ion channels, such as 
metabotropic glutamate receptors (mGluR) and the N-methyl-D-aspartate receptor 
(NMDA-R; Lacor et al., 2007; Renner et al., 2010; Shankar et al., 2007). This 
alteration of ion channel function has been suggested to produce effects on long-
term potentiation (LTP; Lacor et al., 2007; Renner et al., 2010; Shankar et al., 
2007; Shankar et al., 2008; Barghorn et al., 2005; Walsh et al., 2002). Changes in 
the density and morphology of excitatory dendritic spines are apparent after 
oligomeric Aβ treatment, consistent with a disruption of synapses (Lacor et al., 
2007; Shrestha et al., 2006). As the levels of some soluble oligomeric Aβ species 
are reported to correlate with cognitive decline in AD better than fibrillar Aβ 
deposition, Aβ-induced disruption of synaptic function has been suggested to 
underlie cognitive decline in AD (McLean et al., 1999; Villemagne et al., 2010). 
Protofibrillar species of Aβ are also reported to act in a toxic manner. 
Protofibrillar Aβ can induce electrophysiological changes in neurons, causing 
aberrant activity and inhibition of LTP (Arispe et al., 1993; Hartley et al., 2008). 
This disruption of normal electrophysiological function may lead to neurotoxicity 
(Hartley et al., 1999; Walsh et al., 1999). 
Aβ toxicity has been postulated to be mediated by a variety of potential molecular 
mechanisms, which have been reviewed thoroughly elsewhere (Cappai and 
Barnham, 2008; Ng et al., 2007; Small, 2009; Mucke and Selkoe, 2012). One 
 17 
possible mechanism of Aβ toxicity may be dysregulation of calcium homeostasis. 
Aβ increases the resting level of calcium in neurons, rendering them more 
sensitive to excitotoxicity (Mattson et al., 1992). This increased calcium influx 
may be caused by an effect of Aβ on endogenous membrane channels, a direct 
effect of Aβ on the cell membrane, or Aβ forming a pore in the membrane (Arispe 
et al., 1993; Ho et al., 2001; Kayed et al., 2004).  
Importantly, it is not known which mechanism or combinations of mechanisms of 
Aβ toxicity are central to AD progression. In particular, it is not clear which 
molecules Aβ interacts with in vivo. The knowledge of these molecules will help 
decipher the primary mechanisms of Aβ-induced neurotoxicity (Mucke and 
Selkoe, 2012). A simple model whereby Aβ causes neuronal death probably 
cannot account for the neurodegeneration and pathology seen in AD (Small et al., 
2001). Therefore, a loss of synapses is more likely to produce the cognitive 
decline in AD rather than cell death (Terry et al., 1991; Terry, 2000). Synapse loss 
is a much better correlate of cognitive decline in AD than Aβ plaque deposition or 
loss of neurons (Terry et al., 1991; Terry, 2000; Braak and Braak, 1991). 
Therefore, recent data that Aβ can interfere with synaptic function may provide a 
mechanistic basis for cognitive deficits in AD.  
1.4 APP expression, structure and processing 
APP is of great interest for AD research because of its role as the precursor of Aβ 
(Kang et al., 1987). APP is a member of an evolutionarily conserved family of 
proteins (Fig. 1.2). In mammals, there are three family members: APP, the 
amyloid precursor-like protein-1 (APLP1) and the amyloid precursor like protein-
2 (APLP2; Kang et al., 1987; Slunt et al., 1994; Wasco et al., 1992; Wasco et al., 
1993). Non-mammalian APP homologues also exist; apl-1 in C.elegans, APPL in 
D. melanogaster and appa/appb in D. rerio (Daigle and Li, 1993; Luo et al., 1990; 
Musa et al., 2001; Rosen et al., 1989). APP family members have a relatively 
conserved structure.  
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Figure 1.2.  Domain structure of mammalian APP family members. HBD: 
Heparin binding domain. CuBD: Metal binding domain. Ac: acidic region, 
OX2: OX2 antigen domain. KPI: Kunitz-type protease inhibitor domain. 
HBD2: heparin binding domain 2. RC: random coil. YENPTY: NPxY interac-
tion site. The epitopes of the antibodies 6E10 and 22C11 used later in the study 
are also depicted. 
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The extracellular region of APP and other family members have two structured 
domains, termed the E1 domain and the E2 domain, for which crystal structures 
are available (Dahms et al., 2010; Rossjohn et al., 1999; Wang and Ha, 2004). 
The E1 domain is split into a heparin-binding region and a metal-binding region 
(Small et al., 1994; Multhaup et al., 1996). This is followed by a short acidic 
region. APP-770, APP-751 and APLP2 contain a KPI domain (Tanzi et al., 1988), 
the physiological relevance of which is discussed in Section 1.6.4. APP-770 also 
contains an OX-2 antigen domain (Weidemann et al., 1989). The E2 domain is 
reported to contain a second heparin-binding region (Mok et al., 1997; Multhaup, 
1994; Ninomiya et al., 1994). The Aβ region is unique to APP and is partially 
embedded in the cell membrane (Kang et al., 1987; Slunt et al., 1994; Wasco et 
al., 1992; Wasco et al., 1993). The C-terminal intracellular domain sequence is 
conserved throughout the APP family and features a YENPTY motif involved in 
interactions with other proteins and also APP trafficking (discussed in more detail 
in Section 1.6.5). 
1.4.1  APP trafficking and post-translational modification 
After expression, APP can undergo a number of post-translational modifications 
including glycosylation, sulfation, phosphorylation and palmitoylation (Hung and 
Selkoe, 1994; Selkoe, 2001; Bhattacharyya et al., 2013). APP is cotranslationally 
translocated into the endoplasmic reticulum, and is post-translationally modified 
in the Golgi. In the Golgi, an immature N-glycosylated APP species is detectable 
with a half-life of around 30-60 minutes that is processed to produce a mature 
form that is N- and O-glycosylated (Weidemann et al., 1989; Oltersdorf et al., 
1990). Cells expressing an APP mutant that is not O-glycosylated demonstrate 
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reduced secretase processing of APP, suggesting that glycosylation occurs 
upstream of secretase activity. After modification in the Golgi, mature APP is 
then trafficked to the cell surface (Koo et al., 1996). Once at the cell surface, APP 
can then be internalised by clathrin-mediated endocytosis via the endosomal-
lysosomal pathway (Yamazaki et al., 1996). The majority of APP is trafficked 
from the endosome to the lysosome, however a portion is then returned to the cell 
surface (Yamazaki et al., 1996). A pool of APP in the lysosome is degraded 
(Haass et al., 1992).  
Secretase processing of APP can occur during the secretory pathway, at the cell 
surface, or after endocytosis (Koo et al., 1996). Ectodomain shedding (e.g. by α- 
or β secretase) is likely to be a pre-requisite for the action of γ-secretase, based on 
studies of γ-secretase function (Hemming et al., 2008; Struhl and Adachi, 2000). 
Therefore, the majority of β-secretase cleavage and Aβ production is thought to 
occur in acidic endosomal/lysosomal compartments, where β-secretase is most 
active (Vassar et al., 1999; Hussain et al., 1999; Sinha et al., 1999). This is 
consistent with the observation that endocytosis is required for the production of 
Aβ (Koo and Squazzo, 1994). In contrast, most α-secretase cleavage and 
production of sAPPα occurs at the cell surface, although some may occur during 
the secretory pathway (Sisodia, 1992; Tomita et al., 1998; Parvathy et al., 1999). 
The main cellular site of γ-secretase activity remains unresolved, however, this is 
likely to be in the plasma membrane (PM) and the endosomal/lysosomal system 
(Dries and Yu, 2008; Kaether et al., 2002; Tarassishin et al., 2004; Pasternak et 
al., 2004).  
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1.4.1.1 α-Secretase 
α-Secretase cleavage of APP can be undertaken by a number of enzymes, all of 
which are members of the A disintegrin and metalloprotease (ADAM) family. 
The first APP-cleaving ADAM to be identified was ADAM 17, also known as 
tumour necrosis factor-α converting enzyme (TACE; Buxbaum et al., 1998). 
Shortly afterward, ADAM 10 and ADAM 9 were also reported to cleave APP at 
the α-secretase position (Koike et al., 1999; Lammich et al., 1999). 
Although ADAM 10, 9 and 17 all have α-secretase activity, most recent evidence 
suggests that α-cleavage of APP can occur distinctly both in a constitutive manner 
and a regulated (i.e. inducible) manner. It is not yet resolved which ADAM is 
responsible for the constitutive α-secretase activity, as ADAM 10, 17 and 9 can 
all act in an inducible fashion, in response to phorbol ester treatment (Buxbaum et 
al., 1998; Lammich et al., 1999; Tomita et al., 1998). However, recent studies 
suggest the majority of constitutive α-secretase activity may be due to ADAM 10, 
at least in primary neurons (Kuhn et al., 2010; Vingtdeux and Marambaud, 2012).  
Aside from the processing of APP, ADAMs have physiological roles in a variety 
of cellular processes. ADAMs act as sheddases, enzymes that catyalyse the 
release of soluble ectodomains from proteins (Huovila et al., 2005). Ectodomain 
shedding by ADAMs is essential for the release of many cytokines and growth 
factor ligands. ADAM 10 is the major sheddase for epidermal growth factor 
(EGF) and β-cellulin (Sahin et al., 2004). ADAM 17 is the major sheddase for 
epiregulin, transforming growth factor α (TGFα), amphiregulin, tumour necrosis 
factor (TNF) and heparin-binding EGF-like growth factor (HB-EGF; Black et al., 
1997; Moss et al., 1997; Sahin et al., 2004). Additionally, ADAMs also 
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participate in ectodomain shedding of growth factor receptors, such as human 
epidermal growth factor receptor 2 (HER2; Liu et al., 2006) and notch (Bozkulak 
and Weinmaster, 2009). Therefore, sheddase activity by ADAMs can facilitate 
cellular signalling in a variety of modes; either by release of secreted growth 
factors, or by ligand-dependent activation of cellular receptors, or a combination 
of both. This subject is covered in more detail by a number of reviews (Blobel, 
2005; Huovila et al., 2005; Vingtdeux and Marambaud, 2012). Importantly, the 
fact that the APP ectodomain is released by α-secretase suggests that APP may be 
involved in a signalling interaction similar to other α-secretase substrates. 
1.4.1.2 β-Secretase 
The β-secretase cleavage of APP was shown by several groups to be undertaken 
by an enzyme termed β-site APP-cleaving enzyme 1 (BACE1; Hussain et al., 
1999; Lin et al., 2000; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999). 
BACE1 is a type 1 transmembrane aspartyl protease that is expressed in the 
majority of tissues (Lin et al., 2000). There is also a BACE1 homologue that can 
cleave APP at the β-site, termed BACE2. BACE2 is predominantly expressed in 
peripheral tissues, with a lower expression level in the brain than BACE1 (Lin et 
al., 2000). BACE1 has been demonstrated to be the enzyme responsible for the 
majority of Aβ production by neurons, as neuronal Aβ production is abolished in 
BACE1 KO mice (Luo et al., 2001; Roberds et al., 2001; Dominguez et al., 2005). 
As a result, BACE1 has become an attractive target for the treatment of AD 
(Klaver et al., 2010). However, not all Aβ production may be BACE1-dependent 
as glia may produce Aβ in a BACE2-dependent manner (Dominguez et al., 2005). 
Additionally, when BACE1 is overexpressed, a second cleavage site at position 
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11 of Aβ has also been reported, although the significance of this minor cleavage 
site is unclear (Liu et al., 2002; Willem et al., 2004). 
Studies from BACE1 KO mice indicate an important physiological function for 
BACE1. BACE1 KO mice have increased mortality, retinal defects and display a 
hyperactive phenotype compared to wild-type mice (Dominguez et al., 2005; 
Harrison et al., 2003; Cai et al., 2012). BACE1/BACE2 double KO mice have a 
further increased lethality phenotype compared to BACE1 KO mice, indicating an 
important role of BACE1/2 in normal physiology (Dominguez et al., 2005). 
Subsequent characterisation of BACE1 KO mice and over-expressing mice has 
revealed a role of BACE1 in myelination (Hu et al., 2006; Willem et al., 2006). 
This function of BACE1 is attributable to its action in cleaving neuregulin-1 and 
neuregulin-3, which are involved in controlling myelination (Hu et al., 2006; 
Willem et al., 2006; Hu et al., 2008). The combined sheddase action of BACE1 
and ADAM17 on neuregulin releases an ectodomain fragment, which acts in a 
paracrine manner to stimulate myelination (Fleck et al., 2013). Functionally, this 
interaction is important for the development of muscle spindles, sensory bodies 
that detect muscle elongation (Cheret et al., 2013). 
Other BACE1 substrates that have been identified include the sodium channel 
Nav1.1 β2 subunit, β-sialyltransferase-1, P-selectin glycoprotein ligand-1, Low-
density lipoprotein receptor-related protein 1, Interleukin-1 receptor II, APLP1/2, 
and VEGFR1 (Klaver et al., 2010; Cai et al., 2012). Although the biological 
significance of BACE 1 cleavage of these substrates is not yet defined, they may 
have implications for the use of BACE1 inhibitors as a strategy for the treatment 
of AD (Klaver et al., 2010).  
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1.4.1.3 γ-Secretase  
γ-Secretase is a transmembrane protease consisting of at least four protein 
subunits, presenilin (PS) 1 or 2, nicastrin, anterior pharynx-defective phenotype 
(Aph-1), and presenilin enhancer 2 (Pen-2; De Strooper et al., 1998; Francis et al., 
2002; Scheuner et al., 1996; Yu et al., 2000). Presenilin has been shown to be the 
catalytic subunit, and has been demonstrated to have intrinsic catalytic γ-secretase 
activity (Ahn et al., 2010). However, all four subunits of γ-secretase are required 
for full activity (Edbauer et al., 2003). Mutations in nicastrin modulate APP 
processing (Yu et al., 2000), and knock down of Pen-2 or Aph-1 reduces γ-
secretase processing of APP (Francis et al., 2002). 
γ-Secretase has a number of important substrates other than APP, most notably 
Notch (De Strooper et al., 1999; Struhl and Greenwald, 1999). Mechanistic 
dissection of γ-secretase function in a number of these substrates has revealed a 
number of interesting features of γ-secretase cleavage, which has been collectively 
termed “regulated intramembrane proteolysis” (RIP; Ebinu and Yankner, 2002; 
Lichtenthaler et al., 2011). RIP cleavage occurs within the transmembrane domain 
of γ-secretase substrates (Lichtenthaler et al., 2011). This process requires the 
substrate protein to have a short ectodomain and a favourable transmembrane 
region (Hemming et al., 2008; Struhl and Greenwald, 1999). No primary amino 
acid sequence motif is shared by all γ-secretase substrates, so selectivity for 
substrate may be conferred by structural requirements (Hemming et al., 2008).  
RIP cleavage is not thought to occur at a single peptide bond, but as a series of 
cleavages, starting from the C terminal end of the substrate and moving towards 
the N terminal region of the transmembrane domain (Fig.1.3).   
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In APP, these cleavage sites have been named as the γ-, ε- and ζ- sites (Gu et al., 
2001; Qi-Takahara et al., 2005; Sastre et al., 2001; Weidemann et al., 2002; Yu et 
al., 2001; Zhao et al., 2004; Zhao et al., 2005). These cleavages occur in the order 
ε-, ζ- and γ-, however the exact residues can shift (Qi-Takahara et al., 2005). This 
shift may be determined by the three-dimensional orientation of the substrate in 
the γ-secretase active site (Qi-Takahara et al., 2005). As a result, it has been 
suggested that there are two production lines for the γ-secretase processing of 
APP; the Aβ40 producing (major) line and the Aβ42 producing (minor) line (Fig. 
1.3; Qi-Takahara et al., 2005). Increasing membrane thickness has been 
demonstrated to result in the formation of less Aβ42/43, therefore the position of 
the initial γ-secretase cleavage may be regulated by the lipid environment of the γ-
secretase-substrate complex (Winkler et al., 2012).  
1.5 Genetics of AD 
1.5.1 Genetics of FAD 
A small number of families worldwide carry rare heritable mutations that cause 
AD. Studying these mutations has given insight into the molecular etiology of 
AD. There are now over two hundred mutations that have been linked to 
dominantly inherited AD (FAD; Cruts et al., 2012). Importantly, mutations 
associated with AD occur in APP and presenilin, so there are key mechanistic 
links of FAD genes to APP processing and Aβ production, which will be 
discussed in the following sections. 
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1.5.1.1 Mutations in APP 
Thirty-three FAD APP mutations have been characterised in 90 families (Cruts et 
al., 2012). These mutations include point mutations, as well as a number of APP 
locus duplications (Cruts et al., 2012; Rovelet-Lecrux et al., 2006). The first 
pathogenic APP mutation to be discovered was associated with hereditary cerebral 
haemorrhage, a condition in which amyloid is deposited in cerebral blood vessels 
(Levy et al., 1990). Shortly afterward, the V717I mutation, which is a point 
substitution near the Aβ encoding region close to the γ-secretase cleavage site, 
was linked to FAD (Goate et al., 1991). This mutation was named “London” after 
the location of the family group that carried the gene; a convention that has been 
used for a number of other APP mutations.  
In general, the APP point mutations are thought to accelerate AD progression by 
altering either the deposition of Aβ, the aggregation of Aβ or the ratio of 
Aβ40/Aβ42 (Selkoe, 2001; Tanzi and Bertram, 2005). The majority of APP 
mutations cluster in the region of the Aβ sequence, with many mutations found 
close to secretase cleavage sites (Fig. 1.4). For example, the “Swedish" mutation 
results in a substitution of two residues immediately N-terminal to the β-secretase 
cleavage site (K670N/M671L). This double mutation produces a 6 - 8 fold 
increase in the amount of Aβ that is produced (Citron et al., 1992).  
More recently, an APP mutation (A673T) has been reported to be protective 
against late-onset AD and normal age-related cognitive decline (Jonsson et al., 
2012). The A673T mutation is immediately adjacent to the β-secretase cleavage 
site, and results in a 40% reduction in β-cleavage of APP in vitro. This mutation 
provides support for a link between LOAD and Aβ production from APP.   
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1.5.1.2 Presenilin mutations 
The most common causes of FAD are mutations in the presenilins (Selkoe, 2001). 
The presenilins were initially discovered in a screen searching for mutations 
leading to FAD, and were named accordingly (Sherrington et al., 1995; Levy-
Lahad et al., 1995). There are now 185 mutations in PS1 associated with FAD and 
13 mutations in PS2 associated with FAD (Cruts et al., 2012). Interestingly, the 
first person to be diagnosed with Alzheimer’s disease carried a PS1 mutation 
(Muller et al., 2013). Presenilins (PS) are multi-pass transmembrane proteins, 
which form catalytic subunits of the γ-secretase complex (see Section 1.4.1.3). 
Mutations in PS1 and other γ-secretase components have also been implicated in 
familial scarring acne, cardiomyopathy and heart failure (Li et al., 2006; Wang et 
al., 2010; Pink et al., 2013).  
PS mutations associated with FAD cause an increase in Aβ42, which may result in 
the earlier onset of AD symptoms (Duff et al., 1996; Scheuner et al., 1996; Potter 
et al., 2013). However a recent in vitro study reported that although PS mutations 
shift the Aβ40:42 ratio, many PS mutations confer an overall reduction in γ-
secretase activity (Cacquevel et al., 2012). Therefore, further research may reveal 
other detrimental effects of PS mutations, besides alteration of Aβ production.  
1.5.2  Transgenic animal models of AD 
Transgenic animal models have provided strong evidence for Aβ being the causal 
factor in AD. There are many transgenic animal models available of AD, which 
are catalogued on the AlzForum web database 
(http://www.alzforum.org/res/com/tra/default.asp). The first transgenic mouse 
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model of AD reported was the PDAPP mouse, which over-expresses APP 
carrying a mutation around the γ-secretase site (V717F). These mice develop a 
neuropathology similar to AD, including Aβ deposits, neuritic plaques, synaptic 
loss, astrocytosis and microgliosis (Games et al., 1995). Mice expressing human 
APP with the Swedish mutation (APPSW), produce a 14-fold increase in the 
amount of Aβ42, develop Aβ plaques after 11 months and display cognitive 
deficits after 9 months (Hsiao et al., 1996). Mice carrying FAD mutations in PS 
genes produce an elevated amount of Aβ42 due to altered APP processing (Duff 
et al., 1996). When multiple FAD mutations are combined, transgenic mice 
carrying more than one AD mutation develop Aβ deposits and cognitive deficits 
more rapidly than single mutations. Double-transgenic mice harbouring the 
APPSW mutation and a PS1 mutation (A264E) go on to deposit amyloid more 
rapidly than mice with the APPSW mutation alone (Borchelt et al., 1997). 
However, reproducing the complete spectrum of pathology associated with AD 
has not been achieved in mice carrying a single mutation. None of the APP or 
presenilin mice developed to date display tangle pathology with paired helical 
fragments (German, 2007). NFTs have been produced in TauP301L mice, which 
express tau carrying a mutation associated with frontotemporal dementia with 
parkinsonism (Gotz et al., 2001; Lewis et al., 2000). Transgenic mice that express 
multiple human mutations in tau, APP and PS have been reported that reproduce a 
wider range of AD pathology. Triple transgenic mice (3xTg-AD) carrying the 
TauP301L, APPSW and PSM146V mutations develop both plaque and tangle 
pathology, with intraneuronal accumulation of Aβ preceding both tangle 
formation and plaque development (Oddo et al., 2003). 
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1.5.3 Genetics of LOAD  
Whilst the genetic risk factors for FAD have a clear influence on producing AD 
symptoms, the known genetic risk factors for LOAD have less clear effects and 
their roles in enhancing progression of AD are still poorly understood. Until 
recently, only a few genetic risk factors for LOAD had been identified. However, 
the advent of genome-wide association studies (GWAS) has revealed many more 
genetic variants that contribute to LOAD risk. The top ten risk genes for LOAD 
ranked by the Alzgene database meta-analysis are listed in Table 1-1 (Bertram et 
al., 2007). Apolipoprotein E (apoE), clusterin, and phosphatidylinositol-binding 
clathrin assembly protein (PICALM) are the most well studied genetic risk factors 
for LOAD and are discussed in the sections below. Mutations in BIN1, CR1, 
ABCA7, TREM, CD33 and MS4A6A will not be discussed here, as there are no 
studies that have elucidated how these proteins are mechanistically involved in 
AD progression. A recent systems biology study of these LOAD risk factors 
found no effect of siRNA knock down of any of these proteins on Aβ production 
(Bali et al., 2012). Therefore, it is likely that these LOAD risk alleles enhance AD 
progression through other mechanisms unrelated to an increase in Aβ production.   
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Table 1-1 Genetic risk factors for LOAD 
Gene Odds 
Ratio 
Protein Potential Functions  
ApoE 2/3/4 3.685 Apolipoprotein E  Lipid transport 
BIN1 1.116 Bridging-integrator 1 Synaptic vesicle 
endocytosis. Tumour 
suppressor 
CLU 0.879 Clusterin (apolipoprotein J) Lipid transport 
ABCA7 1.229 ATP-binding cassette, sub-
family A, Member 7 
Lipid homeostasis  
CR1 1.174 Complement receptor 1 Immune response 
PICALM 0.879 Phosphatidylinositol-binding 
clathrin assembly protein 
Endocytosis, clathrin 
assembly  
MS4A6A 0.904 Membrane-spanning 4-
domains, subfamily A, 
member 6A 
Unknown 
CD33 0.893 Myeloid cell surface antigen 
CD33 
Unknown 
MS4A4E 1.079 Membrane-spanning 4-
domains, subfamily A, 
member 4E 
Unknown 
CD2AP 1.117 CD2-associated protein Regulation of actin 
cytoskeleton 
TREM2* 2.92 Triggering receptor expressed 
on myeloid cells 2 
Inflammation/ 
phagocytosis 
Table shows risk genes for LOAD, ranked by the Alzgene database meta analysis; 
http://www.alzgene.org, accessed 18 April 2013 (Bertram et al., 2007). * The 
TREM2 association with LOAD has been recently discovered, and has not yet 
been ranked by the Alzgene database meta analysis (Guerreiro et al., 2013; 
Jonsson et al., 2013). 
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1.5.3.1 ApoE  
The most well established genetic risk factor for LOAD is the ε4 allele of 
apolipoprotein E gene (Strittmatter et al., 1993). The ε4 allele is associated with 
an increased risk of AD, and the ε2 allele is associated with a reduced risk (Corder 
et al., 1993; Corder et al., 1994; Strittmatter et al., 1993). Physiologically, the 
main role of apoE is to transport lipids, cholesterol and lipid soluble vitamins 
throughout the body (Mahley, 1988). For example, apoE has a key role in 
transporting lipids for degradation by hepatocytes in the liver, and mutations in 
apoE cause hyperlipoproteinemia type III (Havel and Kane, 1973; Utermann et 
al., 1975). ApoE is a component of chylomicrons, very low-density lipoproteins 
(vLDL), and high-density lipoproteins (HDL; Shore and Shore, 1973; Weisgraber 
and Mahley, 1978). ApoE is a ligand for the low-density lipoprotein receptor 
(LDL receptor), apoE receptor 2, very low-density lipoprotein receptor and the 
low-density lipoprotein receptor-related protein (LRP; Innerarity et al., 1978; Kim 
et al., 1996; Takahashi et al, 1996;Beisiegel et al., 1989).  
In the CNS, apoE is mainly expressed by astrocytes (Boyles et al., 1985; Grehan 
et al., 2001) and astrocytic apoE has been shown to be involved in synaptogenesis 
and neurite outgrowth as a consequence of its role in lipid transport (Mauch et al., 
2001; Nathan et al., 1994). Although apoE knock-out (KO) mice have no major 
cognitive deficit (Anderson et al., 1998; Piedrahita et al., 1992; Anderson et al., 
1998), recent studies have demonstrated that human apoE ε4 carriers have subtle 
changes in brain structure during development (Knickmeyer et al., 2013). 
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1.5.3.2 Role of apoE in AD 
It is not yet resolved how the apoE ε4 allele increases the risk of AD, however the 
majority of mechanistic suggestions are based on the suggestion that apoE binds 
Aβ and increases Aβ load in the brain (Hass et al., 1998). The apoE isotypes ε4, 
ε3, and ε2 have been suggested to bind Aβ with differing affinities, with ε4 
having the weakest affinity for Aβ (Strittmatter et al., 1993; Yang et al., 1997; 
Tokuda et al., 2000). Cells have been reported to internalise apoE-bound Aβ via 
an LRP1-dependent mechanism, which has been suggested to be a possible 
mechanism of Aβ clearance (Yang et al., 1999; Kang et al., 2000). Consequently, 
it is suggested that the apoE ε4 allele, which binds Aβ less strongly, results in a 
perturbed degradation of the Aβ protein, predisposing individuals with the ε4 
allele to LOAD (Kim et al., 2009; Deane et al., 2008). However, It should be 
noted that there is some controversy over whether apoE actually binds Aβ. A 
recent study found that apoE does not specifically bind Aβ, and concluded that the 
observed effects of apoE on Aβ clearance were actually due to competition for the 
same clearance receptor (Verghese et al., 2013). Further, genetic mouse studies do 
not support a role of apoE in Aβ clearance. PDAPP crossed with apoE knock out 
mice display decreased Aβ deposition compared to those expressing apoE (Bales 
et al., 1997). However, when clusterin and apoE double knockout mice are 
crossed with PDAPP mice, Aβ deposition is greatly increased compared to the 
PDAPP mouse model (DeMattos et al., 2004). This may suggest an overlapping 
effect of apoE and clusterin on Aβ metabolism. 
An alternative suggestion for the role of apoE in AD is that apoE may modulate 
the aggregation of Aβ. Several studies have reported that in vitro apoE can 
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increase the fibrillisation of Aβ (Ma et al., 1994; Castano et al., 1995; Wisniewski 
et al., 1994). However, there are also reports that apoE inhibits the fibrillisation of 
Aβ (Evans et al., 1995; Wood et al., 1996), The conflicting results may be due to 
different lipidation states of apoE used in the studies, or isoforms of Aβ (Yang et 
al., 1999; Kim et al., 2009). More recently, apoE ε4 has been shown to increase 
the formation of oligomeric species of Aβ (Cerf et al., 2011; Hashimoto et al., 
2012).  
Importantly, apoE has an important physiological function, which could confer 
increased risk of AD without being involved directly in the central disease 
process. The apoE ε4 allele has been linked to developmental abnormalities, as ε4 
carriers have altered brain structure prior to birth (Knickmeyer et al., 2013). 
Therefore, further studies are required to elucidate the biochemical relationship 
between apoE function and AD progression. 
1.5.3.3 Clusterin/ApoJ  
Clusterin (also known as apolipoprotein J) has been identified as a risk factor for 
LOAD by several large GWAS studies (Harold et al., 2009; Lambert et al., 2009; 
Seshadri et al., 2010). Clusterin has been reported to be upregulated in AD 
patients, prior to its establishment as a genetic risk factor for LOAD (May et al., 
1990). Like apoE, clusterin forms HDL lipoprotein complexes and has a role in 
lipid transport throughout the circulation and the CNS (de Silva et al., 1990; 
Borghini et al., 1995). Also similar to apoE, clusterin has been identified to 
interact with Aβ, and may be involved in Aβ clearance and aggregation (Nuutinen 
et al., 2007; Oda et al., 1995; Nuutinen et al., 2009). Studies in transgenic mice 
reported that double KO of apoE and clusterin could increase the deposition of 
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Aβ, therefore these studies provide evidence that clusterin could be involved in 
the metabolism of Aβ (DeMattos et al., 2004). 
1.5.3.4 PICALM 
Alleles of the phosphatidylinositol-binding clathrin assembly protein gene 
(PICALM) have been associated with increased risk of LOAD by a number of 
large GWAS studies (Seshadri et al., 2010; Harold et al., 2009). PICALM and its 
homologue AP180 play roles in endocytosis, by recruiting AP2 and clathrin to the 
membrane (Ford et al., 2001). This process is involved in the formation of 
clathrin-coated vesicles (Ford et al., 2001). In the brain, PICALM and AP180 
have been demonstrated to play a role in the formation of synaptic vesicles 
(Zhang et al., 1998; Nonet et al., 1999; Xiao et al., 2012). 
PICALM is predominately expressed in endothelial cells in the brain (Baig et al., 
2010). One study reported slightly increased levels of PICALM expression in the 
frontal cortex of AD brain, however, the effects observed were not observed in 
other brain regions, and may need further confirmation (Baig et al., 2010). 
Additionally, there are reports of reduced AP180 expression in AD brain (Yao et 
al., 1999). Therefore, levels of PICALM and AP180 may be affected in AD.  
The mechanistic link between AD pathology and PICALM is still being 
elucidated. There are reports that both AP180 and PICALM are able to alter the 
proteolytic processing of APP. Prior to the establishment of PICALM alleles as 
risk factors for AD, AP180 knockdown was reported to affect the production of 
Aβ (Wu et al., 2009). However, the same study was not able to find an effect of 
PICALM knockdown on Aβ production (Wu et al., 2009). A more recent study 
demonstrated that PICALM and APP colocalise at the cell surface after 
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internalization of APP (Xiao et al., 2012). Knockdown of PICALM decreased the 
amount of internalised APP, and PICALM overexpression increased the 
internalisation of APP, which provides strong evidence that APP endocytosis can 
be regulated by PICALM. Additionally, the same study found an increase in 
amyloidogenic processing of APP in PICALM over-expressing cells and a 
decrease in Aβ production when PICALM expression was knocked down. These 
early studies suggest that PICALM (and AP180) may affect AD pathogenesis 
through their endocytic function (Xiao et al., 2012).  
1.5.4 Summary - Genetics of AD 
The studies reviewed in this section demonstrate central involvement of a number 
of proteins in the pathogenesis of AD. Many mutations in APP and PS are 
associated with FAD. APP and PS are essential for the production of Aβ, which 
deposits in AD to form amyloid plaques. Many FAD-associated APP and PS 
mutations are thought to modify the production of Aβ. Genetic mouse models 
carrying human APP and PS mutations mimic some of the pathology seen in AD. 
Therefore, these studies provide strong evidence implicating APP, Aβ and PS in 
the pathogenesis of AD. The mechanisms by which LOAD-associated mutations 
increase the risk of AD are not as well understood as for FAD-associated 
mutations. However many studies suggest that alleles that confer risk for LOAD 
may also affect the biology of APP and/or Aβ. Therefore, further investigation of 
the function of these genes in AD pathogenesis is required to provide insight into 
the biochemical basis of LOAD. 
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1.6 APP function 
Despite intensive research focus on the links between APP and AD pathogenesis, 
the normal function of APP is not resolved. Understanding the normal role of 
APP may be important for the development of new therapeutic strategies for the 
treatment of AD and also to determine the effects of current treatments that target 
APP processing as a strategy to reduce Aβ production (Citron, 2010). This section 
aims to summarise the main themes of research relating to APP’s function in 
order to highlight current knowledge but also to emphasise directions for further 
research. This topic has also been examined by a number of other reviews (Muller 
and Zheng, 2012; Aydin et al., 2012; Mattson, 1997; Zheng and Koo, 2006). 
1.6.1 Lessons from APP family knock-out and knock-in mice  
Genetic knockout models are one of the most powerful ways of investigating the 
functional roles of genes. APP-KO mice are viable and fertile, indicating that APP 
does not play an essential role in development (Li et al., 1996; Muller et al., 1994; 
Zheng et al., 1995). However, APP-KO mice do have a number of subtle 
phenotypic abnormalities. APP-KO mice are slightly smaller, with a reduced 
weight of 15 - 20%, and reduced brain weight (Magara et al., 1999; Zheng et al., 
1995). APP-KO mice display a number of apparent neurological deficiencies, 
such as a deficit in grip strength and locomotor activity (Ring et al., 2007; Zheng 
et al., 1995). Additionally, aged APP-KO mice have reactive gliosis in the 
entorhinal cortex, hippocampus and parietal cortex (Zheng et al., 1995). APP-KO 
mice have also been reported to have a number of phenotypes that are associated 
with altered neuronal function, such as hypersensitivity to kainate-induced 
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seizures, alterations in dendritic spine density, and reduced performance in tests of 
spatial memory (Dawson et al., 1999; Phinney et al., 1999; Steinbach et al., 1998). 
These observations provide strong evidence that APP is involved in the formation 
or maintenance of the nervous system. 
However, the fact that the phenotype of APP-KO mice is non-lethal does not 
mean that APP has no developmental function. An important insight into the 
nature of APP function has come from the combined KO of APP and its family 
members APLP1 and APLP2. Like APP, APLP1-KO mice and APLP2-KO mice 
are both viable and fertile (Heber et al., 2000; von Koch et al., 1997). Double 
knock out of APLP1 and APP also does not produce a lethal phenotype (Heber et 
al., 2000). However, APP/APLP2 double KO mice and APLP1/APLP2 double 
KO mice both have a post-natal lethal phenotype (Heber et al., 2000; von Koch et 
al., 1997). APP/APLP2 double KO mice have impaired neuromuscular junction 
formation, evident in reduced numbers of synaptic vesicles, excessive nerve 
terminal sprouting, incorrect apposition of pre-and post- synaptic proteins, and 
impaired synaptic transmission (Wang et al., 2005). These synaptic deficits may 
be responsible for the lethality phenotype in APP/APLP2 double KO mice (Wang 
et al., 2005). Together, APP family KO mice suggest that APP and APLP2 have a 
redundant essential function throughout development.  
Further insights into the biological functions of APP have come from conditional 
knockout studies. Knock in of sAPPα into APP/APLP2 KO mice (APPsα-DM 
mice) rescues the lethal phenotype (Weyer et al., 2011). Similarly, APL-1 knock 
out in C. elegans is larval-lethal, and this phenotype can be rescued by knock in of 
the APL-1 extracellular domain (Hornsten et al., 2007). These studies demonstrate 
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that the extracellular domain of APP and/or APLP2 is essential for viability. 
Knock in of APP carrying a non-functional YENPTY (Y682G mutation) motif 
into APP-KO mice (APPYG/YG mice) results in altered endocytosis of APP (Ring 
et al., 2007). Therefore, the C-terminal Y682ENPTY motif of APP probably plays 
an important role in APP trafficking in the cell, and consequently in APP 
processing (Ring et al., 2007; discussed in more detail in Section 1.6.5). 
Importantly, crossing APPYG/YG mice with APLP2-KO mice produces a lethal 
phenotype, presumably because the YENPTY motif in the C-terminus of APP is 
required for APP to function correctly (Barbagallo et al., 2011). These studies 
indicate that the APP family has at least two functional components involved in 
essential developmental functions, the extracellular secreted N-terminus, and the 
YENPTY-containing intracellular domain. However, rescued lethality does not 
exclude the possibility that other regions of APP hold non-essential 
developmental functions (i.e. functions which are not required for survival). For 
example, APPsα-DM mice still display deficits in synaptic maturation and 
hippocampal function (Weyer et al., 2011). In a similar experimental paradigm to 
APPsα-DM mice, sAPPβ has been knocked into APP/APLP2 double KO mice. 
However, there was no rescue of the lethal phenotype in these mice, which 
indicates that the α- and β- pathways of APP processing are likely to have distinct 
functions (Li et al., 2010). Perhaps importantly, the studies from Li et al. (2010) 
and Weyer et al. (2011) raise the possibility that the first 16 amino acids of the Aβ 
sequence are somehow crucial for avoiding the lethal phenotype in the 
APP/APLP2 double KO mice. 
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1.6.2 Trophic functions of APP 
APP may be involved in the growth and survival of neurons. There are a variety 
of reports of neurotrophic functions for APP and some of its metabolites, most of 
which implicate the extracellular region of APP as an important positive effector 
of cell growth. Studies in which recombinant full-length APP has been added into 
cell culture have reported that APP is able to increase neurite outgrowth and 
neuronal survival (Araki et al., 1991; Ohsawa et al., 1995). Similar effects on 
neuronal survival and neurite elongation have been reported with APP purified 
from human and mouse brain, that were attributable to the heparin-binding 
domain in the E1 region of APP (Small et al., 1994). Correspondingly, in vitro 
knockdown of APP expression is reported to reduce neurite outgrowth 
(Allinquant et al., 1995). Mice that overexpress human APP have increased 
numbers of synapses, suggesting a synaptotrophic role for APP (Mucke et al., 
1994). 
sAPPα may act in a trophic manner in a number of cell types and has been 
reported to increase the proliferation and/or survival of fibroblasts, keratinocytes, 
B109 cells, FRTL-5 cells, PC12 cells, and cortical neurons (Saitoh et al., 1989; 
Hoffmann et al., 2000; Ninomiya et al., 1994; Pietrzik et al., 1998; Milward et al., 
1992; Jin et al., 1994; Araki et al., 1991; Young-Pearse et al., 2008). A number of 
these studies also found increases in neurite outgrowth in neuronal and pseudo-
neuronal cells (Araki et al., 1991; Jin et al., 1994; Milward et al., 1992; Ninomiya 
et al., 1994). Additionally, there are some reports that infusion of sAPPα into 
animal models of traumatic brain injury can improve neuronal survival and 
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recovery (Copanaki et al., 2010; Thornton et al., 2006). Collectively, these studies 
provide strong evidence that sAPPα can act in a trophic manner. 
1.6.2.1 APP in stem cell proliferation and differentiation 
Throughout development and adulthood, pluripotent stem cell populations 
differentiate into distinct lineages of progenitor cells, which ultimately form the 
cells of the central nervous system (Gage, 2000). A number of studies have noted 
that APP is expressed in neuroblasts and neurons as they undergo differentiation 
and growth (Clarris et al., 1995; Fukuchi et al., 1992; Salbaum and Ruddle, 1994; 
Small et al., 1992; Masliah et al., 1992). This has led many investigators to 
question whether APP has a role in development in the control of stem-cell 
proliferation or differentiation. In addition, APP is processed in a manner that is 
very similar to the key developmental protein Notch, leading to the suggestion 
that APP could have a similar developmental function (De Strooper et al., 1999; 
Struhl and Greenwald, 1999; Zhang et al., 2000). This section will discuss the 
current evidence for a role of APP in stem cell proliferation and integration. 
There is ample evidence that APP is able to positively modulate the proliferation 
of neural stem and progenitor cells (NSPCs) in vitro. Studies have reported that 
sAPPα and sAPPβ can promote the proliferation of NSPCs (Ohsawa et al., 1999; 
Hayashi et al., 1994; Baratchi et al., 2012). Hayashi et al. (1994) also examined 
the effect of secreted APP-770 on NSPC proliferation and found secreted APP-
770 to have a stronger effect on NSPC proliferation than secreted APP-695. A 
more recent study has also reported that inhibition of α-secretase can reduce 
NSPC proliferation and sAPPα is able to rescue this effect (Demars et al., 2011). 
Therefore, sAPPα appears to be able to modulate NSPC proliferation in vitro. In 
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vivo, sAPPα infused into the ventricles of mice binds selectively to epidermal 
growth factor receptor (EGFR) expressing and PSA-NCAM-expressing stem cells 
in the subventricular zone (Caille et al., 2004). Both the secretion of EGF and the 
proliferation of these EGFR-expressing cells were increased by sAPPα infusion 
(Caille et al., 2004). Therefore, sAPPα may regulate proliferation of NSPCs in 
vivo. 
Aside from the reported ability of sAPPα to modify NSPC proliferation, recent 
evidence has demonstrated an effect of APP gene expression on stem cell 
proliferation. We recently reported that the expression of APP can positively 
modulate the proliferation of NSPCs and this effect was reduced in APP-KO 
NSPCs (Hu et al., 2013). The APP-driven increase in NSPC proliferation was not 
due to the secretion of sAPPα, but rather an effect of APP on the expression and 
secretion of cystatin C (Hu et al., 2013). Therefore, collectively these studies 
indicate that APP may act on NSPC proliferation in two modes. Firstly, through 
the production of sAPPα and secondly, through the modulation of other genes and 
proteins involved in NSPC regulation, such as cystatin C.  
Further indications that APP is involved in the control of NSPC proliferation have 
come from observations made in AD transgene models. Although these models 
are complicated by the presence of disease-associated processes, they have 
nevertheless provided some interesting observations linking APP to NSPC 
function. PDGF-APP(sw, ind) mice which overexpress human APP with the 
Swedish and Indiana FAD mutations, have a 2-fold increase in the number of 
proliferating stem cells in the dentate gyrus and subventricular zone at an age of 3 
months (Jin et al., 2004; Lopez-Toledano and Shelanski, 2007). However, as Aβ 
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starts to accumulate, this effect decreases (Lopez-Toledano and Shelanski, 2007). 
Other studies have also found increased NSPC proliferation in various AD mouse 
models, but suggested the effect was due to Aβ deposition (Kolecki et al., 2008; 
Sotthibundhu et al., 2009; Verret et al., 2007). Conversely, a number of studies 
have reported decreased NSPC proliferation in various AD mouse models 
(Naumann et al., 2010; Dong et al., 2004; Haughey et al., 2002; Donovan et al., 
2006). Therefore, together these studies do not clarify whether it is APP 
expression, APP mutations, Aβ deposition, transgene effects, genetic background 
or age that is able to affect NSPC proliferation in AD mouse models in vivo. 
However, the clear effects of AD mutations and/or APP expression on NSPC 
proliferation in AD mouse models warrant further investigation. 
APP may also play a role in regulating the differentiation of NSPCs. A recent 
study using human embryonic stem cells found that APP overexpression, or 
addition of sAPPα enhanced neuronal differentiation (Freude et al., 2011). We 
also found that the over-expression of APP in Tg2576 derived NSPCs increased 
neural differentiation, and APP knockout decreased neural differentiation (Hu et 
al., 2013). However, a conflicting report presents evidence that sAPPα/β may 
cause an increase in differentiation to a glial lineage (Baratchi et al., 2012). There 
were marked differences in the time scales used between these studies, so further 
investigation will be required to fully establish a role of APP in NSPC 
differentiation. It should also be noted that the APP family of proteins is not 
required for neural differentiation, as embryonic stem cells derived from APP 
triple KO mice still form neuronal precursors (Bergmans et al., 2010).  
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1.6.2.2 Mechanism of the trophic effects of APP 
It is not clear whether APP is able to directly elicit trophic effects, e.g. by 
activating a growth factor receptor. Some receptors for APP that have been 
suggested are β1-integrin, lipoprotein receptor related protein-1, death receptor 6, 
p75 neurotrophin receptor and APP itself (Young-Pearse et al., 2008; Kounnas et 
al., 1995; Nikolaev et al., 2009; Gralle et al., 2009). However, APP may interact 
with many other extracellular proteins (Bai et al., 2008). Therefore, it is unclear 
which of these interactions may be important.  
Importantly, many indirect mechanisms of action have also been reported that 
make mechanistic interpretation of APP’s trophic effects complex. A number of 
studies have demonstrated that APP is able to modify the trophic effects of other 
growth factors. For example, secreted APP is able to potentiate nerve growth 
factor (NGF) signalling, possibly by increasing the affinity of the NGF receptor 
for NGF (Wallace et al., 1997; Milward et al., 1992; Akar and Wallace, 1998). 
More recently, APP has been suggested to regulate NGF/TrkA signalling, through 
an intracellular interaction involving the C-terminal YENPTY phosphorylation 
site (Matrone et al., 2011). Curiously, NGF, EGF, basic fibroblast growth factor 
(FGF2) and brain-derived neurotrophic factor have all been reported to increase 
the expression of APP (Cosgaya et al., 1996; Lahiri and Nall, 1995; Mobley et al., 
1988; Ohyagi and Tabira, 1993; Ruiz-Leon and Pascual, 2001; Villa et al., 2001; 
Clarris et al., 1994). Also, NGF, EGF, insulin and insulin-like growth factor 1 
have been reported to increase the secretion of sAPPα (Caille et al., 2004; Slack 
et al., 1995; Ruiz-Leon and Pascual, 2001; Solano et al., 2000; Jacobsen et al., 
2010). We have recently shown that expression of APP can affect the proliferation 
of neural stem cells in an indirect manner, by modulating the expression and 
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secretion of cystatin C (Hu et al., 2013). Therefore, these studies above highlight 
that the trophic actions of APP are complex, and strongly implicate APP as a 
modulator of cellular growth pathways. Importantly, as APP has some functional 
interplay with other effectors of cell growth, careful consideration of experimental 
conditions is needed to delineate the mechanisms underlying the trophic actions of 
APP.  
1.6.3 Roles of APP in cell adhesion and synaptogenesis 
Some studies have suggested APP could have a function in cell-adhesion. The 
extracellular region of APP can bind laminin, collagen type I, heparin and 
glypican-1 (Beher et al., 1996; Clarris et al., 1997; Kibbey et al., 1993; 
Williamson et al., 1996; Mok et al., 1997). Physical adhesion to these 
extracellular components could explain the effects of APP on neurite outgrowth 
(Kibbey et al., 1993; Small et al., 1994).  
APP has also been proposed to have other roles in cell adhesion beside adherence 
to extracellular matrix components. One suggestion is that APP and its 
homologues APLP1/2 could form physical contacts between cells (Soba et al., 
2005). In the presence of heparin, APP can form trans-dimers that might act as 
cell-to-cell contacts (Dahms et al., 2010; Gralle et al., 2006). Trans-dimerisation 
of APP has also been proposed as a mechanism for the stabilisation of synapses 
by APP (Wang et al., 2009). Another suggestion for a role of APP in cell adhesion 
is that APP may modulate other proteins involved in cell adhesion. APP has been 
suggested to interact with integrin, fasciclin II, contactin 4, neuroglia cell 
adhesion molecule, and transient axonal glycoprotein-1, which are all proteins 
implicated in cell-adhesion (Ashley et al., 2005; Ma et al., 2008; Osterfield et al., 
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2008; Yamazaki et al., 1997; Young-Pearse et al., 2008). These studies provide a 
number of avenues by which APP may perform functions in cell-adhesion. 
However, it is hard to determine whether effects of APP on neurite outgrowth are 
due to increased adhesion or increased growth, and therefore further work will be 
needed to delineate the precise mechanisms of action. 
1.6.4 Non-neuronal functions of KPI domain-containing APP isoforms 
(Protease nexin II) 
The majority of research into the biology of APP has considered the roles of APP-
695, as this is the APP isoform that is predominantly expressed in neurons. 
However, the secreted KPI-domain containing 770 and 751 isoforms of APP 
(collectively termed here APP-770/751, but also known as protease nexin II (Van 
Nostrand et al., 1989) have well-described roles in non-neuronal contexts that 
may be able to inform our understanding of APP function in the brain. 
In the blood, APP is predominantly expressed in platelets (Bush et al., 1990; 
Gardella et al., 1990; Van Nostrand et al., 1991a; Smith and Broze, 1992). In 
platelets, APP, sAPP and Aβ accumulate in α-granules, intracellular vesicles that 
are used to store a variety of clotting factors (Van Nostrand et al., 1991b; Blair 
and Flaumenhaft, 2009). Upon platelet stimulation APP, secreted APP and Aβ are 
released, along with a number of another components of the coagulation cascade 
(Bush et al., 1990; Gardella et al., 1990; Smith, 1997; Smith et al., 1990; Smith 
and Broze, 1992; Van Nostrand et al., 1990). 
APP-770/751 is a potent inhibitor of the coagulation factors XIa, IXa and Xa 
(Scandura et al., 1997; Smith et al., 1990; Mahdi et al., 1995; Schmaier et al., 
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1993). This inhibition of coagulation factors is due to the KPI domain, which 
inhibits faction Xia with a Ki of 400 pM (Scandura et al., 1997; Smith et al., 
1990). However, other regions of APP also participate. Inhibition of factor XIa by 
APP is enhanced by heparin, suggesting an involvement of one of the heparin-
binding regions of APP (Smith et al., 1990). The E1 N-terminal heparin-binding 
domain of APP can inhibit the activation of factor XII and also inhibit platelet 
activation, independently of the KPI domain (Henry et al., 1998; Niwano et al., 
1995). These studies demonstrate that APP has a role as a suppressor of multiple 
stages of the coagulation cascade, which is not only due to the KPI domain.  
Consistent with this role of APP as an inhibitor of multiple stages of the 
coagulation cascade, APP-770/751 stops blood from clotting in vitro (Schmaier et 
al., 1993; Annich et al., 1999). Genetic overexpression of APP in mice decreases 
cerebral thrombosis and also increases the severity of haemorrhage in animal 
models, and knockout of APP has the opposite effect (Xu et al., 2005; Xu et al., 
2007). These functions of APP are conserved among APP family members (Xu et 
al., 2009). There is also evidence that this function of APP action may play a role 
in human disease. Familial hereditary cerebral haemorrhage, Dutch type 
(HCHWA-D) leads to haemorrhage, but also accumulation of APP and Aβ in the 
brain vasculature (Rozemuller et al., 1993). Furthermore, mutations in APP have 
been linked to this condition (Levy et al., 1990; Bakker et al., 1991; Fernandez-
Madrid et al., 1991; Van Broeckhoven et al., 1990). Therefore, considering APP-
770/751 can inhibit blood coagulation, it has been suggested that the over-
accumulation of APP in blood vessels in HCHWA-D may be a cause of 
haemorrhage (Xu et al., 2005). However, this suggestion has not yet been 
experimentally tested. The role of APP as an anti-coagulant has also led to 
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suggestions it could be used for the treatment of conditions such as stroke or as a 
biomarker for coronary syndrome (Kitazume et al., 2012; Wu et al., 2012).  
1.6.5  AICD interactions and functions 
The intracellular domain of APP is highly conserved among APP family members 
(Muller and Zheng, 2012). This region of APP has a number of phosphorylation 
sites and interacts with a number of cytosolic adaptor proteins (Fig. 1.5, Section 
1.6.5.2). Interactions between the intracellular domain of APP and cytosolic 
adaptor proteins can potentially occur with full-length APP, C99, C83, and also 
with the γ-secretase cleavage product AICD (Schettini et al., 2010). The roles of 
cytosolic adaptor protein-interactions in the trafficking and function of APP will 
be discussed in this section. 
1.6.5.1 Functional motifs and phosphorylation sites in AICD 
The APP C-terminus contains a YENPTY motif (residues 682 – 687 of the 
APP695 isoform). This motif is conserved in many tyrosine receptor kinases and 
non-receptor tyrosine kinases, which are type-1 transmembrane proteins that 
orchestrate cellular signalling processes (Lemmon and Schlessinger, 2010). The 
YENPTY motif has been demonstrated to be important in the trafficking of APP 
(Lai et al., 1995; Marquez-Sterling et al., 1997; Perez et al., 1999). 
There are three potential tyrosine phosphorylation sites in the C-terminus of APP 
that have been identified in vitro, tyr653, tyr682, and tyr687 (APP695 numbering 
system; Schettini et al., 2010). Tyr682 and tyr687 are part of the “YENPTY” motif 
in the C-terminus of APP. Proteins containing SH3 domains or phosphotyrosine 
binding (PTB) domains selectively bind tyr682 and tyr687, respectively (Lim and 
Pawson, 2010; Borg et al., 1996; Tarr et al., 2002b). Tyr653 may be involved in the 
sorting of APP to basolateral membranes, however this phosphorylation site is not 
as well characterised as tyr682 and tyr687 (Haass et al., 1995; Schettini et al., 2010).   
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Aside from the tyrosine phosphorylation sites, there are three serine and threonine 
phosphorylation sites: Ser655, thr654 and thr668. The significance of these 
phosphorylation sites is unclear. Some studies have reported contradictory effects 
of thr668 phosphorylation on APP processing (Feyt et al., 2007; Lee et al., 2003). 
Thr668 is phosphorylated in a cell-cycle dependent manner in the G2/M phase, 
suggesting that the metabolism of APP may be affected by cell-cycle state 
(Suzuki et al., 1994).  
The kinases that have been implicated in phosphorylation of AICD are 
summarised in Table 1-2. Many of these kinases have been identified using in 
vitro phosphorylation studies of AICD fragments, but have not yet been 
confirmed in vivo. 
1.6.5.2 Binding of adaptor proteins to AICD 
The AICD has a number of reported cytosolic interacting proteins. Many of the 
adaptor proteins discussed below bind to the YENPTY motif in the C terminus of 
APP. This is a conserved sorting motif that is found in many proteins, and 
accordingly, many of the adaptor proteins that interact with this site in APP are 
reported to affect its trafficking (Bonifacino and Traub, 2003).   
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Table 1-2 Kinases implicated in the phosphorylation of AICD in vitro 
AICD 
phosphorylation 
site 
Implicated kinase Reference 
Tyr682 Tyrosine receptor kinase A 
(TrkA)  
Matrone et al., 2011; Tarr 
et al., 2002a 
 Abl Zambrano et al., 2001 
 Src kinase Zhou et al., 2004 
 Fyn kinase  Hoe et al., 2008 
Tyr687 Unknown Rebelo et al., 2007  
Ser655 Protein kinase C Gandy et al., 1988; Suzuki 
et al., 1992 
 Ca2+/calmodulin-dependent 
protein kinase II  
Gandy et al., 1988 
Thr654 Protein kinase C  Gandy et al., 1988 
 Cyclin dependent kinase 5 
(Cdk5) 
Iijima et al., 2000 
Thr668 Cyclin-dependent kinase 1  
(Cdk1/cdc2k) 
Suzuki et al., 1994 
 c-Jun NH2-terminal kinase 3 
(JNK3) 
Inomata et al., 2003 
 c-Jun NH2-terminal kinase 1/2 
(JNK1-2) 
Scheinfeld et al., 2003 
Table shows potential phosphorylation sites in the C-terminal intracellular 
domain of APP, and kinases that have been implicated in the phosphorylation of 
each residue in vitro. 
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1.6.5.2.1 Fe65 
The first protein to be identified to bind to the AICD was Fe65 (Fiore et al., 1995; 
Borg et al., 1996). Fe65 binds to the YENTPTY motif of AICD in a tyrosine 
phosphorylation-independent manner through its PTB domain (Borg et al., 1996). 
Phosphorylation of thr668 can inhibit Fe65 binding to AICD in vitro (Ando et al., 
2001). The Fe65-AICD interaction is reported to have a number of biological 
consequences. Firstly, Fe65-AICD binding has been reported to affect the 
trafficking and proteolytic processing of APP, including the secretion of Aβ 
(Ando et al., 2001; Guenette et al., 1999; Sabo et al., 1999). As Fe65 also binds to 
the C-terminus of LRP1, LRP1 has been suggested to be necessary for effects of 
Fe65 on APP trafficking (Pietrzik et al., 2004). 
 A more controversial suggestion for the biological basis of the Fe65-AICD 
interaction is in the direct regulation of gene transcription. This idea has been 
formulated based on the similarities of the AICD domain to the Notch 
intracellular-domain (NICD). NICD is released from the plasma membrane after 
γ-secretase cleavage, and can translocate to the nucleus to regulate gene 
transcription (Andersson et al., 2011; De Strooper et al., 1999). γ-Secretase-
cleaved AICD has been reported to translocate to the nucleus in a similar manner 
to the NICD (Cupers et al., 2001; Gao and Pimplikar, 2001). Normally AICD is 
prone to degradation, however Fe65 may stabilise AICD allowing it to translocate 
to the nucleus (Cupers et al., 2001; Kimberly et al., 2001). In the nucleus, the 
Fe65-APP complex has been reported to form a transcriptionally active complex 
in combination with tat-interactive protein 60 (tip60), a histone acetyltransferase 
(Cao and Sudhof, 2001; Gao and Pimplikar, 2001). A number of target genes have 
been reported for this interaction, KAI1 (Baek et al., 2002; von Rotz et al., 2004; 
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Zhang et al., 2007), APP (von Rotz et al., 2004), BACE1 (von Rotz et al., 2004), 
Tip60 (von Rotz et al., 2004), GSK3β (Kim et al., 2003; Ryan and Pimplikar, 
2005; von Rotz et al., 2004), EGFR (Zhang et al., 2007), p53 (Checler et al., 
2007) and LRP1 (Liu et al., 2007). However, controversy surrounding the 
transcriptional role of AICD/Fe65 has arisen from studies that question many 
aspects of the AICD nuclear signalling model. γ-Secretase-induced AICD release 
is not necessary for Tip60 activation (Hass and Yankner, 2005). Fe65 has also 
been reported to signal gene transcription independently of APP (Yang et al., 
2006). Additionally, many of the downstream gene targets of the proposed 
AICD/Fe65 complex have been questioned (Aydin et al., 2011; Chen and Selkoe, 
2007; Repetto et al., 2007; Waldron et al., 2008). Therefore, it is still unclear 
whether the Fe65-AICD gene interaction is involved in the regulation of gene 
transcription. 
1.6.5.2.2  ShcA/C and Grb2 
Of the proteins that interact with the YENPTY motif of APP, only ShcA/C and 
growth factor receptor-bound protein 2 (Grb2) require tyr682 to be phosphorylated 
(Tarr et al., 2002b; Zhou et al., 2004). ShcA contains an SH2 domain and a PTB 
domain that facilitate binding to phospho-tyr682, and this interaction is also 
possibly modulated by thr668 (Tarr et al., 2002b).  
Grb2 also binds to tyr682 in a phosphorylation dependent manner (Zhou et al., 
2004). This interaction may be involved in the trafficking of APP, as Grb2 alters 
the localisation of APP in cells (Raychaudhuri and Mukhopadhyay, 2010). Both 
ShcA and Grb2 are implicated in activating the mitogen-activated protein kinase 3 
pathway (MAPK3, also known as extracellular signal-regulated kinase 1 ERK1), 
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which may represent the downstream signalling mechanism for these processes 
(Nizzari et al., 2007; Schettini et al., 2010).  
1.6.5.2.3  X11/mint 
X11/mint (Munc-18-interacting proteins) proteins also bind the APP YENPTY 
motif through their PTB domains (Borg et al., 1996; Tanahashi and Tabira, 1999). 
The X11/mint proteins are scaffolding components that play roles in polarized 
trafficking of proteins. Studies in Drosophila suggest that X11/mint proteins 
target APP and a number of other proteins to axons (Gross et al., 2013). A number 
of studies have illustrated that the X11/Mint binding to APP reduces Aβ 
production and APP processing in vitro and in vivo (Borg et al., 1998; Lee et al., 
2004; Sastre et al., 1998). This may be due to the altered trafficking and 
metabolism of APP, as the X11/mint interaction prolongs the half-life of full 
length APP (Borg et al., 1998). 
1.6.5.2.4 Dab 
Disabled 1 (Dab1) and Disabled 2 (Dab2) are another family of proteins that bind 
to the YENPTY motif of APP through a PTB domain (Homayouni et al., 1999; 
Howell et al., 1997a; Lee et al., 2008). Dab1 is a key mediator of reelin signalling, 
a process that is crucial during neuronal development (Howell et al., 1997a; 
Howell et al., 1997b). Dab1 binds to the NPxY motifs of apoE receptor 2 
(apoER2) and also vLDL receptor through its PTB domain to initiate reelin 
signalling (Bock et al., 2004). Phosphoinositide binding by Dab1 is also required 
for activity (Huang et al., 2005; Stolt et al., 2003; Stolt et al., 2004; Stolt et al., 
2005). Interestingly, modulation of Dab1-YENPTY interactions alters the 
proteolytic processing of APP and decreases the production of Aβ (Hoe et al., 
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2006). Dab2 has also been demonstrated to affect the trafficking of APP (Lee et 
al., 2008). 
1.6.5.2.5 Jip1 
Members of the APP family also bind the Jun NH2-terminal kinase interacting 
protein (Jip1) via the YENPTY motif (Scheinfeld et al., 2002; Taru et al., 2002). 
This interaction enhances the phosphorylation of APP at Thr668 by JNK1 (Inomata 
et al., 2003; Scheinfeld et al., 2003). Inhibition of JNK phosphorylation of Thr668 
is reported to prevent the ectodomain cleavage of APP and Aβ production and 
also induce degradation of APP (Colombo et al., 2009). Therefore, Jip/JNK 
interactions with the APP C-terminus may play a role in targeting APP for 
degradation. 
1.6.5.2.6  Pin1 
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1), is a 
prolylisomerase that has been found to bind to Thr668 of APP. Pin1 knockout 
increased the secretion of Aβ, while conversely Pin1 overexpression decreased 
the secretion of Aβ, suggesting that Pin1 promotes non-amyloidogenic processing 
of APP (Pastorino et al., 2006). Pin1 binding has been suggested to convert Thr668 
from a cis-conformation to a trans-conformation to mediate this effect (Pastorino 
et al., 2006). However, more recently, Pin1 has also been suggested to affect the 
turnover of APP by inhibiting GSK3β mediated phosphorylation at Thr668 (Ma et 
al., 2012).  
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1.6.5.2.7  Numb  
Numb is a protein that binds to the intracellular domain of APP and also to Notch 
through its PTB domain (Roncarati et al., 2002). Numb has been implicated in a 
number of endocytic pathways, and directly binds to clathrin adaptor protein AP2 
(Ntelios et al., 2012). Numb-APP interactions modulate the trafficking of APP, in 
a Numb-isoform dependent manner (Kyriazis et al., 2008). Levels of different 
Numb isoforms are perturbed in AD brain and also AD mouse models; suggesting 
a role of the Numb/APP interaction in AD (Chigurupati et al., 2011).  
1.6.5.2.8 Sorting nexins 
Sorting nexins (SNX) are endocytic adaptor proteins that are components of the 
endocytic machinery (see Section 1.7.5.2). SNX17 and SNX33 have been 
reported to bind to the YENPTY motif and affect the trafficking of APP (Lee et 
al., 2008; Schobel et al., 2008). As the α-secretase and β-secretase cleavage of 
APP occurs in different cellular compartments, modulation of SNX-APP 
interactions has also been reported to affect APP processing (Lee et al., 2008; 
Schobel et al., 2008). Interestingly, mutations in the Sortilin-related receptor, a 
protein that also interacts with sorting nexins and can affect APP trafficking, have 
been linked to Alzheimer’s disease (Rogaeva et al., 2007). 
1.6.5.3 Summary: Functional roles of the APP intracellular domain 
In summary, although the C-terminal interactions of APP are complex, there are 
clear and overlapping links to a role for this region in controlling the trafficking 
and consequently the proteolytic processing of APP. This idea is supported by 
evidence from APP-conditional knock in mice discussed in Section 1.6.1 that 
have a non-functional YENPTY motif, which have altered trafficking of APP. 
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Importantly, many adaptor proteins that interact with the C-terminus of APP also 
interact with other type-1 transmembrane proteins, allowing for a broader 
reflection on possible roles of these adaptor proteins in the normal biology of 
APP. 
1.6.6 Summary: Function of APP. 
The reported functions of APP are diverse, although there are some broad 
connecting themes between current studies. There are many reports of trophic 
effects of APP on the proliferation, growth and differentiation of cells. However, 
whether these effects are due to secreted APP, full length APP, or a combination 
of both has not yet been conclusively determined in vivo. It is clear that the 
extracellular region of APP is involved in aspects of APP function. This is 
demonstrated by studies with sAPPα that show effects on cell growth in vitro and 
also conditional knock-in studies which show that the extracellular region of APP 
can rescue the lethal phenotype of APP/APLP2 double knockout mice. The 
intracellular region of APP is clearly involved in the regulation of APP trafficking 
through interaction with cytosolic adaptor proteins. However, it is also possible 
that AICD may facilitate some APP functions, for example by regulating the 
expression of a number of genes in combination with Fe65. 
There are a number of aspects of APP biology that complicate interpretation of 
functional data. Firstly, there may be tissue- and cell-specific roles for APP. For 
example, the role of APP in the clotting cascade is apparently distinct from its 
function in the differentiation and growth of neural stem cells. However, the 
modes of action that elicit APP functions in different contexts may be similar. 
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Secondly, the APP homologues APLP1/2 may share functions with APP to some 
extent, which makes experimental determination of APP’s function more difficult. 
This compensation is best illustrated by APP/APLP2 double KO mice, which 
have a lethal phenotype, whereas APP-KO and APLP2-KO mice are viable. 
Thirdly, the secretase processing of APP means that full length APP and its 
derivative proteolytic fragments may all have separate cellular actions. Secreted 
APP fragments may have a paracrine function, as illustrated by the reported 
effects of sAPPα on cell proliferation. However, it is not clear at present if the 
reported effects of sAPPα on cell proliferation are direct or indirect. APP 
ectodomain shedding to produce sAPPα can be stimulated by a number of growth 
factors; therefore, the physiological roles of sAPPα may be closely related to the 
actions of those growth factors. To fully understand the biological roles of APP, 
further research is required, with careful consideration of the complexities 
outlined above. 
1.7 Phosphatidylinositol phosphate lipids: Minor lipids with 
major roles in cellular function 
Lipids are a class of molecule that hold many roles beyond the formation of 
cellular membranes. In the last three decades, studies of lipid metabolism have 
revealed sophisticated lipid signalling interactions, which are involved in almost 
all aspects of cellular physiology. To explain some of the findings presented later 
in this thesis, this section will give a brief introduction to lipid signalling. 
Although the field of lipid signalling is too large to discuss here in complete 
detail, the reader is directed to a number of excellent reviews for further 
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information (Hannun and Obeid, 2008; Wymann and Schneiter, 2008; Di Paolo 
and De Camilli, 2006; McLaughlin and Murray, 2005; Lemmon, 2008; Stace and 
Ktistakis, 2006; Cullen et al., 2001). This next section will discuss a particularly 
interesting class of lipid; the phosphorylated derivatives of phosphatidylinositol, 
known as phosphoinositides or PIPs.  
1.7.1 Structure and nomenclature of phosphatidylinositol phosphates. 
Phosphatidylinositol (PI) is a glycerophospholipid, consisting of an inositol head 
group, linked to two fatty-acid chains via a glycerol backbone and phosphate 
group (Fig. 1.6). Each of the hydroxyl groups of PI can be substituted with a 
phosphate group, resulting in mono, bis- and tris- phosphate PI species. These 
phosphorylated derivatives of phosphatidylinositol are termed 
phosphatidylinositol phosphates, phosphoinositides, PtdInsP or PIPs for short. 
There are seven different species of PIP. The mono, bis- and tris- phosphate 
species are therefore called PIP, PIP2 and PIP3 respectively. As the phosphate 
groups can be added at the 3, 4 or 5 position, both PIP and PIP2 species can exist 
as different regioisomers, for example, monophosphate species PI(3)P, PI(4)P or 
PI(5)P, and the bisphosphate species PI(4,5)P2, PI(3,5)P2 and PI(3,4)P2. 
Confusingly, PIP2 in the older literature is often used to refer specifically to 
PI(4,5)P2, however the other PIP2 regioisomers such as PI(3,4)P2 also hold 
important biological roles (McLaughlin et al., 2002; Posor et al., 2013). 
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Figure 1.6. Figure shows diagrammatic representation of all seven phosphoinositides. The 
structure of phosphatidylinositol is shown on the left. The position of phosphate groups on 
the head groups of each phosphoinositide species is shown on the right. Abbreviations: PI – 
Phosphatidylinositol, PI(3)P - Phosphatidylinositol (3) phosphate,   PI(4)P - Phosphati-
dylinositol (4) phosphate, PI(5)P - Phosphatidylinositol (5) phosphate,  PI(3,4)P2 - Phos-
phatidylinositol (3,4) bisphosphate, PI(3,5)P2 - Phosphatidylinositol (3,5) bisphosphate, 
PI(4,5)P2 - Phosphatidylinositol (4,5) bisphosphate, PI(3,4,5)P3 - Phosphatidylinositol 
(3,4,5) trisphosphate. 
PI
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1.7.2 Introduction to modes of PIP signalling 
PIPs account for less than 1% of the total lipid content in mammalian cells 
(McLaughlin and Murray, 2005; van Meer et al., 2008; Lemmon, 2008). 
However, PIP lipids are intimately involved in many cellular processes. Levels of 
PIPs are tightly controlled by an elaborate network of kinases and phosphatases 
that can rapidly convert PIP isoforms (discussed in Section 1.7.3). This means the 
cell has exquisite control of the PIP composition of membranes and can alter this 
upon stimulation. Many proteins contain evolutionarily conserved modular PIP-
binding domains, which can selectively bind to specific PIP regioisomers (Section 
1.7.4). The combination of these two features of PIP biology means that proteins 
containing a PIP-binding domain can be targeted to a particular membrane within 
the cell in a reversible fashion. As different cellular compartments have different 
prevalent PIP compositions, PIP-protein interactions ensure that proteins are in 
the correct cellular location (Di Paolo and De Camilli, 2006; Varnai and Balla, 
1998; Balla and Varnai, 2002). For example, endosomal membranes 
predominantly contain PI(3)P and endosomal proteins such as EEA1 associate 
with endosomes through a domain that specifically binds to PI(3)P (Gaullier et al., 
1998; Simonsen et al., 1998). Further, PIPs carry a strong negative charge, and 
there is some indication that this is involved in the lateral clustering of proteins 
into discrete membrane domains to enable function (Khuong et al., 2013; van den 
Bogaart et al., 2011; Huang et al., 2004). Therefore, PIPs can ensure proteins are 
in the right location at the right time, to facilitate a variety of functions within the 
cell.  
1.7.3 PIP metabolism 
PIP levels in the cell are tightly controlled by a number of kinases and 
phosphatases outlined in (Fig. 1.7). A summary of the main phosphoinositide 
kinases and phosphatases is presented below. The structure, function and 
regulation of PIP kinases is discussed in more detail in a recent volume (Balla, 
Wymann and York, 2012a).   
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Figure 1.7. Metabolism of phosphoinositides. The phosphorylation of PIPs in the 
cell is controlled by the action of phosphoinositide kinases (shown in blue) and 
phosphoinositide phosphatases (shown in red, numbers correspond to enzymes in 
list). Phospholipase C-mediated production of IP3 and DAG is shown in green. 
Figure based on Wymann (2012), Di Paolo and Di Camilli (2006) and Rusten and 
Stenmark (2006).
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1.7.3.1 Phosphoinositide kinases  
PI and PIP kinases are grouped into three main families based on their substrate 
specificity (Table 1-3). These are the phosphatidylinositol 3-kinases (PI3K), 
phosphatidylinositol 4-kinases (PI4K), and phosphatidylinositol phosphate 
kinases (PIPK). 
PI3Ks are enzymes that phosphorylate PI and PIP at the three position of the 
inositol head group. There are three classes of PI3Ks, type I, II and III based on 
structural homology (Table 1-3A). PI3Ks generally consist of a regulatory subunit 
and catalytic subunit, with a conserved catalytic core (Wymann, 2012; Wymann 
and Schneiter, 2008). PI3Ks have been intensively studied as these kinases have 
central roles in the regulation of cell proliferation, which means that they are 
strongly implicated in many human cancers (Wymann, 2012; Wymann and 
Schneiter, 2008).  
Phosphatidylinositol 4-kinases (PI4K) and phosphatidylinositol phosphate kinases 
(PIPKs or PIP4Ks) phosphorylate PI and PIP respectively in the 4 position of the 
inositol head group. There are two classes of PI4Ks based on structural homology 
with two genes (α, β) in each class (Table 1-3B). Confusingly, PI4Ks only use PI 
as a substrate, whereas PI3K use both PI and PIP as substrates. PIPKs (or PIP4Ks) 
are the enzymes that phosphorylate PIPs in the 4 positions. The PIPKs are also 
divided into three main classes (Table 1-3C), with three genes (α,β,γ) in each 
class.   
 65 
Table 1-3 Classes of phosphoinositide kinases 
 
Class Genes Substrate Product References 
A. Phosphoinositide 3-Kinases (PI3K) 
 Catalytic 
Subunits 
Regulatory 
Subunits 
   
PI3K 1A 
 
p110α, 
p110β,  
or 
p110δ 
 
p85α, p55α, 
p50α, p85β, 
p55γ 
PI(4,5)P2, PI(3,4,5)P3 Vanhaesebroeck et 
al., 2010 
PI3K 1B p110γ p101, p84    
PI3K II PI3K-C2α, 
PI3K-C2β 
PI3K-C2γ 
 PI, PI(4)P PI(3)P, 
PI(3,4)P2 
Vanhaesebroeck et 
al., 2010 
PI3K III Vps34 Vps15 PI PI(3)P Vanhaesebroeck et 
al., 2010 
B. Phosphoinositide 4-Kinases (PI4K) 
PI4K II α, β PI PI(4)P Endemann et al., 
1987; Whitman et 
al., 1987; Minogue 
and Waugh, 2012 
PI4K III α, β PI PI(4)P Endemann et al., 
1987; Whitman et 
al., 1987; Minogue 
and Waugh, 2012 
C. Phosphatidylinositol phosphate kinases (PIPK) 
PIPK I 
(also referred to 
as PI(4)P 5-
Kinase) 
α, β, γ PI(4)P PI(4,5)P2 Ishihara et al., 
1996; Jenkins et al., 
1991; Schramp et 
al., 2012 
PIPK II 
(also referred to 
as PI(5)P 4-
Kinase) 
α, β, γ PI(5)P PI(4,5)P2 Boronenkov and 
Anderson, 1995; 
Rameh et al., 1997; 
Schramp et al., 
2012 
PIPK III 
(also referred to 
as PI(3)P 5-
Kinase) 
PIKfyve (human) PI(3)P PI(3,5)P2 Cabezas et al., 
2006; Schramp et 
al., 2012 
Table shows classes of phosphoinositide kinases and substrates. Individual genes in each class are 
indicated. Functional PI3K 1 and PI3K III proteins are expressed by two genes, a regulatory subunit 
and a catalytic subunit. 
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1.7.3.2 Phosphoinositide phosphatases 
There are currently over 35 known mammalian phosphoinositide phosphatases 
that remove phosphate groups from PIP (Dyson et al., 2012). These can be 
separated into 3-phosphatases, 4-phosphatases and 5-phosphatases, although there 
are some phosphatases (e.g. SAC1) that have mixed specificity (Table 1-4). By 
counteracting the role of many PI kinases, phosphoinositide phosphatases control 
many important developmental and disease related processes. A well known 
example is phosphatase and tensin homolog (PTEN), a phosphatase that 
dephosphorylates PI(3,4,5)P3. Mutations in PTEN are frequently associated with 
cancer due to its critical role in deactivation of PI(3,4,5)P3-dependent signalling 
(Li and Sun, 1998).  
1.7.4 PIP-binding domains 
Lipid-binding domains are a feature of many proteins that interact with cellular 
membranes. The scientific literature surrounding the discovery and 
characterisation of lipid-binding domains is too extensive to review 
comprehensively here. However, lipid-binding domains have been discussed by a 
number of excellent reviews (Balla, 2005; Lemmon, 2008; McLaughlin et al., 
2002; McLaughlin and Murray, 2005; Carlton and Cullen, 2005).  
In general, lipid-binding domains interact with acidic phospholipids, such as 
phosphatidylserine, phosphatidic acid, PI and PIPs (Lemmon, 2008). There is 
great structural diversity amongst different lipid-binding domain families, ranging 
from relatively ordered domains with high specificity for a particular lipid, to 
loosely structured regions that interact with the membrane in a broad electrostatic 
manner (McLaughlin and Murray, 2005).  
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Table 1-4. Mammalian phosphoinositide phosphatases 
Name Locus Substrate(s) Product(s) Reference 
3-phosphatases 
Phosphatase and tensin 
homolog deleted on 
chromosome ten 
PTEN  PI(3,4,5)P3 
PI(3,4)P2 
 
PI(4,5)P2 
PI(4)P 
 
Li et al., 1997; Leslie 
et al., 2012 
Myotubularins and 
myotubularin-related 
phosphatases 
MTM 
MTMR 
(16 family 
members) 
PI(3)P 
PI(3,5)P2 
PI 
PI(5)P 
Leslie et al., 2012 
4-phosphatases 
Inositol polyphosphate 4-
phosphatase type I  
INPP4A PI(3,4)P2 PI(3)P Norris and Majerus, 
1994 
Inositol polyphosphate 4-
phosphatase type II 
INPP4B PI(3,4)P2 PI(3)P Norris et al., 1997 
PI(4,5)P2 4-phosphatase 
type I 
 
TMEM55A PI(4,5)P2 PI(5)P Ungewickell et al., 
2005 
PI(4,5)P2 4-phosphatase 
type I 
 
TMEM55B PI(4,5)P2 PI(5)P Ungewickell et al., 
2005 
5-phosphatases 
Inositol-polyphosphate 5-
phosphatase type II 
INPP5B PI(4,5)P2 
PI(3,4,5)P3 
PI(4)P 
PI(3,4)P2 
Jefferson and Majerus, 
1995 
SH2- containing inositol 
phosphatase SHIP-1 
INPP5D PI(3,4,5)P3 PI(4,5)P2 Damen et al., 1996 
SHIP2 INPPL1 PI(3,5)P2 
PI(4,5)P2 
PI(3,4,5)P3 
PI(3)P 
PI(4)P 
PI(3,4)P3 
Hejna et al., 1995; 
Pesesse et al., 1997 
Pharbin 
Type IV 5-phosphatase 
INPP5E PI(3,5)P2 
PI(4,5)P2 
PI(3,4,5)P3 
PI(3)P 
PI(4)P 
PI(3,4)P3 
Asano et al., 1999; 
Kisseleva et al., 2000; 
Kong et al., 2000 
Lowe oculocerebrorenal 
syndrome protein  
OCRL 
OCRL 
INPP5F 
PI(3,5)P2 
PI(4,5)P2 
PI(3,4,5)P3 
PI(3)P 
PI(4)P 
PI(4,5)P2 
Zhang et al., 1995 
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Table 1-4. Mammalian phosphoinositide phosphatases 
Name Locus Substrate(s) Product(s) Reference 
Synaptojanin-1  INPP5G 
SYNJ1 
PI(3,5)P2 
PI(4,5)P2 
PI(3,4,5)P3 
PI(3)P 
PI(4)P 
PI(4,5)P2 
McPherson et al., 1996 
Synaptojanin-2 INPP5H PI(3,5)P2 
PI(4,5)P2 
PI(3,4,5)P3 
PI(3)P 
PI(4)P 
PI(4,5)P2 
Nemoto et al., 1997 
PIPP 
Proline rich inositol 
polyphosphate 5-
phosphatase 
INPP5J PI(3,5)P2 
PI(4,5)P2 
PI(3,4,5)P3 
PI(3)P 
PI(4)P 
PI(4,5)P2 
Mochizuki and 
Takenawa, 1999 
SKIP 
Skeletal muscle and 
kidney inositol 
phosphatase  
INPP5K PI(3,4,5)P3 
PI(4,5)P2 
PI(3,4)P2 
PI(4)P 
Ooms et al., 2006 
PLIP 
Phospholipid-inositol 
phosphatase 
PLIP PI(5)P PI Pagliarini et al., 2004 
Sac Phosphatases 
SAC1 SACM1L PI(4,5)P2 
PI(3,4,5)P3 
PI(4)P 
PI(3,4)P2 
Nemoto et al., 2000 
SAC2  INPP5F PI(3)P 
PI(4)P 
PI Minagawa et al., 2001 
SAC3  FIG4 PI(4,5)P2, 
PI(3,4,5)P3 
PI(3,5)P2 
PI(4)P 
PI(3,4)P2 
PI(3)P 
Sbrissa et al., 2007 
Table shows the classes of known phosphoinositide phosphatases, genetic loci, substrates and products. 
Note, these phosphatases have been characterised in vitro, and are differentially expressed throughout the 
body. 
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Although PIPs are a relatively minor cellular lipid, a disproportionate number of 
classes of PIP-binding domains have been identified (Table 1-5). The first PIP-
binding domain to be identified was in a region of pleckstrin that specifically 
binds to PI(4,5)P2 (Harlan et al., 1994). Later, a homologous region of 
phospholipase C also was identified to bind to PI(4,5)P2, which was then named 
the pleckstrin-homology (PH) domain (Lemmon et al., 1995; Garcia et al., 1995). 
About 250 PH domain-containing proteins are present in the human genome, 
making PH domains the eleventh most common protein domain (Yu et al., 2004). 
However, only about 10% of PH domains bind phosphoinositides with high 
affinity, based on studies in S. cerevisiae (Yu et al., 2004).  
Since the identification of PH domains, other PIP-binding domain families have 
been discovered (Table 1-5). These include the epsin amino terminal homology 
(A/ENTH) domain; Fab1, YOTB, Vac1 and EEA1 (FYVE) domains; band 4.1, 
ezrin, radixin and moesin (FERM) domain and phox homology domains (PX). 
Additionally, domains that have other functions in the cell also bind to PIPs. 
Phosphotyrosine binding domains (PTB) are well known to bind to 
phosphotyrosine NPxY sorting motifs, however a number of these domains also 
bind PIP and this may be required for function (Huang et al., 2005; Mishra et al., 
2002; Stolt et al., 2004; Stolt et al., 2005).  
Many lipid-binding domains share little primary amino-acid sequence similarity, 
however some computational methods exist for identifying lipid-binding regions 
based on structural and electrostatic properties (Honing et al., 2005). There are 
also some examples of lipid-binding domains that may be very difficult to identify 
from computational methods alone. There are reports of ‘split’ PH domains,   
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Table 1-5: PIP-binding domains, binding specificity and examples of domain 
containing proteins 
PIP-binding domain  Binding 
specificity  
Examples of proteins 
containing domain 
A/ENTH domain (epsin amino 
terminal homology)  
PI(4)P 
PI(3,5)P2 
PI(4,5)P2 
EpsinR 
Ent3p, Ent5p 
AP180, PICALM, Epsin 
C2 domain PI(4,5)P2 Synaptogamin 
FERM domain (band 4.1,ezrin, 
radixin and moesin) 
PI(4,5)P2 Ezrin, Moesin, radixin, talin 
FYVE domain (Fab1, YOTB, 
Vac1 and EEA1)  
PI(3)P EEA1, Hrs, SARA, PIKfyve 
GRAM domain (glucosyl 
transferase, Rab-like GTPase 
activator and myotubularins)  
PI(3,5)P2 Myotubularin 
 PDZ domain (PSD-95, Dig1, zo-
1) 
PI(4,5)P2 Syntenin 
PH domain (pleckstrin homology 
domain) 
 
PI(4)P 
PI(3,4)P2 
PI(4,5)P2 
PI(3,4,5)P3 
FAPP1/2, OSBP 
AKT, TAPP1,2 
PLCδ1, dynamin 
BTK, AKT, ARNO, GRP1 
PHD finger (plant homeo domain) PI(5)P ING2 
PTB domain (phosphotyrosine 
binding domain) 
PI(4,5)P2 
PI(3,4,5)P3 
Dab, ARH, SHC 
SHC 
 PX domain (Phox homology 
domains) 
PI(3)P 
PI(5)P 
PI(3,4)P2 
PI(4,5)P2 
PI(3,4,5)P3 
SNX2,3,7,13 
SNX13 
P47phox 
Class II PI(3) Kinase 
CISK 
Table shows examples of PIP-binding domains, binding specificity and examples of proteins that 
contain each domain. Table based on Di Paolo and De Camilli, 2006.  
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domains that are split into two halves that are found within separate regions of 
proteins, or even between two distinct proteins (Teo et al., 2006; van Rossum et 
al., 2005). Split PH domains can form functional lipid-binding sites when the two 
halves of the domain come together in their cellular context (Teo et al., 2006; van 
Rossum et al., 2005). Therefore, it is quite likely that the number of proteins 
known to contain PIP-binding domains will continue to expand.  
In general, the affinity of lipid domains for their specific ligands is lower than 
would be expected to be biologically significant for a receptor binding to a soluble 
ligand. For example, the PH domain of PLC binds PI(4,5)P2 with a Kd of 2 µM 
(Hirose et al., 1999; Lemmon et al., 1995). However, the restriction of lipids and 
lipid-binding proteins to a membrane interface (i.e. resulting in reduced 
dimensionality) can greatly increase the effective concentration of lipid that is 
encountered by the domain (McLaughlin et al., 2002). In addition, lipid-binding 
domains commonly act in co-operation with other binding domains, in a 
phenomenon known as co-incidence detection (Carlton and Cullen, 2005; Di 
Paolo and De Camilli, 2006; Lemmon, 2008). In co-incidence detection, multiple 
low affinity binding interactions can add to produce a stronger interaction. There 
are a number of examples of different modes of this phenomenon, illustrated in 
Fig. 1.8.  
In summary, a rapidly expanding number of proteins have been identified to 
contain lipid-binding and PIP-binding domains. These can act in a variety of 
modes, and in combination with other binding domains, giving a diverse range of 
functional interactions. The next sections will discuss examples of how PIP-
binding domains are used in a number of important neuronal functions.   
Weak Strong
1. Oligomerisation - e.g. dynamin
pYpYWeak
Weak Strong
2. Co-receptor - e.g. dab1  
Weak Strong
3. Co-receptor - two lipids - e.g. SNX1   
Figure 1.8. Coincidence detection by PIP-binding domains. The combination of mul-
tiple low-affinity domains can produce high specificity for recognising target mem-
branes. Example 1: Dynamin has low affinity for membranes until it oligomerises, 
which results in a higher affinity interaction. Example 2: the combination of a lipid-
binding domain and a tyrosine binding motif, as found in the PTB domain of dab1, can 
produce a high affinity interaction to a particular receptor, such as apoER2. Example 3: 
the combination of multiple low affinity lipid-binding domains can produce high affin-
ity interactions. SNX1 is depicted, which contains a PI(3)P-binding PX domain and a 
BAR (Bin/Amphiphysin/Rvs) domain that binds to curved membranes and targets 
SNX1 to endosomes. Figure adapted from Lemmon (2008).
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1.7.5 Neuronal roles of PIPs 
PIPs are ideally suited to the control of many cellular processes, due to the 
combination of high turnover, regulated location and specific recognition by PIP-
binding proteins (Di Paolo and De Camilli, 2006). Comprehensively reviewing 
the current state of knowledge regarding biological roles of PIPs will not be done 
here as this topic has been extensively reviewed in a recent volume (Balla, 
Wymann and York, 2012b). The important cellular functions involving PIPs that 
are not discussed here include the regulation of cytoskeleton, roles in the cell 
nucleus, Golgi complex function, signal transduction, and chemotaxis. Instead, 
this section will illustrate some ways that PIP interactions are important in 
neuronal function with a focus on processes that are intimately involved in 
synaptic transmission.  
1.7.5.1 Roles of PIPs in synaptic vesicle exocytosis 
Studies of large dense core vesicle (LDCV) secretion in PC12 and chromaffin 
cells gave early insight into the role of PIPs in exocytosis (Eberhard et al., 1990; 
Hay et al., 1995). PI(4,5)P2 is required for exocytosis and PIPK1 has been 
identified as a factor required for LDCV vesicle priming (Eberhard et al., 1990; 
Hay et al., 1995). A number of components of the secretory system in LDCV 
exocytosis have now been identified as PIP-binding proteins (Osborne et al., 
2006; Wen et al., 2012). These PIP-binding components of the secretory system 
include synaptogamin (Syt; Schiavo et al., 1996), calcium-dependent activator 
protein for secretion (CAPS; Loyet et al., 1998) and SNARE proteins (Lam et al., 
2008). CAPS, SNARE and Syt all have roles in bringing secretory vesicles into 
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proximity with the plasma membrane (“priming”) and facilitating fusion with the 
plasma membrane (Frere et al., 2012).  
Although LDCV exocytosis and synaptic vesicle exocytosis may operate by 
slightly different mechanisms, there are strong indications of the importance of 
PIP in synaptic vesicle exocytosis. For example, deficiency in PIPK1γ, the main 
PIP kinase in neuronal synapses results in impaired neurotransmitter release (Di 
Paolo et al., 2004). Additionally, inhibition of PI(4)P synthesis with phenylarsine 
oxide decreases the release of glutamate from synaptosomes (Wiedemann et al., 
1998). More recently, it has been shown that PI(4,5)P2 and PI(3,4,5)P3 are 
required for the clustering of syntaxin 1A (a SNARE protein) at neurotransmitter 
release sites to allow synaptic vesicle release (Aoyagi et al., 2005; Khuong et al., 
2013; van den Bogaart et al., 2011). Therefore, PIPs are involved in many aspects 
of the regulation of correct release of synaptic vesicles. 
1.7.5.2 Roles of PIPs in synaptic vesicle recycling and endocytosis 
To maintain sustained signalling at the synapse, neurons must be able to recover 
membrane from PM-fused synaptic vesicles, to enable production of new synaptic 
vesicles. This process is known as synaptic vesicle recycling (Rohrbough and 
Broadie, 2005; Sudhof, 2004). A number of modes of endocytosis are involved in 
this event (Rohrbough and Broadie, 2005; Sudhof, 2004). The best-characterised 
PIP-dependent mechanism is clathrin-mediated endocytosis (Doherty and 
McMahon, 2009; Royle and Lagnado, 2003; Frere et al., 2012). The early 
evidence for the involvement of PIPs in synaptic vesicle recycling came from the 
observation that a number of proteins intimately involved in endocytosis also bind 
to phosphoinositides. Examples include Dynamin, AP180/PICALM, and AP2, 
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which are components of clathrin assemblies and all contain PIP-binding domains 
(Ford et al., 2001; Jost et al., 1998; Salim et al., 1996; Klein et al., 1998).  
A compelling model involving PIPs for the co-ordination of clathrin-coated 
vesicle (CCV) formation has emerged (Frere et al., 2012; Posor et al., 2013). At 
sites of endocytosis, an accumulation of PI(4,5)P2 recruits PIP-binding adaptor 
proteins such as epsins, AP2 or AP180 to the membrane (Jost et al., 1998). 
Adaptor protein binding to the membrane is essential for assembly of the clathrin 
coat (Ford et al., 2001; Jost et al., 1998). Recent evidence suggests the maturation 
of the endocytic vesicle may then be co-ordinated by spatiotemporal regulation of 
PIP composition in the forming vesicle bud. The phosphoinositide phosphatase 
synaptojanin associates with the membrane and hydrolyses PI(4,5)P2 to PI(4)P 
(Posor et al., 2013; Cremona et al., 1999). PI(4)P is then converted to PI(3,4)P2 by 
the phosphoinositide kinase PI3K C2α (Posor et al., 2013). PI(3,4)P2 production 
allows for the association of sorting nexin 9 (SNX9) with the forming vesicle. 
SNX9 is a BAR-domain (Bin/Amphiphysin/Rvs) containing protein that binds to 
the PI(3,4)P2 produced by PI3K C2α (Posor et al., 2013). BAR domains are large, 
banana-shaped domains with a charged surface that bind anionic lipids such as 
PIP and induce membrane curvature (Takei et al., 1999; Peter et al., 2004). 
Therefore, SNX9 may help the formation of the budding vesicles (Posor et al., 
2013). 
Fission of the endocytic vesicle from the plasma membrane is achieved by the 
GTPase dynamin, which requires PI(4,5)P2 binding for function (Salim et al., 
1996; Klein et al., 1998). Once the endocytic vesicle has separated from the 
plasma membrane (PM), disassembly of the endocytic machinery has been 
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suggested to occur through the action of a number of phosphoinositide 
phosphatases such as synaptojanin, however the exact mechanism has not yet 
been elucidated (Cremona et al., 1999).  
Perturbation of PIP dependent processes in endocytosis leads to a number of 
neuronal phenotypes. Knockout or mutation of synaptojanin, the synaptic PIP 
phosphatase, results in failure of synaptic vesicle endocytosis and accumulation of 
clathrin coated vesicles within the synapse, consistent with its proposed role in 
clathrin coated vesicle maturation (Cremona et al., 1999; Harris et al., 2000; 
Verstreken et al., 2003). Loss of PIPK1γ function in the synapse decreases the rate 
of synaptic vesicle endocytosis, resulting in the accumulation of bulk endosomes 
(Di Paolo et al., 2004). These examples illustrate that PIPs have many roles in the 
regulation of endocytosis. 
1.7.5.3 Modulation of ion channel function by PIPs 
An interesting emerging role of PIPs is as modulators and facilitators of ion 
channel function. PI(4,5)P2 is known to directly regulate inwardly rectifying 
potassium channels (Kir channels; Rohacs et al., 2003; Du et al., 2004), voltage 
gated calcium channels (Wu et al., 2002) and transient-receptor potential (TRP) 
channels (Wu et al., 2002). Kir channels and TRP channels interact with PIPs 
through lipid-binding domains in the cytoplasmic regions of the proteins (Lopes et 
al., 2002; Nilius et al., 2008). Most of these channels are activated in the presence 
of PI(4,5)P2, which has led to the suggestion that PI(4,5)P2 binding by ion 
channels prevents their activity while they are trafficked to the PM (Hilgemann et 
al., 2001). Some TRP channels are also inhibited by PIPs, which has been 
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suggested to be a physiological mechanism of negative TRP channel regulation to 
allow proper function (Gamper and Rohacs, 2012; Cao et al., 2013). 
A number of ion channels may also be regulated by PIPs in an indirect manner. 
NMDA-R activity can be modulated by PI(4,5)P2 (Michailidis et al., 2007). 2-
Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid receptor (AMPA-R) 
activity can also be modulated by PIPs, which are involved in the clustering of 
AMPA-R and control of cell surface levels of AMPA-R (Jin et al., 2006; Frere et 
al., 2012). As neuronal function is highly dependent on the action of ion channels, 
PIP-ion channel interactions therefore provide further evidence for the wide 
utilization of PIP in cellular function. 
1.7.5.4 PI(4,5)P2 as the metabolic precursor of IP3 and DAG 
PIPs are probably most well known for their role in Ca2+ signalling. The Ca2+ 
signalling pathway has been largely elucidated (Berridge et al., 2000). Activation 
of G-protein coupled receptors or receptor tyrosine kinases can activate 
phospholipase C (Berridge et al., 2000). Phospholipase C at the plasma membrane 
catalyses the hydrolysis of PI(4,5)P2 into inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG; Lapetina and Michell, 1973). Interestingly, phospholipase 
C has a higher affinity for IP3 than for PI(4,5)P2, which probably represents an in-
built negative feedback mechanism (Garcia et al., 1995). IP3 is water-soluble so it 
can diffuse into the cell and act as a second messenger. IP3 binds to the IP3 
receptor on the endoplasmic reticulum, and stimulates the release of Ca2+ from the 
intracellular calcium stores (Streb et al., 1983; Ferris et al., 1989). The activation 
of the IP3 receptor results in a rapid local increase in cytosolic calcium, that can 
have a number of effects in controlling cellular processes such as gene 
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transcription, apoptosis, proliferation and activation of ion channels (Berridge et 
al., 2000).  
DAG also acts as a second messenger once produced from PI(4,5)P2. Where IP3 
produces rapid cellular responses, DAG produces a longer lasting signalling 
response through protein kinase C (PKC; Nishizuka, 1995; Rosse et al., 2010). 
DAG activates PKC in combination with Ca2+ and other phospholipids (Rosse et 
al., 2010). PKC is inactive in its resting state, however the binding of its C1 and 
C2 domains to DAG and/or Ca2+ promotes a conformational change to an active 
form (Oancea and Meyer, 1998). Once active, PKC can phosphorylate a number 
of downstream signalling proteins in processes such as cell-growth and control of 
the cytoskeleton (Nishizuka, 1995; Rosse et al., 2010).  
1.7.6 Summary 
The studies reviewed in this section demonstrate that PIP-lipid signalling 
represents a highly sophisticated, evolutionarily conserved system that is involved 
in many cellular processes. The cell has a high degree of control over the location 
and level of PIPs, so PIP-binding by proteins can facilitate the targeting of 
proteins to particular cellular locations. As a result, PIP lipids appear to be 
involved in almost all aspects of cellular physiology (Balla, 2005; Di Paolo and 
De Camilli, 2006).  
1.7.7 General links between PIP and AD 
There are some reports of perturbed PIP metabolism in patients with AD and in 
experimental animals models of AD. Studies report that there is a reduction in 
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PI3K and PI4K activity in the AD brain, when compared to healthy controls 
(Bothmer et al., 1994a; Jolles et al., 1992; Zubenko et al., 1999; Wallace, 1994). 
A reason for this loss of PI3K and PI4K activity may be that the AD brain has 
reduced synapses, where there is a significant pool of PI3K and PI4K (Bothmer et 
al., 1994b). However, synaptic PIP kinase activity was found to be unaffected in 
some of these studies, potentially supporting the possibility of a selective down-
regulation of PI4K in AD (Bothmer et al., 1994b; Jolles et al., 1992; Wallace, 
1994).  
A number of in-vitro studies suggest that the reported decrease in PI3K and PI4K 
activity in AD may be related to some of the pathology in AD. Aβ has been 
reported to directly inhibit PI4K in a competitive manner (Wallace, 1994; Wu et 
al., 2004). Levels of PI(4)P and PI(4,5)P2 are also lowered in cells by Aβ 
treatment, and this has been suggested to be a mechanism of Aβ toxicity (Berman 
et al., 2008). Interestingly, overexpression of the synaptic PIP phosphatase 
synaptojanin1 reportedly reduces the toxic effects of Aβ in cell culture and also in 
mouse models of AD (Berman et al., 2008; McIntire et al., 2012). These studies 
suggest Aβ could modify PIP levels. 
Some studies also suggest that PIPs may have a role in the metabolism of APP. 
Inhibition of PI3K with wortmannin or LY294002 inhibits Aβ and sAPPα 
secretion in cell-based systems, suggesting that PIPs can regulate APP processing 
(Haugabook et al., 2001; Petanceska and Gandy, 1999). Wortmannin has also 
been reported to significantly reduce Aβ deposition in Tg2576 mice, which 
suggests that PI3K inhibition could form a therapeutic strategy for the treatment 
of AD (Haugabook et al., 2001). Recently, the trafficking of APP has been shown 
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to be dependent on PI(3)P (Morel et al., 2013). This could explain why inhibition 
of PI3K is able to reduce the secretion of sAPPα and Aβ.  
There is also some evidence to suggest that PIPs may regulate γ-secretase to some 
extent. PI and PI(4,5)P2 have been reported to potently inhibit γ-secretase activity, 
suggesting that PIP may be an endogenous inhibitor of γ-secretase (Osenkowski et 
al., 2008; Osawa et al., 2008). Interestingly, cells expressing presenilin mutations 
associated with Alzheimer’s disease have a consistently lower level of PI(4,5)P2 
(Landman et al., 2006). These reports suggest that γ-secretase activity could be 
affected by PIP and also affect PIP metabolism in a feedback loop. However, 
more research would be needed to establish whether this is the case.  
In summary, there are some suggestions that PIP metabolism is perturbed in AD 
and that PIPs can affect the processing of APP to form Aβ. However, it is not 
known whether the alterations of PIP metabolism that have been reported are 
involved in AD progression or a result of the disease state. 
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1.8 Hypothesis and aims of the study. 
The studies reviewed in this chapter demonstrate that APP is intimately involved 
in the pathogenesis of AD. However, despite intensive research, the normal 
function of APP is unclear. Further understanding of the biology of this protein 
may provide insight not only into the biochemical processes that are disrupted in 
AD, but also into the normal function of the brain. 
Several functions of APP have been suggested to be mediated through the 
production of a secreted factor, sAPPα. sAPPα may act in a trophic manner and 
elicit effects on cellular proliferation, differentiation and neurite outgrowth 
(Saitoh et al., 1989; Hoffmann et al., 2000; Ninomiya et al., 1994; Pietrzik et al., 
1998; Milward et al., 1992; Jin et al., 1994; Araki et al., 1991; Young-Pearse et 
al., 2008; Caille et al., 2004; Baratchi et al., 2012). This trophic capacity of 
sAPPα suggests that it may interact with a cell surface receptor or receptors on 
the signal-receiving cell. However, the cell-surface interactions of sAPPα have 
been incompletely characterised. Understanding the interactions of sAPPα with 
the surface of cells will give insight into the mechanisms of binding and possibly 
also mechanisms of signalling that are directly activated by APP.  
Some cell-surface receptors for sAPPα have been proposed. sAPPα is known to 
bind to cell-surface or extracellular-matrix components such as laminin, glypican-
1 and other heparan sulfate containing matrix components (Narindrasorasak et al., 
1992; Williamson et al., 1996; Ninomiya et al., 1994; Small et al., 1994). 
However, binding interactions with glycosaminoglycans may not be the sole 
determinant of binding to the cell surface, as proteoglycans often act in 
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combination with other receptors (Spivak-Kroizman et al., 1994). Several studies 
have reported both heparitinase-sensitive and heparitinase-insensitive cell-surface 
sAPPα binding sites on cells, supporting this idea (Hoffmann et al., 1999; 
Ninomiya et al., 1994; Kounnas et al., 1995). In addition to its interaction with 
heparan sulfate proteoglycans, sAPPα may also interact with β1-integrin, 
lipoprotein receptor related protein-1, death receptor 6, p75 neurotrophin receptor 
and APP itself (Young-Pearse et al., 2008; Kounnas et al., 1995; Nikolaev et al., 
2009; Gralle et al., 2009). However, APP may interact with many other 
extracellular proteins (Bai et al., 2008). Therefore, it still remains to be established 
which of these interactions are most important in vivo. 
In addition to its potential interaction with proteins and carbohydrates, there are 
some reports that APP may also interact with lipids. sAPPα has also been 
reported to localise to a novel ‘lipid raft’ fraction on cells (Tikkanen et al., 2002) 
and more recently, a direct interaction of sAPP with gangliosides has been 
proposed (Zhang et al., 2009). However, the interactions of APP with lipids have 
not been studied in detail. The studies reviewed in Section 1.7 demonstrate that 
lipids play active roles in many signalling processes, by targeting proteins to 
membranes. Therefore, the aim of the experiments presented in this thesis was to 
further investigate the role of APP-lipid interactions in its binding to cells. 
1.8.1 Hypothesis 
The central hypothesis behind the studies presented in this thesis is: 
Secreted forms of APP function through direct interactions with lipids on the cell 
surface 
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1.8.2 Aims 
To address the central hypothesis, the experimental aims in this thesis were to: 
1. Examine the ability of secreted APP to bind to lipids in vitro;  
2. Investigate the role of lipid binding in the cell-surface interactions of 
secreted APP; 
3. Investigate which regions of APP are involved in binding to cells;  
4. Examine the ability of secreted APP to affect levels of lipids in cells; 
5. Investigate if APP can affect lipid-signalling pathways. 
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Chapter 2 Materials and methods 
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2.1 Materials  
All materials and suppliers of materials used in this study are listed in Appendix I. 
2.1.1 Buffers, solutions and cell culture media  
All buffers and solutions used in this study are listed in Appendix II. 
2.1.2 Antibodies and dilutions  
All primary antibodies, suppliers and antibody dilutions used in this study are 
listed in Appendix III. All secondary antibodies and antibody dilutions used in 
this study are listed in Appendix IV.  
2.2 Methods 
2.2.1 Protein-lipid overlay assay  
Commercially available hydrophobic membranes (PIP StripsTM, SphingoStripsTM, 
Membrane Lipid StripsTM) spotted with 27 different lipids were used to examine 
the binding of sAPPα to lipids in vitro. For experiments investigating the effect of 
diC8PI(4,5)P2 and mucosal heparin on PI(4,5)P2 binding, PI(4,5)P2 was spotted 
on hydrophobic membranes according to the method of Dowler et al. (2002). 
Briefly, a 1 mM stock solution of 37:4 PI(4,5)P2 in CH3Cl:CH3OH was prepared 
and stored at -80°C. For spotting, the PI(4,5)P2 stock was diluted to 100 µM 
concentration in 1:2:0.8 CHCl3:CH3OH:H2O and 1 µL of the PI(4,5)P2 solution 
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containing 100 pmol of PI(4,5)P2 was spotted on to Hybond C Extra nitrocellulose 
at 4°C. Membranes were dried for one hour before use.  
Membranes were incubated with recombinant sAPPα or APP-E1 (described in 
Appendix I) at the concentrations indicated in figure legends overnight at 4°C in 
2.5 mL of 2 mg mL-1 fatty-acid free bovine serum albumin (BSA) in tris-buffered 
saline with tween-20 (TBS-T). Alternatively, membranes were incubated with 
conditioned cell medium for one hour. Membranes were then washed five times 
over 30 min with TBS-T. Lipid-bound sAPPα or APP-E1 was detected using an 
anti-6xHis antibody, 22C11 or 6E10. The concentrations of primary antibodies 
that were used are listed in Appendix III. Primary antibodies were incubated for 1 
h at room temperature in 2.5 mL 2 mg mL-1 BSA/TBS-T. Membranes were 
washed five times in TBS-T over 30 min, followed by incubation with horse 
radish peroxidase (HRP)-conjugated secondary antibody in 2.5 mL BSA/TBS-T 
for 1 h. Membranes were then washed in TBS-T five times over 30 min, and 
bound secondary antibody was detected using Immobilon chemiluminescent 
detection substrate which was incubated with membranes for 5 min before 
detection. Chemiluminescence was monitored using a Chemi-smart 5000 and 
images were collected using Chemicapt 5001 software (Vilber-Lourmat GmbH, 
Eberhardzell, Germany). For quantification of immunoreactivity, 16-bit 2x2 
binned images were collected and the integrated density of luminescence for each 
lipid spot was measured using Image J (National Institutes of Health, Maryland, 
USA). 
 87 
2.2.2 Neural stem and progenitor cell culture and conditioned medium 
collection 
Neural stem and progenitor cells (NSPCs) were cultured from the cerebral 
cortices of newborn Tg2576 or wild-type (WT) littermate mice (P0). Brain 
cortices were cleared of meninges and hippocampus, and then incubated in 
1×TrypLE Express for 10 min at 37°C. Tissue was disrupted mechanically with 
1000 µL fine tip and then the tissue was passed through a 40 µm cell strainer (BD 
Biosciences, North Ryde, Australia) to remove undissociated cells. NSPCs were 
grown as neurospheres by culturing cells in suspension in T75 cell culture flasks 
at a density of 20,000 cells mL-1 in proliferation medium. Neurosphere cultures 
were incubated in a humidified incubator at 37°C with 5% CO2. After 7 days in 
culture, cells were centrifuged at 500 x g for 5 min. At this stage, the supernatant 
conditioned medium was collected and stored at -80°C. Neurospheres in the cell 
pellet were dissociated mechanically with 200 µL fine tips, cells were counted in 
a Bright-LineTM haemocytometer (Sigma-Aldrich Pty. Ltd. Castle Hill, Australia) 
and then reseeded as suspension cultures in a T75 cell culture flask. 
2.2.3 Primary murine hippocampal and cortical culture 
All animal use was approved by the University of Tasmania Animal Ethics 
Committee (Permit No. A12555). Mice were housed in the animal facility at the 
University of Tasmania. For immunocytochemistry, primary neuronal cultures 
were prepared from the hippocampi of neonatal C57BL/6xSJL mice. For western 
blotting and lipid extraction, primary neuronal cultures were prepared from the 
whole cortices of neonatal C57BL/6xSJL mice.  
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Dissected tissue was transferred to 0.25% (w/v) papain and 0.06% (w/v) 
deoxyribonuclease-1 in Hank’s balanced salt solution and incubated for 15 min at 
37°C. Tissue was then washed in Neurobasal medium three times and dissociated 
by trituration. Single cell suspensions were centrifuged at 500 x g for 5 min and 
re-suspended in Neurobasal plating medium. The number of viable cells was 
determined using the Trypan blue exclusion method, and a Bright-LineTM 
Haemocytometer (Sigma-Aldrich). For immunocytochemistry, hippocampal cells 
were plated on nitric acid-washed poly-L-lysine-coated 13 mm glass coverslips in 
24-well tissue culture plates at a density of 1.25 x 105 viable cells per well. For 
western blotting and lipid extraction, cortical cells were plated in 12-well tissue 
culture plates, at a density of 1 x 106 viable cells per well. Cultures were 
maintained at 37° C in 5% CO2. After 24 h, the medium was replaced with 
Neurobasal maintenance medium. Half of the cell culture media was replaced 
every 4 days and cultures were used for experiments after 10 days in vitro (DIV). 
2.2.4 Immunocytochemistry 
Antibody labelling was performed on live, unfixed cells except where explicitly 
stated. Cells were washed twice in 500 µL Neurobasal maintenance medium 
warmed to 37°C. After washing, all antibody incubations and washes were 
performed at 4°C to prevent endocytosis of the antibodies. Cells were labelled by 
incubation with primary antibodies in 100 µL of imaging buffer (Appendix II). 
Incubations with primary antibodies were performed for 30 min, and the cells 
were washed three times with 500 µL of imaging buffer. Alexa-fluor-conjugated 
secondary antibodies were incubated for 30 min in 100 µL of imaging buffer, 
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before washing three times with 500 µL of imaging buffer. Cells were then fixed 
in 4% paraformaldehyde in phosphate buffered saline (PBS) for 20 min, washed 
twice in PBS and stained with 300 nM 4',6-diamidino-2-phenylindole (DAPI) in 
PBS for five min. Coverslips were then washed two times in PBS and once in 
dH2O. Coverslips were mounted in DAKO mounting medium and allowed to dry 
overnight before imaging.  
2.2.5 Microscopy and image analysis 
Confocal images were acquired using a Zeiss 510 confocal microscope, using a 
63x/1.4 oil immersion objective and Zen software (Carl Zeiss, Pty. Ltd. Sydney, 
Australia). Confocal slices were collected with one Airy unit pinhole size. 
Epifluorescence images were acquired using a Nikon Ti-E microscope (Nikon 
corporation, Tokyo, Japan) with 20x/0.5, 40x/0.95, 60x/1.27 objectives. 
Representative images are shown of at least 3 independent experiments.  
To quantify the level of immunoreactivity, 10 random fields from 3 coverslips 
were collected for each treatment group. Multichannel images were acquired 
using a microscope with an automated stage, automated filters and Nikon Perfect 
Focus system. Twelve-bit, 2x2 binned images were collected using a 40x/0.95 
objective. The average background intensity for each channel was defined as the 
sum pixel intensity measured from appropriate negative controls. For each field, 
the sum of all pixel intensities was measured and background was subtracted from 
these values. Statistical analysis was performed using Graph-Pad Prism v.6 
(Graphpad software Inc. La Jolla, CA, USA). Statistical significance was assumed 
at a 95% confidence level was determined using an unpaired Student’s t-test or 
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one-way analysis of variance (ANOVA) with Tukey’s or Dunnett’s post-hoc tests. 
Data with a p value < 0.05 were considered significantly different. 
2.2.6 Western blotting 
Cells were grown for 7 DIV before lysis and analysis of proteins. All extraction 
steps were performed on ice to reduce degradation of the extracted proteins. Cells 
were washed twice in warmed Neurobasal medium, prior to the addition of 150 
µL of lysis buffer containing protease inhibitor cocktail (Roche cOmplete ultra 
protease inhibitor tablets; 1 tablet 10 mL-1). For the experiments investigating the 
phosphorylation state of Akt, phosphatase inhibitor cocktail was included in the 
lysis buffer (Roche PhosStop phosphatase inhibitor tablets; 1 tablet 10 mL-1). 
Cells were scraped, triturated 15 times and transferred to an Eppendorf tube. Cell 
membranes were removed by centrifugation (13,000 rpm, 10 min, 4°C). The 
supernatant fraction was flash frozen in liquid nitrogen and stored at -80°C prior 
to analysis.  
The amount of protein in each sample was measured using the Bio-Rad DC 
protein assay, using bovine serum albumin as the standard. Absorbance was 
measured on a Fluostar Optima microplate reader (BMG Labtech GmbH, 
Ortenberg, Germany). The protein concentration in each sample was normalised 
by the addition of an appropriate volume of MilliQ H2O. Laemmli Sample buffer 
(Appendix II) was added to samples, which were then heated at 95°C for 10 min. 
Samples were briefly centrifuged and 15 – 25 µg of protein was loaded on an 8% 
tris-glycine polyacrylamide gel. To determine the ratio of pAkt to total Akt, 
individual samples were run twice on two separate gels in parallel. Samples were 
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separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred to polyvinylidene fluoride (PVDF) membranes. Blots 
were blocked for 20 min in TBS-T containing 5% (w/v) non-fat dry milk powder 
(NFDM). Specific proteins were detected using primary antibodies at 
concentrations outlined in Appendix III. An anti-GAPDH antibody was used to 
verify equal loading of samples. Primary antibodies were incubated with blots in 
TBS-T/NFDM for 1 h at room temperature or at 4°C overnight. Blots were 
washed three times in TBS-T, prior to incubation with a HRP-conjugated 
secondary antibody for 1 hour at room temperature in TBS-T/NFDM. Blots were 
washed three times, and signal was detected using Immobilon chemiluminescent 
detection substrate according to the manufacturer’s instructions. 
Chemiluminescence was monitored using a Chemi-smart 5000 image acquisition 
system and images were collected using Chemicapt 5001 software (Vilber-
Lourmat GmbH, Eberhardzell, Germany). For quantification of immunoreactivity, 
12-bit 2x2 binned images of chemiluminescence were collected and the integrated 
density of luminescence for each band was measured using Image J. Data analysis 
was performed using Graph Pad Prism V.6. Statistical significance was 
determined using one-way ANOVA with Tukey’s or Dunnett’s post-hoc tests, or 
Student’s t-tests. Data with a p value < 0.05 were considered significantly 
different. 
2.2.7 Computational modelling of IP3 binding sites on APP 
Modelling of potential binding sites in APP was performed using Protein Data 
Bank (PDB) crystal structures for the heparin-induced APP E1 dimer (PDB ID: 
3KTM; chains B + D; Dahms et al., 2010) and the pleckstrin homology domain of 
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β-spectrin (PDB ID: 1BTN; Hyvonen et al., 1995). The binding of D-myo-inositol 
1,4,5-triphosphate (Zinc database accession No. 6973597) and inositol (Zinc 
database accession No. 1530357) was computationally modelled using the 
SwissDock server (Grosdidier et al., 2011b; Grosdidier et al., 2011a). Molecular 
graphics and analyses were performed with the University of California San 
Francisco Chimera package (Pettersen et al., 2004). Docked ligands were viewed 
using the ViewDock function of Chimera. The predicted free energy of binding 
(ΔG) values were calculated using SwissDock, which uses SwissParam (Zoete et 
al., 2011) and CHARMM (Brooks et al., 2009) to predict ΔG. To generate figures, 
predicted binding sites were sorted according to predicted ΔG values using 
ViewDock, and binding clusters with a calculated ΔG more than was calculated 
for inositol were displayed. Figures were generated using Persistence of Vision 
RaytracerTM V3.6 (Persistence of Vision Pty. Ltd., Williamstown, Australia). 
Electrostatic surface calculations were performed using PDB2PQR (Dolinsky et 
al., 2007), APBS (Baker et al., 2001) with default settings and visualised using 
Chimera.  
2.2.8 Lipid extraction 
To measure changes in total levels of PIP, a reverse phase UPLC-MS method was 
developed, based on methods previously reported (Ivanova et al., 2007; Ogiso and 
Taguchi, 2008; Ogiso et al., 2010; Pettitt, 2010). Cells were washed in warmed 
Neurobasal medium, prior to scraping in PBS containing PhosStop phosphatase 
inhibitor cocktail (1 tablet 10 mL-1) at 4°C. Cell suspensions were centrifuged 
(13,000 rpm, 10 min, 4°C in a microcentrifuge) and the supernatant fraction was 
removed. Extraction buffer (200 µL of 1:1 CHCL3:MeOH with 0.25% (v/v) 12N 
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HCL) containing 50 pmol of each non-natural internal PIP standard (37:4 PI, 37:4 
PI(3)P, 37:4 PI(3,4)P2, 37:4 PI(3,4,5)P3) was added to the cell pellets. Cell pellets 
were then thoroughly mixed for 30s using a vortex mixer. The phases were split 
by addition of 40 µL 1M HCL and 5.7 µL 2M NaCl, and separated by a brief 
pulse of centrifugation. The lower organic phase (80 µL) was transferred to a new 
Eppendorf tube, and the solvent was removed by evaporation using a centrifugal 
evaporator (Centrivap: Labconco Kansas City, USA). The dried lipid was 
resuspended in 50 µl 1:2:0.8 CHCL3:MeOH:H2O, thoroughly mixed using a 
vortex mixer and then centrifuged in a microcentrifuge (13,000 rpm, 20 min, 4°C) 
to remove any cellular debris. The supernatant fraction (45 µL) was then 
transferred to an autosampler vial with a small volume insert (Waters Australia 
Pty. Ltd, Rydalmere, Australia). Samples were snap frozen in liquid nitrogen and 
stored at -80°C prior to analysis. Samples were analysed by UPLC-MS within 24 
hours after lipid extraction. 
2.2.9 UPLC-MS lipid analysis 
Cell lipid extracts were analysed by UPLC-MS in a random order. Cell lipid 
extracts (10 µL) were injected into a Waters Acquity H-series UPLC coupled to a 
Waters Xevo triple quadrupole mass spectrometer (Waters Australia). A Waters 
Acquity UPLC C18 column (2.1 x 100mm x 1.7 micron particles) was used for 
reverse phase liquid chromatography, with 0.13% ethylamine in water as solvent 
A and 0.13% ethylamine in acetonitrile as solvent B at a flow rate of 0.35 mL 
min-1. The column was eluted with an initial isocratic mobile phase mixture of 
90% A: 10% B for 1 min followed by a linear gradient to 0% A: 100% B over 9 
min. The column was then washed with 0% A: 100% B for a further 3 min before 
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re-equilibration to initial conditions over 3 min. The column temperature was 
40°C and the samples maintained at 6°C prior to injection. The mass spectrometer 
was operated in negative ion electrospray mode, and selected ion monitoring 
(SIM) was used to detect the specific phospholipids. The SIM masses for each ion 
and cone voltage are shown below in Table 2-1. The ion source temperature was 
150°C, the desolvation gas was nitrogen (950 L hr-1), and the desolvation 
temperature was 450°C. It was noticed that signals improved after priming the 
column, so before each batch of samples a 37:4 PIP2 standard solution was 
injected 4 times. A PIP2 standard solution was run after every 12 samples to 
ensure system performance was maintained.   
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Table 2-1 SIM ions, dwell times and cone voltages used for 
UPLC-MS 
Lipid (acyl chain) Ion m/z [M-H]- 
Dwell time 
(ms) 
Cone voltage 
(V) 
PI 37:4 standard 871.4 18 55 
PI 36:4 857.4 18 55 
PI 38:5 883.4 18 55 
PI 38:4 885.4 18 55 
PI 38:3 887.4 18 55 
PI(3)P 37:4 standard 951.4 18 65 
PIP 36:4 937.4 18 65 
PIP 38:5 963.4 18 65 
PIP 38:4 965.4 18 65 
PIP 38:3 967.4 18 65 
PI(3,4)P2 37:4 standard 1031.4 18 70 
PIP2 36:4 1017.4 18 65 
PIP2 38:5 1043.4 18 65 
PIP2 38:4 1045.4 18 65 
PIP2 38:3 1047.4 18 70 
PI(3,4,5)P3 37:4 standard 1111.4 18 70 
PIP3 36:4 1097.4 18 70 
PIP3 38:5 1123.4 18 70 
PIP3 38:4 1125.4 18 70 
PIP3 38:3 1127.4 18 70 
Table shows the m/z ions that were monitored using selective ion monitoring 
(SIM), as well as the dwell times and cone voltages used for detection of each 
ion. 
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2.2.10 Mass spectroscopy data analysis 
The total SIM intensity for each lipid elution peak was calculated by integrating 
the elution peak area. Elution peaks were selected for measurement according to 
the following criteria. Firstly, peaks had to be unambiguously identified using 
expected m/z and elution time relative to standards and/or other acyl chain 
variants. Secondly, the signal-to-noise ratio had to exceed 1:10, to allow for 
proper measurement. To account for variations in extraction efficiency between 
samples, PIP levels were normalized to the applicable internal standard. For each 
individual sample, the pmol of lipid per 1 million cells were calculated according 
to the formula (Raw elution intensity / 10 pmol internal standard elution intensity) 
x (total lipid extract volume / injection volume). Mean values for each treatment 
group were derived from 5 – 12 replicate wells (1 x 106 cells each) per treatment 
group. Experiments shown are representative of three independent experiments. 
Data analysis was performed using Graph Pad Prism V.6. Statistical significance 
was determined using one-way ANOVA with Tukey’s or Dunnett’s post-hoc 
tests, or Student’s t-tests. Data with a p value < 0.05 were considered significantly 
different.  
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3.1 Studies on the binding of APP to lipids 
sAPPα has been reported to elicit trophic effects in a number of cell types 
(Hoffmann et al., 2000; Pietrzik et al., 1998; Saitoh et al., 1989; Chasseigneaux et 
al., 2011; Gakhar-Koppole et al., 2008; Milward et al., 1992; Small et al., 1994; 
Jin et al., 1994; Ninomiya et al., 1994; Wallace et al., 1997; Caille et al., 2004; 
Demars et al., 2011; Freude et al., 2011; Ohsawa et al., 1999). sAPPα also binds 
to the surface of cells (Hoffmann et al., 1999), however the interactions of sAPPα 
with molecules on the surface of cells have been incompletely characterised.  
There have been some reports that suggest sAPPα could interact directly with 
lipids on the cell surface. sAPPα has been reported to localise to a lipid raft type 
domain (Tikkanen et al., 2002). Recently sAPPα has been reported to directly 
interact with GM1-ganglioside (Zhang et al., 2009). However, the ability of 
sAPPα to bind to different types of lipids has not been explored in detail. 
Therefore, the first aim of the experiments presented in this thesis was to identify 
the types of lipid that sAPPα is able to bind. 
3.1.1 Examination of the ability of sAPPα to bind to lipids 
To investigate whether secreted forms of APP are able to bind to lipids, the 
binding of a recombinant sAPPα with an N-terminal 6xHis affinity tag (Appendix 
I) to lipids was examined using a protein-lipid overlay assay. This assay allows 
for the comparison of a protein’s ability to bind to different types of lipid (Dowler 
et al., 2002). Recombinant sAPPα was incubated with hydrophobic membranes 
onto which 27 different types of lipid were immobilised. Membranes were 
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washed to remove any unbound sAPPα and the lipid-bound sAPPα was detected 
using an anti-6xHis antibody.  
No significant sAPPα immunoreactivity was associated with major lipid species 
such as phosphatidylcholine, phosphatidylethanolamine and cholesterol (Fig. 3.1). 
However, sAPPα immunoreactivity was associated with several 
phosphatidylinositol phosphates (PIPs) and 3-sulfogalactosylceramide (Fig. 3.1). 
The most sAPPα immunoreactivity was associated with the PIP species PI(3)P, 
PI(4)P and PI(5)P, followed by PI(3,5)P2 (Fig. 3.1B,C). Interestingly, there was 
minimal sAPPα immunoreactivity associated with phosphatidylinositol, which is 
structurally closely related to PIPs, but lacks the phosphate groups. Furthermore, 
there was no significant sAPPα immunoreactivity associated with GM1 (Fig. 
3.1A), which has previously been reported to be capable of binding to sAPPα 
(Zhang et al., 2009).  
To exclude the possibility that the binding of the recombinant sAPPα was due to 
an interaction of PIPs with the 6xHis tag, the binding of native sAPPα produced 
by mammalian cells was also examined. sAPPα-containing conditioned medium 
(Tg2576-CM) was collected from neural stem and progenitor cell (NSPC) 
cultures that were derived from Tg2576 mice. These cells over-express human 
APP carrying the K670N/M671L Swedish mutation and secrete human sAPPα 
into the cell medium (Hu et al., 2013). The ability of APP in the conditioned 
medium to bind to lipids was then examined using the protein-lipid overlay assay. 
As a control, wild-type conditioned medium (WT-CM) was also collected from 
NSPC cultures that were derived from littermate wild–type mice, which do not 
express human APP.  
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Figure 3.1. Recombinant 6xHis-tagged sAPPĮ binds selectively to PIP lipids and 
sulfatide. Panels A-C: Lipid binding preference of sAPPĮ for 50 pmol of each lipid 
was compared using a protein-lipid overlay assay. Membranes were incubated with 
1 nM sAPPĮ RYHUQLJKW0HPEUDQHVZHUHZDVKHG DQG OLSLGERXQG SURWHLQZDV
detected using a 6xHis antibody. Panel C: 6xHis immunoreactivity (I.R.) of 3 
experiments as shown in panel B was quantified by densitometry. Bars show 
PHDQV6(0RI V$33Į ,5 6WDWLVWLFDO VLJQLILFDQFHZDV GHWHUPLQHG E\ ZD\
ANOVA with Tukey’s post-hoc test ( * = p < 0.05 vs. PI). Abbreviations:  Sps – 
Sphingosine, S1P - Sphingosine-1-phosphate, PhyS – Phytosphingosine, CER – 
Ceramide, SM – Sphingomyelin, SPC - Sphingosylphosphorylcholine, LPA - 
Lysophosphatdic acid, MS - Myriosine, GM1- Monosialoganglioside, GD3 - 
Disialoganglioside, ST - 3-sulfogalactosylceramide (sulfatide),  Psy – Psychosine, 
Ch – Cholesterol, LPC - Lysophosphocholine, PC – Phosphatidylcholine, PI – 
Phosphatidylinositol, PI(3)P - Phosphatidylinositol (3) phosphate,   PI(4)P - Phos-
phatidylinositol (4) phosphate, PI(5)P - Phosphatidylinositol (5) phosphate, PE – 
phosphatidylethanolamine, PI(3,4)P2 - Phosphatidylinositol (3,4) bisphosphate, 
PI(3,5)P2 - Phosphatidylinositol (3,5) bisphosphate, PI(4,5)P2 - Phosphatidylinosi-
tol (4,5) bisphosphate, PI(3,4,5)P3 - Phosphatidylinositol (3,4,5) trisphosphate, PA 
- Phosphatidic acid, PS – Phosphatidylserine.
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The conditioned medium was incubated with hydrophobic membranes onto which 
different lipids were immobilised. Membranes were washed to remove any 
unbound APP, and lipid-bound APP was then detected using the monoclonal 
antibody 6E10, which detects amino acid residues 672 to 688 of human APP. No 
lipid-associated sAPPα immunoreactivity was present using the conditioned 
medium collected from WT neurosphere cultures (Fig. 3.2A). When membranes 
were incubated with Tg2576-CM, no lipid-associated APP immunoreactivity was 
present for major lipid species such as phosphatidylcholine, 
phosphatidylethanolamine or cholesterol (Fig. 3.2B). However, sAPPα 
immunoreactivity was associated with PIPs, phosphatidic acid and 3-
sulfogalactosylceramide (Fig. 3.2B). As the epitope of 6E10 antibody used to 
detect sAPPα is residues 1 - 16 of the Aβ region of APP, this antibody can detect 
both sAPPα and Aβ in the cell medium. Therefore, to determine if sAPPα bound 
to PIPs, the anti-APP N-terminus antibody 22C11 was also used to confirm that 
sAPPα in the Tg2576-CM binds to PIPs. When membranes were incubated with 
Tg2576-CM, 22C11 immunoreactivity was also associated with PIPs, 
demonstrating that sAPPα in the Tg2576-CM binds to PIPs (Fig. 3.2C). 
3.1.2 Identification of a PIP-binding region in the E1 domain of APP  
As the E1 domain of APP has a highly ordered structure, with some positively 
charged surfaces (Rossjohn et al., 1999), it was hypothesised that this region of 
APP could be responsible for the binding of sAPPα to the anionic PIPs observed 
in the experiments described in Section 3.1.1. Therefore, the possibility that there 
may be a PIP-binding domain in the E1 region of APP was examined using the 
protein-lipid overlay assay.   
Figure 3.2. Human sAPPĮ VHFUHWHG E\ KXPDQ$33RYHUH[SUHVVLQJ163& FXOWXUHV 
ELQGVWR3,3OLSLGV0HPEUDQHVWULSVZHUHLQFXEDWHGZLWKFRQGLWLRQHGFHOOPHGLXP
FROOHFWHG IURP:7GHULYHG QHXURVSKHUH FXOWXUHV :7&0 SDQHO$ RU 7J
GHULYHGQHXURVSKHUHFXOWXUHV7J&0SDQHOV%DQG&IRUK0HPEUDQHVZHUH
ZDVKHG DQG OLSLGERXQG$33 ZDV GHWHFWHG XVLQJ WKH PRQRFORQDO ( DQWLERG\
SDQHOV$ DQG % RU WKH PRQRFORQDO$33 1WHUPLQDO  DQWLERG\ & SDQHO &
$EEUHYLDWLRQV QRW XVHG SUHYLRXVO\ 7*  WULJO\FHULGH '$*  GLDF\OJO\FHURO 3*
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A recombinant protein corresponding to the E1 domain of APP with a C-terminal 
6xHis affinity tag (APP-E1) was incubated with hydrophobic membranes onto 
which lipids were immobilised. Membranes were washed, and lipid-associated 
APP-E1 was detected using an antibody against the 6xHis tag. Like sAPPα, the 
APP-E1 immunoreactivity was not associated with most lipids (Fig. 3.3). APP-E1 
immunoreactivity was associated with PIPs and 3-sulfogalactosylceramide (Fig. 
3.3). The APP-E1 bound more uniformly to all PIPs than was observed for sAPPα 
and gave a stronger chemiluminescent signal under similar incubation conditions 
(Fig. 3.1C vs. Fig. 3.3C). Therefore, these results suggested that APP has a PIP-
binding region in the N-terminal E1 domain.  
3.1.3 Competition of APP-E1 binding to PI(4,5)P2 with a water soluble PIP 
analogue and mucosal heparin.  
To determine that the binding of APP-E1 recombinant protein to PI(4,5)P2 in the 
protein-lipid overlay assay was due to a specific interaction and could be reduced 
by competition, a water soluble short acyl chain PI(4,5)P2 analog (diC8PI(4,5)P2) 
was used to compete for binding. The effect of a range of concentrations of a 
water-soluble PIP analogue diC8PI(4,5)P2 on APP-E1 binding to PI(4,5)P2 was 
determined in the protein-lipid overlay assay. These results demonstrated that at 
least 5µM concentration of diC8PI(4,5)P2 was required to significantly block the 
binding of 0.5 nM APP-E1 to 100 pmol PI(4,5)P2 in vitro (Fig. 3.4A).  
Figure 3.3. APP-E1 binds selectively to PIP lipids. Panels A -C: The lipid 
binding of APP-E1 was examined using the protein-lipid assay. Membranes 
were incubated with 1 nM APP-E1 overnight and lipid-bound protein was 
detected using a 6xHis antibody. Panel C: Immunoreactivity (I.R.) of lipid-
bound APP-E1 from 3 experiments as shown in panel B was quantified by 
densitometry. Bars show means ± SEM APP-E1 immunoreactivity. Statisti-
cal significance determined by 1 way ANOVA with Tukey’s post-hoc test (* 
= p < 0.05 vs. PI). 
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Figure 3.4. Dic8PI(4,5)P2 but not mucosal heparin (MH) com-
petes for APP-E1 binding to PI(4,5)P2. Panel A: The effect of 
increasing diC8PI(4,5)P2 concentration on APP-E1 (0.5 nM) 
binding to PI(4,5)P2 (100 pmol) was examined in the protein-lipid 
overlay assay. Panel B: APP-E1 (0.5 nM) was incubated with  
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ȝJP/-1) or PBS (control). PI(4,5)P2-bound APP-E1 immunoreac-
tivity (I.R.) was then quantified using densitometry. Bars show 
mean ± SEM of PI(4,5)P2-bound APP-E1 immunoreactivity 
expressed as a percentage of PBS control from 9 replicates per 
treatment. Statistical significance was determined using 1-way 
ANOVA and Dunnett’s post-hoc test (*p < 0.05 vs control). 
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The amount of APP-E1 immunoreactivity associated with PI(4,5)P2 in the 
presence of 0.5 µM, 5 µM and 50 µM diC8PI(4,5)P2 was observed to be 80%, 
50% and 20% of control respectively (Fig 3.4A). However, only the 5 µM and 50 
µM concentrations were significantly different from the PBS control (Fig. 3.4A). 
These data demonstrated that diC8PI(4,5)P2 can compete for APP-E1 binding to 
PI(4,5)P2, and also that the protein-lipid overlay assay was suitable for measuring 
the effect of a competitive inhibitor. 
The E1 domain of APP contains a heparin-binding region (residues 95 – 110) and 
a metal-binding region (Small et al., 1994; Multhaup et al., 1996). As the heparin-
binding region carries a positively charged surface (Rossjohn et al., 1999), it was 
hypothesised that this region of APP could be responsible for binding to PIPs. To 
investigate whether the heparin-binding domain could be responsible for the 
binding of APP to PIP, the ability of heparin to inhibit the binding of APP-E1 to 
PI(4,5)P2 was assessed using the protein-lipid overlay assay. The concentration of 
heparin that was used (100 µg mL-1) was a ≈ 40-fold molar excess compared to 
the amount of PI(4,5)P2. This concentration of heparin has previously been 
demonstrated to block the binding of APP to cells (Ninomiya et. al., 1994). 
Heparin was not able to block the binding of APP-E1 to PI(4,5)P2 in the protein-
lipid overlay assay (Fig. 3.4B). In contrast, half the amount by weight (58.4 µg 
mL-1) of dic8PI(4,5)P2 was able to block the binding of APP-E1 to PI(4,5)P2 in the 
protein-lipid overlay assay (Fig. 3.4B). This suggests that the binding of APP-E1 
to PI(4,5)P2 is not via the heparin-binding domain in APP-E1 between residues 95 
– 110, but through another region (Small et al., 1994; Clarris et al., 1997).  
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3.1.3.1 Computational modelling of the PIP-binding domain in the E1 domain of 
APP 
The E1 domain of APP is a highly structured region, for which crystal structures 
are available (Dahms et al., 2010; Rossjohn et al., 1999). To identify possible 
binding sites for PIP in the APP E1 domain, a computational modelling approach 
was used. D-myo-inositol 1,4,5-trisphosphate (IP3) is homologous in structure to 
the head group of PI(4,5)P2. As a result, PI(4,5)P2 binding proteins often bind to 
IP3 with similar or higher affinity than to PI(4,5)P2 (Lemmon et al., 1995; Garcia 
et al., 1995; Hyvonen et al., 1995). Therefore, the binding of IP3 to the APP E1 
domain was computationally modelled using the SwissDock protein-ligand 
docking tool (Grosdidier et al., 2011b; Grosdidier et al., 2011a). This tool models 
the interactions of small molecule ligands with proteins, to allow for visualisation 
of clusters of potential binding sites. The SwissDock server also estimates the free 
energy of binding (ΔG) based on electrostatic interactions calculated using the 
CHARMM fields for the protein (Brooks et al., 2009) and SwissParam field for 
the ligand (Zoete et al., 2011). These estimated ΔG values were used to indicate 
how strongly IP3 could potentially interact with a particular binding site on the 
APP E1 domain.  
The computational modelling of the interactions between the APP E1 domain and 
IP3 suggested that there were two potential IP3 binding pockets present on the E1 
domain of APP (Fig. 3.5). The highest ranked binding pocket was at the heparin-
binding loop, with energetically favorable predicted free energy of binding values 
(ΔG) in the range of -12.5 to -6.6 kcal mol-1 (Fig 3.5).  
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Figure 3.5. Possible binding sites of D-myo-inositol 1,4,5-trisphosphate (IP3) on the  
APP E1 domain. The binding of IP3 to the crystal structure of the APP E1 domain 
(PDB ID: 3KTM, Chain B) was modelled using the SwissDock protein docking 
server. Panel A: Electrostatic surface charge representation of the APP E1 domain.  
Panel B: Secondary structure cartoon representation of the APP E1 domain. Alpha-
helices are coloured in orange and beta-sheets are coloured in purple. The heparin-
binding domain (residues 95 - 110) has been highlighted in yellow. Clusters of 
predicted binding sites for IP3 with a predicted free energy of binding (∆*PRUHQHJD-
tive than -6.52 kcal mol-1 are shown. Labels indicate the range of predicted ∆*IRU
each binding cluster. The positions of histidine 151, lysine 155, glycine 90 and proline 
91 are also indicated. 
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Electrostatic surface modelling demonstrates this region of the APP E1 domain 
has a positively charged surface, which could theoretically interact with anionic 
PIP (Fig 3.5A). A second potential IP3 binding pocket was present closer to the N-
terminus in a pocket formed by the amino acid residues histidine 151, lysine 155, 
glycine 90 and proline 91. This potential binding site had a slightly less negative 
range of predicted ΔG values, in the range of -9.85 to -6.6 kcal mol-1 (Fig 3.5).  
As the E1 domain of APP may also form a dimer (Dahms et al., 2010), the 
binding of IP3 was also modelled to the APP E1 domain dimer (PDB ID: 3KTM). 
The computational modelling suggested a number of potential binding sites for 
IP3 on the APP E1 dimer (Fig. 3.6). A number of binding pockets were predicted 
around the heparin-binding region (residues 95 - 110) and interestingly, these had 
more negative predicted ΔG values (in the range of -17 to -9 kcal mol-1) than was 
predicted for the APP E1 domain monomer (Fig. 3.6). The positively charged 
surface around the heparin-binding site is larger in the APP E1 domain dimer, 
which could explain the more negative predicted ΔG (Fig. 3.6A). Additionally, 
there were other potential binding pockets closer to the N-terminus of the APP E1 
domain, with less negative predicted ΔG values in the range of -9 to -7 kcal mol-1.  
To provide context to these modelled interactions of APP with IP3, positive and 
negative control models were produced. As a negative control, the binding of the 
APP E1 domain to inositol was computationally modelled. Inositol was used as a 
control as inositol is structurally similar to IP3, but does not have the negatively 
charged phosphate groups.  
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Figure 3.6. Possible binding sites for D-myo-inositol 1,4,5-trisphosphate (IP3) on the 
heparin-induced APP dimer. The binding of  IP3 to the crystal structure of the heparin-
induced APP E1 dimer (PDB ID: 3KTM, Chains B+D) was modelled using the Swiss-
Dock protein docking server. Panel A: Electrostatic surface charge representation of 
the APP E1 dimer. Panel B: Secondary structure cartoon representation of the APP E1 
dimer. Alpha-helices are coloured in orange and beta-sheets are coloured in purple. 
The heparin-binding domain (residues 95 - 110) has been highlighted in yellow. Clus-
ters of predicted binding sites for IP3 with a predicted ∆*PRUHQHJDWLYHWKDQNFDO
mol-1 are shown. Labels indicate the range of predicted ∆*IRUHDFKELQGLQJFOXVWHU
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The computational modelling of the binding of inositol to the APP E1 domain 
monomer and the APP E1 domain dimer produced a number of potential binding 
sites on the APP E1 domain (Fig. 3.7 A, B). The potential binding sites for 
inositol were distinct from those predicted for IP3, and all had less energetically 
favourable predicted ΔG values (in the range of -6.7 to -4.2 kcal mol-1) than was 
predicted for APP binding to IP3. Therefore, these results suggested that 
interactions of IP3 with the APP E1 domain were more energetically favorable 
than the interaction of inositol with the APP E1 domain. This was consistent with 
the results of the protein-lipid overlay assay, which found that APP-E1 bound to 
PIP but not to PI.  
As a positive control model, the binding of IP3 to the pleckstrin homology domain 
of spectrin (spectrin-PH) was modelled using the SwissDock server. The 
pleckstrin homology domain of spectrin (spectrin-PH) binds selectively to 
PI(4,5)P2 with a dissociation constant (Kd) of around 40 µM (Hyvonen et al., 
1995). Further, the IP3 binding site for spectrin-PH has been identified using X-
ray crystallography (Hyvonen et al., 1995). Modelling the interactions between 
spectrin-PH and IP3 produced a number of potential binding sites for IP3 that 
matched the previously reported binding site (Fig. 3.7C; Hyvonen et al., 1995). 
The range of predicted ΔG values for these interactions were -15.8 to -7.87 kcal 
mol-1 (Fig 3.7C). Therefore, this modelling suggested that some of the potential 
IP3 binding sites identified for the APP E1 domain (predicted ΔG range -17.0 to -
6.6 kcal mol-1) were as energetically favorable as were predicted for the spectrin 
PH domain (predicted ΔG range -15.8 to -7.87 kcal mol-1). Therefore, these 
theoretical data supported the presence of a PIP-binding region in the E1 domain 
of APP.   
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Figure 3.7. Positive and negative tests of the computational docking model. Panel A shows 
WKHSUHGLFWHGELQGLQJFOXVWHUVDQGWKHUDQJHRISUHGLFWHGIUHHHQHUJ\RIELQGLQJ∆*IRU
inositol binding to the APP E1 domain 3'%,'.70FKDLQ%modelled using the 
SwissDock protein docking server. Panel B shows the predicted binding clusters and the 
UDQJHRISUHGLFWHG∆*IRULQRVLWROELQGLQJWRWKHKHSDULQLQGXFHG$33(GLPHU(PDB ID: 
.70FKDLQ%DQG'. 7KHKHSDULQELQGLQJGRPDLQUHVLGXHVKDVEHHQKLJK
lighted in yellow.3DQHO&VKRZVSUHGLFWHGELQGLQJVLWHVDQGSUHGLFWHG∆*IRU'P\R
LQRVLWROWULVSKRVSKDWH,33ELQGLQJWR WKHSOHFNVWULQKRPRORJ\GRPDLQRIVSHFWULQ
3'%,'%71$OSKDKHOLFHVDUHFRORXUHGLQRUDQJHDQGEHWDVKHHWVDUHFRORXUHGLQ
purple. 
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3.2 Studies on the binding of APP to hippocampal neurons 
The central hypothesis of this thesis was that APP directly interacts with lipids on 
the cell surface. The results reported in Section 3.1 showed that sAPPα and APP-
E1 are able to bind to PIPs in an in vitro assay. Therefore, to test the hypothesis 
that APP can interact with PIPs on the cell surface, a cell culture model was 
developed. Previous studies have reported that sAPPα binds to the surface of a 
number of different cell types (Hoffmann et al., 1999; Tikkanen et al., 2002). In 
these studies, purified sAPPα was added to cell cultures and cell-bound sAPPα 
was detected using immunocytochemistry (Hoffmann et al., 1999; Tikkanen et al., 
2002). Therefore, the same experimental approach was chosen for the following 
experiments. 
Primary murine hippocampal cultures were prepared at a low density of 1x105 
cells per coverslip to enable visualisation of individual cells. Cultures were 
initially plated in 10% serum, which produced a glial feeder layer, with neuronal 
cells growing on top (Fig. 3.8A). To examine the binding of APP to cells, the 
primary murine hippocampal cultures were incubated with recombinant 6xHis 
tagged sAPPα and recombinant 6xHis tagged APP-E1, after which unbound 
protein was removed by washing with culture medium. Cell-bound sAPPα or cell-
bound APP-E1 was then detected using an antibody directed against the 6xHis tag 
on the recombinant proteins.   
Figure 3.8. APP-E1 and sAPP_ bind to neuronal cells. Primary hippocampal cultures 
were incubated with PBS control (panel A), 50 nM sAPP_ (panel B) or 50 nM APP-E1 
(panel C) for 2 h. Cells were washed, and cell-surface bound APP was detected by immu-
nocytochemistry using an anti-6xHis antibody. The nuclei of glial cells in the feeder layer 
are visible in the DAPI channel on the left. Note: the contrast in panel C is lower than 
panels A and B. Insets show enlargement of cell soma region shown in white boxes, 
IRFXVVHGRQWKHFHOOVXUIDFH6FDOHEDUV ȝP3DQHO'VKRZVDZHVWHUQEORWRIUHFRP-
binant sAPP_ immunoreactivity over time, showing evidence for low stability of the 
recombinant sAPP_. Recombinant sAPP_QJZDVLQFXEDWHGLQȝ/WULVEXIIHUHG
VDOLQHDW&$WHDFKWLPHSRLQWȝ/QJHTXLYDOHQWZDVUHPRYHGDGGHGWR6'6-
PAGE sample buffer and heated to 95°C for 10 minutes. The samples were then analysed 
by SDS-PAGE, blotted onto PVDF membranes, and immunolabelled using the monoclo-
nal antibody 6E10.  
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Some sAPPα bound to cells with a punctate pattern, however, this 
immunoreactivity was only visible when the contrast of the images was enhanced, 
and the signal was difficult to distinguish from background fluorescence (Fig. 
3.8B, A). However, much more immunoreactivity associated with cells was 
observed using the APP-E1 recombinant protein than was observed using sAPPα 
recombinant protein (Fig. 3.8). APP-E1 bound selectively to neurons, with a 
distinctive punctate pattern along the dendrites and over the surface of the cell 
soma (Fig. 3.8C). There was no binding of APP-E1 to the glial cells in the feeder 
layer (Fig. 3.8C), indicating that the cell binding of exogenously added APP-E1 is 
to a specific site present on neuronal cells.  
Subsequent investigation suggested that the recombinant sAPPα was unstable, as 
the 6E10 immunoreactivity of the recombinant sAPPα spontaneously declined 
over time with a half-life of approximately two hours (Fig. 3.8C). This may 
explain why the cell-associated APP immunoreactivity was weak. Therefore, as 
the recombinant sAPPα was unstable and the sAPPα immunoreactivity associated 
with cells was weak, the APP-E1 recombinant protein was used for the majority 
of experiments in this study. 
3.2.1 Identification of PIPs on the extracellular surface of the cell membrane  
As APP-E1 was able to bind to PIP in vitro and was also able to bind to the 
surface of neurons, the possibility that APP-E1 could bind to PIPs on the surface 
of neurons was investigated. Although there have been some reports of the 
presence of PIPs on the surface of cells (Gascard et al., 1991; Fogler et al., 1987; 
Kale et al., 2010), most studies of PIPs have focussed on the role of PIPs on the 
cytoplasmic side of the plasma membrane (PM). Therefore, to investigate whether 
APP could interact with PIPs on the cell surface, it was first necessary to 
determine whether PIPs were present on the surface of cells. 
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3.2.1.1 Immunocytochemical detection of cell-surface PIPs 
A number of studies have used monoclonal antibodies to investigate the 
localisation of PIPs inside the cell (Hammond et al., 2012; Hammond et al., 
2009). To determine whether PIPs were present on the surface of cells, primary 
hippocampal cultures were incubated with anti-PIP monoclonal antibodies. 
Antibody labelling was performed on live cells at 4°C to minimise the possibility 
of disruption of the cell membrane and the consequent detection of intracellular 
PIPs (Rusten and Stenmark, 2006; Hammond et al., 2009). 
PI(4)P, PI(3)P, PI(3,5)P2 and PI(3,4,5)P3 immunoreactivity was not detected on 
the surface of primary hippocampal cultures (Fig. 3.9A, B, D, E). However, 
PI(4,5)P2 immunoreactivity was detectable on the surface of cells in primary 
hippocampal cultures (Fig. 3.9C). The anti-PI(4,5)P2 antibody labelled the surface 
of both neurons and glia in the feeder layer (Fig. 3.9C, 3.10A). PI(4,5)P2 
immunoreactivity exhibited a punctate distribution with puncta < 1 µm present 
along dendrites and on the surface of the neuron soma (Fig. 3.10A). The 
specificity of the anti-PI(4,5)P2 monoclonal antibody for binding to cellular 
PI(4,5)P2 was demonstrated by pre-adsorbing the antibody with a 1000x molar 
excess of a water-soluble analog of PI(4,5)P2 (diC8 PI(4,5)P2). Pre-absorption of 
the PI(4,5)P2 antibody abolished antibody binding to cells (Fig. 3.10B).  
To confirm that the PI(4,5)P2 immunoreactivity that was observed on the cells 
was extracellular and not intracellular, the localisation of the PI(4,5)P2 
immunoreactivity was compared with that of the intracellular proteins MAP2 and 
GFAP using both live unfixed cells and cells that had been fixed and 
permeabilised with 4% paraformaldehyde and 0.3% triton X-100. The principle of 
the experiment was that the antibodies directed against intracellular antigens 
would not be immunoreactive with cells when the cell membrane is intact, but 
extracellular antigens would be detected.  
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Figure 3.9. Evidence for the presence of cell-surface PI(3)P, PI(4)P, 
PI(4,5)P2 PI(3,5)P2  and PI(3,4,5)P3 immunoreactivity on cells in 
hippocampal culture. Live hippocampal cultures were labelled at 4 ºC with 
monoclonal PIP antibodies. Inset shows enlargement of region in white 
ER[IRFXVHGRQVXUIDFHRIWKHQHXURQVRPD6FDOHEDUV ȝP
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Figure 3.10. Effect of preabsorption of anti-PI(4,5)P2 antibody with 
diC8PI(4,5)P2 on cell-surface PI(4,5)P2 staining. Primary hippocampal 
FXOWXUHVZHUH ODEHOOHGDWÛ&ZLWKD3,32 antibody (Panel A), or a 
PI(4,5)P2 antibody that had been preabsorbed withȝ0GL&3,32  
(approx. 1000x molar excess; Panel B). Insets show enlargement of 
region indicated in white box, but focussed on the surface of the neuron 
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Anti-MAP2, anti-GFAP and anti-PI(4,5)P2 antibodies were incubated with live 
cells and with cells that had been first fixed and permeabilised prior to 
immunolabelling. MAP2 immunoreactivity was not detectable in the live-cell 
labelled cells (Fig. 3.11A), but punctate PI(4,5)P2 immunoreactivity was 
detectable along the dendrites and over the surface of cells (Fig. 3.11C). Cells that 
were fixed and permeabilised prior to antibody labelling were immunoreactive for 
both antibodies (Fig. 3.11B, D). In the fixed/permeabilised cells, the MAP2 
antibody labelled the dendrites and soma of neurons, and intracellular PI(4,5)P2 
immunoreactivity was present in neurons and glia (Fig. 3.11B, D).  
Similarly, GFAP immunoreactivity was not detectable in the live-cell labelled 
cells (Fig. 3.11E), but punctate PI(4,5)P2 immunoreactivity was present on the 
surface of glia (Fig. 3.11G). When cells were fixed and permeabilised prior to 
antibody labelling, GFAP immunoreactivity was present in glia and PI(4,5)P2 
immunoreactivity was present in neurons and glia (Fig. 3.11F, H). Therefore, 
these results demonstrated that PI(4,5)P2 is present on the surface of both neuronal 
and glial cells in the hippocampal cultures.  
3.2.1.2 Biosensor detection of cell-surface PIP 
To confirm the specificity of the staining of PIPs on the cell surface, 
commercially available PIP biosensors were also used. PIP biosensors are 
recombinant glutathione-s-transferase (GST) -tagged PIP-binding domains that 
have been well characterised for their ability to bind selectively to individual PIP 
species. Cells were incubated with a PI(3)P biosensor (recombinant GST-tagged 
PX domain of p40phox; Stahelin et al., 2003), a PI(4)P biosensor (recombinant 
GST-tagged SidC_3C domain; Weber et al., 2006), a PI(4,5)P2 biosensor   
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Figure 3.11. PI(4,5)P2 immunoreactivity is present on the surface of cells in hippocampal 
cultures. Live or fixed/permeabilised primary hippocampal neurons were labelled with 
anti-MAP2, anti-GFAP and anti-PI(4,5)P2 antibodies. DAPI staining is shown in panels 
A,C,E and G. Panels A, C: Extracellular MAP2 and PI(4,5)P2 immunoreactivity of live 
FHOOVODEHOOHGDWÛ&3DQHOV%DQG'VKRZ0$3DQG3,32 immunoreactivity, with 
ODEHOOLQJSHUIRUPHGLQSDUDOOHODWÛ&RQFHOOVWKDWKDYHEHHQIL[HG3)$PLQXWHV
SHUPHDELOLVHGPLQ7ULWRQ;LQ3%6DQGZDVKHGLPPHGLDWHO\SULRUWRODEHO-
OLQJ1RWHWKHFRQWUDVWEHWZHHQSDQHOV$%&'DQG%'LVQRWHTXLYDOHQWDV
intracellular PI(4,5)P2 immunoreactivity is much higher than extracellular PI(4,5)P2 
LPPXQRUHDFWLYLW\ &RQWUDVW EHWZHHQ SDQHOV$  & LV HTXLYDOHQW 3DQHOV (  + VKRZ
HTXLYDOHQWH[SHULPHQWXVLQJDQDQWL*)$3DQWLERG\3DQHOV(*VKRZH[WUDFHOOXODU
GFAP and PI(4,5)P2LPPXQRUHDFWLYLW\RIOLYHFHOOVODEHOOHGDWÛ&3DQHOV)+VKRZ
GFAP and PI(4,5)P2 LPPXQRUHDFWLYLW\ZLWK ODEHOOLQJ SHUIRUPHG LQ SDUDOOHO DW Û&RQ
cells that have been fixed, permeabilised and washed immediately prior to labelling. 
1RWH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(recombinant GST tagged pleckstrin homology domain of phospholipase C-δ1; 
Kavran et al., 1998) or a PI(3,4,5)P3 biosensor (recombinant GST-tagged 
pleckstrin homology domain of general receptor for phosphoinositides-1; Kavran 
et al., 1998). Cells were washed and then cell-bound biosensors were detected 
using an antibody directed against the GST affinity tags attached to the 
biosensors. 
The PI(4,5)P2 biosensor was the only biosensor that was observed to bind to the 
surface of primary neuronal cultures (Fig. 3.12D). The PI(4,5)P2 biosensor 
binding pattern was similar to that observed with the anti-PI(4,5)P2 antibody, as it 
stained cells with a punctate distribution on the surface of both neurons and glia. 
PI(4)P, PI(3)P and PI(3,4,5)P3 biosensors stained the surface of cells poorly, or 
not at all (Fig. 3.12B, C, E). A low-level of biosensor binding was observed using 
the PI(3)P biosensor (Fig. 3.12B). The PI(3,4,5)P3 biosensor had a high 
propensity to bind to extracellular debris, visible as regions of high intensity 
staining (Fig. 3.12E). These data supported the conclusion that PI(4,5)P2 is present 
extracellularly on neuronal and glial cells. Some of the other PIPs may also be 
present on the surface of cells, although the detectable levels of these lipids are 
much lower than PI(4,5)P2. 
3.2.2 Co-localisation of exogenous APP-E1 and cell-surface PI(4,5)P2 
The data presented in Section 3.1 demonstrate that APP-E1 contains a PIP-
binding domain, while the data presented in Section 3.2.1 demonstrate that 
PI(4,5)P2 is present on the surface of hippocampal cells in culture. Therefore, to 
assess whether APP-E1 could bind to PI(4,5)P2 on the neuronal cell surface, the 
distribution of PI(4,5)P2 immunoreactivity, as well as the distribution of the   
Figure 3.12. Detection of cell-surface PIPs using PIP biosen-
sor proteins. Primary hippocampal cultures were incubated 
with 50 nM of each biosensor for 2h at 37°C. Cells were 
washed, and cell-bound biosensors were detected by fluores-
cence immunocytochemistry using an anti-GST antibody 
performed on live cells at 4°C. Insets show enlargement of 
the neuronal soma shown in white boxes, focused on the cell 
surface. Scale bars = 20 µm 
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PI(4,5)P2 biosensor and APP-E1 was examined. First, primary hippocampal 
cultures were incubated with APP-E1, or APP-E1 and the PI(4,5)P2 biosensor. 
Cells were washed and cell-bound APP-E1 was detected using antibodies directed 
against the 6xHis tag and cell-bound PI(4,5)P2 biosensor was detected using an 
antibody directed against the GST tag. Alternatively, the cell-surface PI(4,5)P2 
was labelled using the PI(4,5)P2 antibody.  
A high degree of co-localisation of APP-E1 and PI(4,5)P2 was observed on 
neuronal cells using both the PI(4,5)P2 biosensor and the PI(4,5)P2 antibody (Fig. 
3.13C, F). This co-localisation was confirmed using confocal microscopy (Fig. 
3.14A). APP-E1 bound to neurons with a punctate pattern and PI(4,5)P2 was 
present in small puncta that were highly colocalised with APP-E1 (Fig. 3.13, 
3.14). However, APP-E1 was found to bind only to neuronal cells, whereas 
PI(4,5)P2 immunoreactivity was present both on neurons and on the surface of 
glia in the feeder layer (Fig. 3.13). Taken together the data suggest that APP-E1 
binds to the neuronal cell surface and localises to PI(4,5)P2 micro-domains. The 
data also show that while APP-E1 colocalises with PI(4,5)P2 on neurons, 
PI(4,5)P2 cannot be the sole determinant of APP binding to the cell surface, as 
PI(4,5)P2 was detected on glia where no APP-E1 was bound.  
3.2.3 Competition of APP-E1 binding to cells with diC8PI(4,5)P2 
The data in Section 3.2.2 indicated that PI(4,5)P2 and APP-E1 was co-localised on 
the cell surface of neurons. However, these data also suggested that the binding of 
APP-E1 to PI(4,5)P2 was not sufficient for binding to neurons, as PI(4,5)P2 was 
also detected on glial cells where APP-E1 did not bind.   
Figure 3.13. Co-localisation of PI(4,5)P2 and APP-E1 on the neuronal cell surface. Panels A, 
B, C show APP-E1 immunoreactivity and PI(4,5)P2 immunoreactivity after incubation of 
primary hippocampal cultures with 50 nM APP-E1 for 2h. Panels D, E, F show APP-E1 
immunoreactivity and PI(4,5)P2 biosensor immunoreactivity after incubation of cultures with 
25 nM APP-E1 and 25 nM PI(4,5)P2 biosensor for 2h at 37°C prior to detection of cell-bound 
APP-E1 and cell-bound PI(4,5)P2 biosensor by immunocytochemistry at 4°C. DAPI staining 
of nuclei is shown in panels C and F in blue. The nuclei of glia in the feeder layer are marked 
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Figure 3.14.  APP-E1 co-localises with cell-surface PI(4,5)P2 microdomains. 
Cells were incubated with 50 nM of  APP-E1 (panel A) or PBS (control; 
SDQHO%IRUKRXUVDWÛ&&HOOVZHUHZDVKHGDQGFHOOERXQG$33(
and cell-surface PI(4,5)P2 were detected by immunocytochemistry 
performed at 4Û&([RJHQRXV$33( LV VKRZQ LQJUHHQ DQG FHOOVXUIDFH
PI(4,5)P2  is shown in red.3DQHOV$DQG%VKRZPD[LPXPLQWHQVLW\SURMHF-
tion of a confocal z-stack of primary hippocampal neurons. Insets (A’ - B’’’) 
VKRZLPDJHVRIDVLQJOHDLU\XQLWFRQIRFDOVOLFHRIWKHFHOOVRPDUHJLRQ
LQGLFDWHGLQWKHZKLWHER[IRFXVHGRQWKHFHOOVXUIDFH6FDOHEDUV ȝPRU
ȝPLQLQVHWV
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To further examine the possibility that APP-E1 only binds to PI(4,5)P2 on the cell 
surface, the ability of a water-soluble PI(4,5)P2 analogue (diC8PI(4,5)P2) to 
compete for APP-E1 binding to the cell surface was investigated. APP-E1 (10 
nM) was pre-incubated with 500 µM diC8PI(4,5)P2 for two hours, prior to 
incubation with primary hippocampal cultures. This concentration of 
diC8PI(4,5)P2 was chosen based on the protein-lipid overlay assay data in Fig. 3.4 
and was determined to be sufficient to inhibit the binding of APP to PI(4,5)P2. 
After incubation, cells were washed, and cell-bound APP-E1 was detected using 
an antibody directed against the 6xHis tag.  
The water soluble PI(4,5)P2 analogue did not significantly reduce the binding of 
10 nM APP-E1 to primary hippocampal cultures (Fig. 3.15A, B). Therefore, the 
results did not provide clear evidence that PIPs were the major binding site for 
APP-E1 on the cell surface, as diC8PI(4,5)P2 could not compete for binding of 
APP-E1 to the cell surface. 
3.2.4 Investigation into the role of the heparin-binding domain in the binding of 
APP-E1 to the cell surface 
The APP-E1 recombinant protein also contains an N-terminal heparin-binding 
domain (residues 95 - 110). This heparin-binding domain has been reported to be 
important in the stimulation of neurite outgrowth (Small et al., 1994). 
Furthermore, APP has been demonstrated to bind to heparan sulfate proteoglycans 
such as glypican 1 (Williamson et al., 1996). Therefore, the cell surface receptor 
for APP could be a heparan sulfate proteoglycan. As the results in Sections 3.2.2 
and 3.2.3 indicated that PIPs might not be the main binding site for APP-E1 on 
the cell surface, the role of the heparin-binding region in cell-surface binding by 
APP-E1 was investigated.   
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Figure 3.15. Incubation of APP-E1 with diC8PI(4,5)P2 has no effect on APP-E1 
binding to hippocampal neurons. Primary hippocampal cultures were incubated 
ZLWK $33(  Q0 IRU  KRXUV DW & LQ WKH SUHVHQFH RI  ȝ0
diC8PI(4,5)P2 or PBS (control) prior to detection of cell-bound APP-E1 by immu-
nocytochemistry performed at 4°C. Panel A shows representative images of 
$33(LPPXQRUHDFWLYLW\,56FDOHEDUV ȝP3DQHO%VKRZVTXDQWLILFD-
tion of cell-bound APP-E1 immunoreactivity. Bars show mean ± SEM cell-bound 
APP-E1 immunoreactivity expressed as a percentage of control determined from 
30 fields per treatment group. n.s. - Data not significantly different between treat-
ment groups determined by Students t-test (p > 0.05)
Control
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To investigate whether the heparin-binding domain in APP-E1 could facilitate the 
binding of APP-E1 to cells, primary hippocampal cultures were incubated with 
APP-E1 in the presence or absence of a large excess of mucosal heparin. Cells 
were washed and cell-bound APP-E1 was detected by immunocytochemistry. 
Mucosal heparin (100 µg mL-1) significantly reduced the amount of APP-E1 
immunoreactivity associated with cells (Fig. 3.16). The concentration of mucosal 
heparin that blocked binding to cells was not sufficient to block binding to 
PI(4,5)P2 in the protein-lipid overlay assay (Fig. 3.4). This indicated that the 
heparin-binding region and the PIP-binding region on APP-E1 may be distinct, 
and that the heparin-binding region is required for binding to the cell surface. 
To investigate whether APP-E1 can bind to endogenous cell-surface heparan 
sulfate proteoglycans, the effect of removal of endogenous heparan sulfate on the 
ability of APP-E1 to bind to the cells was investigated. Primary hippocampal 
cultures were incubated with heparitinase, prior to incubation with APP-E1. Cells 
were washed and APP-E1 was detected using an antibody against the 6xHis tag. 
Heparitinase treatment significantly reduced the amount of cell-surface heparan 
sulfate immunoreactivity (Fig. 3.17A, C). However, removal of endogenous 
heparan sulfate with heparitinase did not affect the amount of APP-E1 that bound 
to cells (Fig. 3.17B, D). As endogenous heparan sulfate was present on cells in the 
glial feeder layer where APP-E1 did not bind, this also suggested that heparan 
sulfate proteoglycans do not represent the major binding site for APP-E1 (Fig 
3.17A). Together the results suggested that the heparin-binding domain in APP-
E1 is involved in the binding of APP-E1 to the cell surface, however the heparin-
binding domain of APP-E1 may not bind to a heparan sulfate proteoglycan on the 
cell surface. This data suggests that there may be another type of receptor on the 
surface of neurons that is responsible for binding to APP. 
050
100
150
 A
PP
-E
1 
I.R
.
(%
 c
on
tro
l)
*
MH - +
Figure 3.16. Incubation of APP-E1 with mucosal heparin (MH) blocks 
the binding of APP-E1 to cells. APP-E1 (25 nM) was incubated with 
ȝJP/-1 MH or PBS control for 1h in cell culture medium, prior to 
LQFXEDWLRQZLWK SULPDU\ KLSSRFDPSDO QHXURQV IRU K DW Û& &HOOV
were then washed and cell-bound APP-E1 was detected by immunocy-
WRFKHPLVWU\DWÛ&3DQHO$VKRZVUHSUHVHQWDWLYHLPDJHVRIFHOOERXQG
$33(LPPXQRUHDFWLYLW\6FDOHEDUV ȝm. Panel B shows quanti-
ILFDWLRQ RI  FHOOERXQG$33( LPPXQRUHDFWLYLW\PHDVXUHG IURP
ILHOGV%DUV VKRZPHDQ6(0$33( LPPXQRUHDFWLYLW\ SHU ILHOG
expressed as a percentage of control.  *Statistically significant as deter-
mined by Student’s t-test (p < 0.05).
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Figure 3.17. Heparitinase treatment does not affect APP-E1 binding to 
cells. Cells were treated with or without 0.8 mU ML-1 heparitinase I (Hep. I) 
for 24 hours, prior to incubation with 25 nM APP-E1 for 2 hours at 37ºC. 
Cells were washed and cell-surface heparan sulfate (HS) and cell-bound 
APP-E1 was detected using immunocytochemistry performed at 4ºC. 
Panels A and B show representative images of the effect of heparitinase 
treatment on cell-surface heparan sulfate immunoreactivity (I.R.) and corre-
sponding effect of heparitinase treatment on cell-bound APP-E1 I.R. Scale 
bars = 20 µm. Panels E + F show quantification of the effect of heparitinase 
treatment on HS I.R. and APP-E1 I.R. measured from 60 fields. Bars show 
mean ± SEM I.R. expressed as a percentage of untreated controls. *Statisti-
cally significant as determined by Student’s t-test (p < 0.05).
 131 
3.3 Studies on the biological effects of APP-PIP interactions 
3.3.1 Effect of sAPPα on PIP levels in primary cortical cultures 
Many important cellular signalling mechanisms are reliant on changes in the 
levels of PIPs, for example calcium signalling (Lapetina and Michell, 1973) and 
PI3K/Akt signalling (Watton and Downward, 1999; Andjelkovic et al., 1997). 
Therefore, changes to levels of PIPs could potentially result in effects on cellular 
signalling pathways. As APP was found to bind to PI(4,5)P2, it was hypothesised 
that APP might be able to affect levels of cellular PIPs. Therefore, the effect of 
sAPPα treatment on total cellular levels of PIPs was assessed.  
In order to examine the effect of APP on PIPs, a mass spectrometry (MS) method 
was used. The principle of this technique is that PIP lipids can be extracted from 
cells using an acidified-chloroform extraction (Ivanova et al., 2007; Ogiso and 
Taguchi, 2008; Pettitt, 2010). PIPs can then be separated by reverse-phase ultra 
performance liquid chromatography (UPLC), which allows for the rapid 
chromatographic separation of PIPs. PIPs can be selectively identified from a 
complex cellular extract using electrospray MS with selective ion monitoring 
(SIM; Ogiso and Taguchi, 2008). In selective ion mode, the MS detector only 
measures ions at selected m/z, which results in significantly greater sensitivity 
that full scan-based MS. Quantification of the relative levels of PIPs can then be 
inferred by integration of the chromatographic elution peaks. Theoretically, this 
approach allows for the detection of different acyl chain species of PIP, and also 
the different phosphorylated isoforms, e.g. PIP vs. PIP2 vs. PIP3. However, this 
method does not allow for the quantitative determination of individual PIP 
regioisomers, as these have identical mass (Pettitt, 2010).  
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To achieve chromatographic separation of PIPs by reversed phase UPLC on a 
C18 column, a mixture containing non-natural acyl chain 37:4 PI(3)P, 37:4 
PI(3,4)P2 and 37:4 PI(3,4,5)P3 standards was first analyzed. Lipids in the eluate 
were detected by SIM. The solvent system gave good chromatographic separation 
of each one of the standards in the mixture. Elution peaks for each of the 37:4 
PI(3)P, 37:4 PI(3,4)P2 and 37:4 PI(3,4,5)P3 standards were detected at the 
appropriate m/z and eluted at 6.52 min, 5.90 min and 5.63 min respectively (Fig. 
3.18). There was a small elution peak detected at 5.63 min in the 37:4 PI(3,4)P2 
and 37:4 PI(3)P channels, which was attributed to an in-source fragmentation 
product of the 37:4 PI(3,4,5)P3 standard (Fig. 3.18B).  
To determine if cellular PIPs could be detected using UPLC-MS with SIM, lipids 
were extracted from cultures using an acidified-chloroform extraction. As large 
numbers of cells were needed, cultures from the whole cortex were used instead 
of hippocampal cultures. Synthetic non-naturally occurring 37:4 PI, 37:4 PI(3)P, 
37:4 PI(3,4)P2 and 37:4 PI(3,4,5)P3 were added as internal standards to the cell 
extracts to correct for differences in the efficiency of the extraction procedure. PI, 
PIP and PIP2 species were all detectable in the primary cortical neuron extracts 
(Fig. 3.19, Fig. 3.20, Fig. 3.21). The retention times for different acyl chain 
species followed a clear pattern consistent with the number of carbons and 
saturation, for example different PIP acyl chain species eluted from the column in 
the order 38:5, 38:4, 38:3, corresponding to the degree of saturation (Fig. 3.20 C, 
B, A). The amount of PIP that was detectable was approximately inversely 
correlated to the degree of phosphorylation. For example, the SIM intensity was 
an approximately an order of magnitude lower for PIP2 (in the 104 range) than for 
PIP (in the 105 range; e.g. Fig. 3.20C vs. 3.21C). Natural PIP3 species were not 
detectable using this method (data not shown), in agreement with previous studies 
(Ogiso and Taguchi, 2008; Ogiso et al., 2010; Pettitt, 2010).   
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Figure 3-18. Separation of a mixture of non-natural 37:4 PIP standards by reverse 
SKDVH83/&DQGGHWHFWLRQE\06ZLWK6,0$VROXWLRQFRQWDLQLQJȝJPL-1 of 
each PIP standard was subjected to reverse phase UPLC on a C18 column (2.1 x 
100 mm x 1.7 µm particles). The column was eluted with an initial isocratic 
mobile phase mixture of 90% A: 10% B for 1 minute followed by a linear gradient 
to 0% A: 100% B over 9 minutes. PIPs were detected by SIM of the mass to 
charge ratios (m/z) indicated on the right. Chromatograms A, B and C show 
elution peaks for 42 pmol 37:4 PI(3,4,5)P3, 46 pmol 37:4 PI(3,4)P2 and 50 pmol 
37:4 PI(3)P standards respectivelyVHSDUDWHGIURPDVLQJOHȝ/LQMHFWLRQ7KH\
axis shows SIM current intensity, expressed as a % of the maximum SIM current 
intensity for each m/z ion, which is indicated on the right.
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Figure 3.19. Chromotagraphic separation and SIM detection of PI species 
extracted from primary cortical cultures. Lipid extracts were subjected to reverse 
phase UPLC on a C18 column (2.1 x 100mm x 1.7 micron particles). The column 
was eluted with an initial isocratic mobile phase mixture of 90% A: 10% B for 1 
minute followed by a linear gradient to 0% A: 100% B over 9 minutes. PIPs were 
detected by SIM of the mass to charge ratios (m/z) indicated on the right. Chro-
matograms A - E show the results obtained from analysis of a 10 µL injection of 
lipids extracted from 1x106 cells. Each chromatogram shows SIM monitoring of an 
individual PI acyl chain species. Chromatogram E is the 37:4 PI internal standard 
which represents 10 pmol of standard assuming perfect extraction. The y axis 
shows SIM current intensity, as a % of the maximum SIM current intensity for 
each m/z ion, which is indicated on the right.  
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Figure 3.20. Chromatographic separation and detection by SIM of PIP species 
extracted from primary cortical cultures. Lipid extracts were subjected to reverse 
phase UPLC on a C18 column (2.1 x 100 mm x 1.7 µm particles). The column was 
eluted with an initial isocratic mobile phase mixture of 90% A: 10% B for 1 minute 
followed by a linear gradient to 0% A: 100% B over 9 minutes. PIPs were detected by 
SIM of the mass to charge ratios (m/z) indicated on the right. Chromatograms  A - E 
show the results obtained from analysis of a 10 µL injection of lipids extracted from 
1x106 cells. Each chromatogram shows SIM monitoring of an individual PIP acyl 
chain species. Chromatogram E is the 37:4 PI(3)P internal standard which represents 
10 pmol of standard assuming perfect extraction. The y axis shows SIM current inten-
sity, expressed as a % of the maximum SIM current intensity for each m/z ion, which 
is indicated on the right.  
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Figure 3.21. Chromatographic separation and SIM detection of PIP2 species extracted 
from primary cortical cultures. Lipid extracts were subjected to reverse phase UPLC on 
a C18 column (2.1 x 100mm x 1.7 µm particles). The column was eluted with an initial 
isocratic mobile phase mixture of 90% A: 10% B for 1 minute followed by a linear 
gradient to 0% A: 100% B over 9 minutes. PIP2 species were detected by SIM of the 
mass to charge ratios (m/z) indicated on the right. Chromatograms  A - E show the 
results obtained from analysis of a 10 µL injection of lipids extracted from 1x106 cells. 
Each chromatogram shows SIM monitoring of an individual PIP2 acyl chain species. 
Chromatogram E is the 37:4 PI(3,4)P2 internal standard which represents 10 pmol of 
standard assuming perfect extraction. The y axis shows SIM current intensity, as a % of 
the maximum SIM current intensity for each m/z ion, which is indicated on the right.       
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The area for each elution peak was then measured to calculate the levels of 
individual PIPs in the cell extracts (Table 3-1). The PI, PIP, PIP2 internal 
standards were added to lipid extracts at the same molar amounts (50 pmol), but 
were not recovered at the same levels (Table 3-1). This suggested that the PIP and 
PIP2 species may undergo degradation during the lipid extraction process. 
Therefore, levels of PIPs in the cell extracts were corrected to the level of the 
internal standard, to calculate the amount of PIPs in pmol per million cells (Ogiso 
and Taguchi, 2008). The 38:4 and 38:3 PIPs were the most abundant acyl chain 
species of PIPs in the primary cortical cultures (Table 3-1). The amount of each 
acyl chain species was summed to estimate the total levels of PIPs in the cells, 
which was 143.7±14.1 pmol PIP 106 cells-1 and 127.1±25.5 pmol PIP2 106 cells-1 
(Table 3-1). The level of PIP and PIP2 species was approximately an order of 
magnitude below that of PI, which was present at 1010.81±55 pmol PI 106 cells-1 
(Table 3-1). 
To confirm that the assay could detect changes in levels of cellular PIPs, the effect 
of wortmannin on PIP levels was assessed. Wortmannin is a potent inhibitor of 
PI3K and at higher concentrations can inhibit PI4K (Arcaro and Wymann, 1993; 
Yano et al., 1993). Both PI3K and PI4K are essential for the production of PIP. 
Therefore, wortmannin treatment would be expected to cause a reduction in the 
levels of 3-phosphorylated and 4-phosphorylated PIPs. Primary cortical cells were 
treated with a high concentration (10 µM) of wortmannin for 30 min prior to 
extraction of lipids and analysis by UPLC-MS. The primary cultures treated with 
wortmannin had lower levels of PIP and PIP2 relative to vehicle-treated control 
cultures (Fig. 3.22). In contrast, the level of PI was unaffected by wortmannin 
treatment as expected (Fig. 3.22). Therefore, it was concluded that the assay 
method was appropriate for measuring changes in levels of cellular PIPs extracted 
from primary cortical cultures.   
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Table 3-1 Levels of PIPs in mouse primary cortical cultures 
 PI PIP  PIP2 
Acyl 
chain 
isoform 
Raw elution 
intensity 
Arb. Unit. 
(±SD) 
Corrected 
mean pmol 
lipid/106 cells 
(±SD) 
Raw elution 
intensity 
Arb. Unit. 
(±SD) 
Corrected 
mean pmol 
lipid/106 cells 
(±SD) 
Raw elution 
intensity 
Arb. Unit. 
(±SD) 
Corrected 
mean pmol 
lipid/106 cells 
(±SD) 
37:4 
Standard 
21.04 (3.9) 50.00 8.22 (1.6) 50.00 1.01 (0.2) 50.00 
36:4 60.76 (9.8) 144.92 (6.4) 3.08 (0.6) 18.86 (2.1) n.d. n.d. 
38:5 47.98 (7.0) 114.65 (7.3) 2.60 (0.5) 15.96 (1.8) n.d. n.d. 
38:4 235.40 (36.4) 562.12 (36.2) 15.40 (2.4) 94.44 (9.1) 2.01 (0.4) 99.58 (17.3) 
38:3 80.06 (20.1) 189.13 (21.6) 2.39 (0.7) 14.47 (2.3) 0.57 (0.2) 27.61 (17.8) 
Total 424.20 (67.8) 1010.81(55.4) 23.47 (4.1) 143.74 (14.1) 2.59 (0.7) 127.19 (25.5) 
 
PIPs were measured in primary cortical culture lipid extracts by UPLC-MS. Each value 
represents mean (± SD) derived from 12 replicates. Mean raw elution intensities, calculated 
from the mass chromatogram elution peak area for each lipid are shown, including the PIP 
internal standards. There were significant differences in the recovery of PI, PIP and PIP2 
internal standards suggesting some degradation of PIP and PIP2 throughout lipid extraction 
and measurement (shown in bold, p > 0.05, 1-way ANOVA). Levels of PIPs were corrected 
to the amount of internal standards according to the formula: (raw elution intensity / internal 
standard elution intensity) x (total lipid extract volume / injection volume) to calculate the 
amount of lipid in pmol per million cells. n.d. = lipid was not detectable at measurable levels. 
 
  
Figure 3.22. Wortmannin reduced the levels of PIP and PIP2 in 
primary cortical cultures.  Primary cortical neurons were treated with 
ȝ0ZRUWPDQQLQRUYHKLFOH'062FRQWUROIRUPLQXWHVSULRUWR
OLSLGH[WUDFWLRQDQGDQDO\VLVE\83/&063,3Lnternal standards 
were used to correct for differences in extraction efficiency between 
samples. Graph shows the total amounts of PI, PIP and PIP2 species, 
expressed as a percentage of the control. Bars show mean lipid level  ± 
6(0GHWHUPLQHG IURP UHSOLFDWHZHOOVFRQWDLQLQJ[cells per 
WUHDWPHQWJURXS6WDWLVWLFDOO\VLJQLILFDQWDVGHWHUPLQHGXVLQJLQGL-
YLGXDO6WXGHQW¶VWWHVWVS
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As the UPLC-MS method was determined to be suitable for measuring levels of 
total PIPs in the primary cortical cultures, the effect of sAPPα treatment was then 
investigated. Cells were treated with sAPPα for 72 hours prior to the extraction of 
lipids and measurement of PIPs. However, no significant effect of sAPPα was 
found on levels of PI or on the levels of PIP or PIP2 in the cultures (Fig. 3.23). 
Therefore, the results suggested that total levels of PIP and PIP2 in primary 
cortical cultures were unaffected by sAPPα treatment. 
3.3.2 Effect of APP-E1 on levels of cell-surface PIP  
Many functions of PIPs in the cell are highly localised to specific membrane 
compartments and possibly also to distinct lateral domains within the membrane 
(Di Paolo and De Camilli, 2006; Posor et al., 2013; Khuong et al., 2013). 
Therefore, APP binding to PIPs could theoretically produce small, rapid changes 
in the levels of PIPs that would not be detectable by measuring the total cellular 
levels of PIPs. The experiments described in Section 3.2.2 reported evidence for 
discrete PI(4,5)P2 domains on the cell surface, and APP-E1 was found to localise 
to these domains. Therefore, the possibility that APP-E1 could affect the amount 
of PIPs on the cell surface was also examined.  
3.3.2.1 Effect of APP-E1 on cell-surface PI(4,5)P2 
The data in Section 3.2.1 showed that PI(4,5)P2 was on the surface of primary 
hippocampal cultures. To examine whether APP-E1 can alter the level of cell-
surface PI(4,5)P2, cells were incubated with APP-E1 and the level of PI(4,5)P2 
immunoreactivity was measured. In the presence of APP-E1, there was a 
significantly higher level of PI(4,5)P2 immunoreactivity observed on the surface 
of neurons, but not on glia (Fig. 3.24A, C). As APP-E1 binds selectively to the 
neurons in the hippocampal cultures (Section 3.2), this suggests that the effect 
was due to the binding of APP-E1 to the cell surface.  
Figure 3.23. sAPPĮGRHVQRWDIIHFW WRWDO3,3 OHYHOV LQSULPDU\
FRUWLFDOFXOWXUHV3ULPDU\FRUWLFDOFXOWXUHVZHUHWUHDWHGZLWKQ0
V$33Į RU 3%6 FRQWURO IRU K SULRU WR OLSLG H[WUDFWLRQ DQG
DQDO\VLVE\83/&06,QWHUQDOVWDQGDUGVZHUHXVHGWRFRUUHFWIRU
GLIIHUHQFHV LQ H[WUDFWLRQ HIILFLHQF\ EHWZHHQ VDPSOHV *UDSKV
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Figure 3.24. APP-E1 increases cell-surface PI(4,5)P2 immunoreactivity, but 
decreases PI(4,5)P2 biosensor binding. Panel A and C: Primary hippocampal 
FXOWXUHVZHUHLQFXEDWHGZLWKQ0$33(RU3%6FRQWUROIRUKRXUVDWÛ&
prior to labelling with the PI(4,5)P2 DQWLERG\DWÛ&3DQHO$VKRZVUHSUHVHQWD-
tive image of PI(4,5)P2 immunoreactivity. Panel C shows quantification of 
PI(4,5)P2 immunoreactivity (I.R.) from 60 fields. Panels B and D: Primary 
hippocampal cultures were incubated with 25 nM APP-E1 or PBS control and 
25 nM PI(4,5)P2 biosensor for 2 hours at 37ºC prior to labelling of cell-bound 
biosensor by immunocytochemistry at 4ºC. Panel B shows representative image 
of PI(4,5)P2 biosensor immunoreactivity. Panel D shows quantification of cell 
bound PI(4,5)P2  biosensor immunoreactivity from 60 fields. Bars show mean ± 
SEM I.R. Statistical significance determined using Student’s t-tests. * = Signifi-
cantly different from PBS control p < 0.05. Scale bars = 10 µm.  
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Despite the previous result, it was not possible to reproduce the effect of APP-E1 
on PI(4,5)P2 when a biosensor was used to measure the PIP levels (Fig. 3.24B, D). 
In contrast to the result with the PI(4,5)P2 antibody, the amount of PI(4,5)P2 
biosensor that bound to cells decreased in the presence of APP-E1 (Fig. 3.24D). 
As the PI(4,5)P2 antibody was incubated with cells after APP-E1 treatment, but 
the PI(4,5)P2 biosensor was incubated at an equal concentration as APP-E1 and at 
the same time, it was hypothesised that the PI(4,5)P2 biosensor could compete 
with APP-E1. To investigate this possibility, the binding of APP-E1 to cells was 
assessed in the presence of a 10-fold molar excess of the PI(4,5)P2 biosensor. 
Under these conditions, it was observed that the amount of APP-E1 that bound to 
cells was significantly reduced by the excess of the PI(4,5)P2 biosensor (Fig. 
3.25). Therefore, these results supported the conclusion that the PI(4,5)P2 
biosensor and APP-E1 can compete for PI(4,5)P2 binding to the cell surface. This 
result explained why an increase in cell-surface PI(4,5)P2 after incubation with 
APP-E1 was only observed using the antibody and not the PI(4,5)P2 biosensor. 
Presumably, the PI(4,5)P2 biosensor present in an excess can obstruct the binding 
of APP-E1 to the cell surface. 
3.3.2.2 Effect of APP-E1 on cell-surface PI(3,4,5)P3 
As there was an increase in the levels of PI(4,5)P2 immunoreactivity in the 
presence of APP-E1 (Section 3.3.2.1), the possibility that APP-E1 might affect the 
levels of other PIPs was investigated. Although the experiments described in 
Section 3.2.1 indicated that PI(3)P, PI(4)P, PI(3,4)P2 and PI(3,4,5)P2 were not 
present at detectable levels on the cell surface under resting conditions, it seemed 
possible that APP-E1 might increase levels of PIPs on the cell surface.   
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Figure 3.25. A molar excess of the PI(4,5)P2 biosensor decreases 
APP-E1 binding to cells. Primary hippocampal cultures were incu-
bated with 100 nM PI(4,5)P2 biosensor and 10 nM APP-E1 for 2 
hours at 37°C, and cell-bound APP-E1 was detected using immuno-
cytochemistry at 4°C. Scale bars = 10 µm. Graphs show quantifica-
tion of cell bound APP-E1 immunoreactivity (I.R.), derived from 30 
fields per treatment. Bars show mean ± SEM APP-E1 I.R. Statisti-
cal significance determined using Student’s t-test (*p < 0.05).
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To examine whether APP binding to the cell surface could alter the levels of other 
cell-surface PIPs, the binding of the PI(3)P biosensor, the PI(4)P biosensor and 
the PI(3,4,5)P3 biosensor was examined in the presence or the absence of APP-E1. 
Neither the PI(4)P biosensor nor the PI(3)P biosensors bound to cells in the 
presence or absence of APP-E1 (Fig. 3.26). However, an increase in the binding 
of the PI(3,4,5)P3 biosensor to neurons was observed in the presence of APP-E1 
(Fig. 3.27). The cell-bound PI(3,4,5)P3 biosensor was highly co-localised with 
APP-E1 on the surface of neurons in puncta <1 µm (Fig. 3.27). This effect was 
not due to non-specific cross-reaction of the anti-6xHis antibody with the anti-
GST antibody as the APP-E1-only control showed staining in the APP-E1 channel 
but no other channels (Fig. 3.27B, E). Neither was the effect due to spectral 
overlap or bleedthrough, because the increase in neuronal PI(3,4,5)P3 biosensor 
immunoreactivity was also observed when APP-E1 was not detected using 
antibodies (Fig. 3.28). However, quantification of pixel intensities was not 
possible, because the PI(3,4,5)P3 biosensor had a propensity to bind to 
extracellular debris (Fig. 3.28A, 3.12E). The high intensity staining of the 
extracellular debris obscured measurement of the increase in PI(3,4,5)P3 biosensor 
observed on neurons in the presence of APP-E1. Despite repeated attempts to 
optimise the experimental conditions to reduce the amount of extracellular debris, 
this issue could not be resolved. 
Instead, the same experimental paradigm was performed using an antibody to 
detect the cell surface PI(3,4,5)P3. The PI(3,4,5)P3 antibody did not label cells in 
the absence of APP-E1 and there was minimal non-specific binding to 
extracellular debris (Fig. 3.28B). When APP-E1 was added, cell surface 
PI(3,4,5)P3 immunoreactivity was observed on neurons (Fig. 3.28B).   
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Figure 3.27. Exogenous APP-E1 induces an increase in cell-surface 
PI(3,4,5)P3. Panels A - I show confocal slice of primary hippocampal 
cultures treated with APP-E1 (50 nM) or PBS control and/or PI(3,4,5)P3 
biosensor (50 nM) for 2 h at 37°C. Cells were washed and cell-bound 
APP-E1 and cell-bound PI(3,4,5)P3 biosensor were detected by immuno-
cytochemistry performed at 4°C. Insets show enlargement of cell-soma 
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Figure 3.28. APP-E1 increases PI(3,4,5)P3 biosensor and PI(3,4,5)P3 antibody 
binding to primary hippocampal cells. Panel A: Primary hippocampal cultures 
were incubated with 50 nM APP-E1 or PBS control and 50 nM PI(3,4,5)P3 biosen-
sor for 2 hours at 37°C prior to labelling of cell-bound PI(3,4,5)P3 biosensor at 4°C 
by immunocytochemistry. Panels B, C: Primary hippocampal cultures were 
treated with 25 nM APP-E1 or PBS control for 2 hours at 37°C prior to labelling 
with a PI(3,4,5)P2 antibody at 4°C. Panel C shows quantification of PI(3,4,5)P2 
immunoreactivity from 30 fields. Bars show mean ± SEM PI(4,5)P2 immunoreac-
tivity. Statistical significance determined using a Student’s t-test. *Significantly 
different from control, p < 0.05. Scale bars = 20 µm.  
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Quantification of pixel intensities confirmed that the presence of APP-E1 
significantly increased the amount of PI(3,4,5)P3 immunoreactivity (Fig. 3.28C). 
Therefore, these data suggest that the binding of APP-E1 to the cell surface 
induces an increase in the level of cell-surface PI(3,4,5)P3.  
3.3.3 Effect of APP-E1 on Akt phosphorylation 
Many cellular signalling pathways are dependent on PIPs (Di Paolo and De 
Camilli, 2006). One such pathway is the PI3K/Akt pathway, which is activated by 
growth factors such as PDGF, NGF and IGF-1, all of which bind to receptors on 
the cell surface (Franke et al., 1995; Park et al., 1996; Kulik et al., 1997). 
Receptor activation by these growth factors results in activation of PI3K, which 
produces PI(3,4,5)P3 (Franke et al., 1995; Park et al., 1996; Kulik et al., 1997). 
The production of PI(3,4,5)P3 results in the downstream phosphorylation of Akt, 
which can be measured using phospho-specific antibodies (Andjelkovic et al., 
1997). APP N-terminally truncated species similar to the APP-E1 recombinant 
protein used in this study have also been reported to exist in the brain (Vella and 
Cappai, 2012). Therefore, it was hypothesised that APP-E1 might induce an 
increase in cell-surface PI(3,4,5)P3, which might result in a change in Akt 
phosphorylation. 
To examine the effect of APP-E1 on Akt phosphorylation, primary cortical 
neurons were treated with APP-E1, proteins were extracted and the 
phosphorylation state of Akt was investigated by western blotting. Two anti-Akt 
antibodies were used, a phospho-specific antibody that only detects Akt that is 
phosphorylated at the serine 473 position, and a pan Akt antibody that detects 
total Akt. The ratio of the pAkt473/total Akt was used to indicate changes in the 
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phosphorylation state of Akt. The PI3K inhibitor wortmannin was used as a 
negative control (Arcaro and Wymann, 1993), and insulin was used as a positive 
control because insulin receptor activation results in the phosphorylation of Akt 
(Kulik et al., 1997). As the B27 supplement routinely used to culture these cells 
contains insulin, cultures were grown in the absence of B27 supplement for two 
hours prior to treatment.  
There was a significant increase in the pAkt:total Akt ratio for the insulin-treated 
positive control cells, and a significant decrease in the pAkt:total Akt ratio in 
wortmannin treated negative control cells, which demonstrated that the assay was 
suitable for assessing Akt phosphorylation in primary cortical neurons (Fig. 3.29). 
However, there was no effect of APP-E1 on the pAkt:total Akt ratio after two 
hours APP-E1 treatment (Fig. 3.29). Therefore, the results did not support the 
hypothesis that the up-regulation of PI(3,4,5)P3 observed on the cell surface after 
two hours of APP-E1 treatment would coincide with an increase in the 
phosphorylation state of Akt.   
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Figure 3.29. APP-E1 treatment does not affect the phosphorylation of 
Akt at residue 473. Primary cortical cultures were deprived of B27 
supplement for 2 hours prior to incubation with a combination of 25 
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were lysed and Akt phosphorylation was analysed by western blot-
ting. Bars show mean ± SEM ratio of phospho (p) Akt-473 immunore-
activity / total Akt immunoreactivity, derived from 4 replicate wells 
containing 1 x 106 cells each. Statistical significance was determined 
by one-way ANOVA with Dunnett’s post-hoc test. * Statistically 
different from untreated control (p < 0.05).  
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Chapter 4 Discussion and conclusions 
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4.1 Summary of results 
The experiments presented in this thesis provide a number of novel conclusions 
relating to the biological interactions of APP and the role of PIPs in cell 
signalling. APP was found to contain a PIP-binding domain. This domain was 
located in the N-terminal E1 region of APP. The presence of the E1 PIP-binding 
domain was demonstrated by the experiments that showed that sAPPα and APP-
E1 selectively bound to PIPs in the protein-lipid overlay assay (Fig 3.2, 3.1). Both 
sAPPα and APP-E1 did not bind to any major lipid species such as 
phosphatidylinositol, phosphatidylglycerol or phosphatidylethanolamine. 
Furthermore, the binding of APP-E1 to PI(4,5)P2 could be reduced by competition 
with a water soluble analogue of PI(4,5)P2 (Fig. 3.4A). This demonstrated 
specificity of the interaction of the APP E1 domain with PI(4,5)P2. Computational 
modelling using the crystal structure of the E1 domain suggested that there could 
be at least two energetically favourable possible binding sites for IP3 on the APP 
E1 domain (Fig. 3.5). Therefore, these data suggest that the E1 domain of APP is 
a bona-fide PIP-binding domain. 
The data also suggested that the E1 domain of APP is sufficient for targeting 
secreted forms of APP to the cell surface. The APP-E1 recombinant protein bound 
selectively to neurons and not to glia (Fig 3.8). APP-E1 bound to the surface of 
neurons with a punctate distribution, in puncta less than 1 µm in size (Fig 3.8). 
Therefore, the lack of APP-E1 binding to glial cells suggested that the E1 domain 
of APP interacts with a particular binding site that is only found on neurons (Fig. 
3.8).  
 154 
The results also demonstrate that mouse hippocampal cells possess discrete 
domains on the cell surface that are rich in PIP lipids, which were detected using 
specific monoclonal antibodies and biosensor proteins (Section 3.2.1). These PIP 
domains had a punctate distribution over the surface of neurons and glia, and were 
less than 1 µm in size. APP-E1 bound to neurons and was highly co-localised with 
the cell-surface PI(4,5)P2 domains (Fig. 3.14 and 3.13). These data suggested that 
APP interacts with PI(4,5)P2 on the surface of neurons. However, the results also 
suggested that the binding of APP to PI(4,5)P2 was not sufficient for binding to 
cells. This insufficiency was evident as PI(4,5)P2 was also present on glial cells to 
which APP-E1 did not bind (Fig. 3.13). Furthermore, the binding of APP to the 
surface of cells could not be reduced using competition with a water soluble 
PI(4,5)P2 analogue (Fig 3.15). Therefore, the interaction of APP-E1 with cell-
surface PI(4,5)P2 was not sufficient to explain why APP-E1 binds to the cell 
surface.  
Instead, the results suggest that APP may interact not only with PIP on the cell 
surface, but also another cell-surface component, which binds to the heparin-
binding site. Heparin could block the binding of APP-E1 to the cell surface (Fig. 
3.16), but not the binding of APP-E1 to PI(4,5)P2 in the protein-lipid overlay 
assay (Fig. 3.4). This suggested that the heparin-binding domain was sufficient for 
binding to cells and was distinct from the PIP-binding domain. However, 
heparitinase treatment of cells, which significantly reduced cell surface heparan 
sulfate immunoreactivity, did not affect the binding of APP-E1 to cells (Fig. 
3.17). This evidence, along with the high specificity of APP-E1 binding to 
particular cells, suggested that APP-E1 might bind to a specific cell-surface 
receptor that is not heparan sulfate.  
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As the data suggest that the PIP-binding domain in APP-E1 does not determine 
the binding of APP-E1 to cells, it is possible that the PIP-binding site may be 
involved in eliciting another biological function. Many cellular signalling 
pathways are PIP-dependent; therefore, it was hypothesised that changes in the 
levels of PIPs may reflect a biological action of APP. To determine if APP could 
affect levels of PIPs, the effect of sAPPα on levels of total PIPs was examined 
and the effect of APP-E1 on levels of cell-surface PIPs was also examined. No 
effect of sAPPα was found on total cellular levels of PIP. However, the binding of 
APP-E1 to the cell surface increased the levels of cell-surface PI(4,5)P2 (Fig. 
3.24) and cell-surface PI(3,4,5)P3 (Fig. 3.27). The increase in cell-surface PIP was 
highly localised to where APP-E1 bound to neurons (Fig. 3.27). This suggests that 
the effect was due to the binding of APP-E1 to the cell surface. Therefore, APP-
E1 may bind to the neuronal cell surface and alter the levels of PIPs. 
To investigate whether APP-E1 could affect a known PI(3,4,5)P3-dependent 
signalling pathway, the effect of APP-E1 on Akt phosphorylation was examined. 
In these experiments, APP-E1 was not found to effect the phosphorylation of Akt 
(Fig 3.29) after two hours APP-E1 treatment. This data suggested that two hours 
APP-E1 treatment does not activate the PI3K/Akt signalling pathway. Therefore, 
binding of APP to cell surface PIPs may alter other cellular signalling pathways.  
These results support the existence of a PIP-binding domain in the E1 domain of 
APP. The data also suggest the presence of a specific receptor for APP, that is not 
heparan sulfate, which binds to APP via the heparin-binding site. The PIP-binding 
site may facilitate the binding of APP to the cell-surface receptor, or hold a 
functional role by modulating cell-surface PIP levels.   
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4.2 Discussion 
APP has been a subject of intense investigation since it was first cloned in 1987 
(Kang et al., 1987). APP is intimately involved in the pathogenesis of Alzheimer’s 
disease as it is the precursor of Aβ, the protein that is deposited in the AD brain to 
form amyloid plaques (Glenner and Wong, 1984; Masters et al., 1985; Selkoe et 
al., 1986). Despite much research into the biosynthesis, structure and metabolism 
of APP, the normal function of APP is unresolved. Importantly, understanding the 
biological function of APP will give insight into systems that are perturbed in AD, 
and will also be important for assessing possible off-target effects for AD 
treatments that target APP processing. 
Numerous studies suggest that APP is likely to have an important physiological 
function. Many studies suggest that the major secreted form of APP (sAPPα) may 
mediate some of these functions. For example, sAPPα is able to act in a 
neurotrophic and a neuritotrophic manner (Chasseigneaux et al., 2011; Gakhar-
Koppole et al., 2008; Milward et al., 1992; Jin et al., 1994; Ninomiya et al., 1994; 
Wallace et al., 1997; Hoffmann et al., 2000; Pietrzik et al., 1998; Saitoh et al., 
1989; Demars et al., 2011; Freude et al., 2011; Ohsawa et al., 1999). The fact that 
sAPPα can specifically bind to particular types of cells suggests the presence of a 
receptor for APP that could mediate trophic effects (Hoffmann et al., 2000; 
Reinhard et al., 2013). A number of carbohydrates and proteins have been 
reported to interact with APP on the cell surface (Young-Pearse et al., 2008; 
Kounnas et al., 1995; Nikolaev et al., 2009; Gralle et al., 2009; Narindrasorasak et 
al., 1992; Williamson et al., 1996; Ninomiya et al., 1994; Small et al., 1994). 
However, the role of lipids in the binding of APP to cells has not been 
 157 
investigated in detail. Therefore, this study explored the interactions of APP with 
lipids to evaluate if APP-lipid interactions could contribute to APP binding to the 
cell surface. 
The experiments presented in this thesis showed that both APP-E1 and 
sAPPα were highly selective for binding to PIPs and did not bind to other major 
types of lipid. This selectivity is illustrated by the fact that sAPPα and APP-E1 
did not bind to PI, but did bind to PIPs, which only differ by the presence of one 
phosphate group. Interestingly, APP was not found to bind to GM1-ganglioside in 
this study, in contrast to a previous report (Zhang et al., 2009). Although the 
experiments did not find that APP bound to GM1 in the protein-lipid overlay 
assay, the data did suggest that the E1 region of APP was responsible for binding 
to PIPs, which was the same region suggested to be a lipid-binding region by 
Zhang et al. (2009).  
PIPs are quantitatively minor lipids in the cell, but are of great biological interest 
as PIPs are signalling lipids that are involved in many aspects of cellular function 
(Di Paolo and De Camilli, 2006; Section 1.6). For example, PIPs are involved in 
the regulation of endocytosis (Posor et al., 2013), exocytosis (Khuong et al., 
2013), Ca2+signalling (Lapetina and Michell, 1973), ion channel function 
(Gamper and Rohacs, 2012) and cytoskeletal function (Golub and Caroni, 2005). 
PIP signalling represents a sophisticated and evolutionarily conserved system in 
eukaryotes for controlling the interactions of proteins with membranes (discussed 
in Section 1.7). The levels of PIPs can be rapidly and precisely controlled in the 
cell by the action of phosphoinositide kinases and phosphatases (Di Paolo and De 
Camilli, 2006). Furthermore, PIP-binding domains are highly common in biology 
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and are present in many proteins (Lemmon, 2008; Michell, 2008). This means that 
PIPs target proteins to particular cellular locations, through interactions with 
specific lipid-binding domains (Lemmon, 2008). As PIPs are involved in many 
cellular functions, it is highly likely that the PIP-binding domain in APP identified 
in this study is involved in the biological function of APP. 
4.2.1 PIP-binding regions in APP 
The E1 domain of APP has been suggested to be an important functional region of 
APP as it has a growth factor-like structure and contains a heparin-binding region 
(D1) and a metal-binding region (D2; Small et al., 1994; Multhaup et al., 1996). 
Furthermore, previous studies have suggested that this region of APP could bind 
to gangliosides (Zhang et al., 2009). For these reasons, the ability of an APP-E1 
recombinant protein to bind to PIPs was examined in the protein-lipid overlay 
assay. These experiments found that APP-E1 bound to PIPs, suggesting that a 
PIP-binding domain in APP resides within the E1 domain.  
Based on the crystal structures of the APP E1 domain that are available, there are 
some candidate regions that could be involved in PIP binding by APP-E1. 
(Rossjohn et al., 1999; Dahms et al., 2010). The E1 heparin-binding region 
(residues 95 - 110) has a large positively charged surface that could interact with 
PIPs (Small et al., 1994). A positively charged surface of this type is typical of 
many PIP-binding domains, which in general bind to PIPs through electrostatic 
interactions (McLaughlin et al., 2002; McLaughlin and Murray, 2005; Lumb and 
Sansom, 2012; Lemmon, 2008). The computational modelling of APP-E1 IP3 
interactions predicted that APP could interact with PIP at the heparin-binding site 
in an energetically favorable manner, consistent with the suggestion that the 
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positively charged heparin-binding region could bind to PIP. However, in the lipid 
overlay assay, heparin did not block the binding of APP to PIP, which suggested 
that the PIP-binding region of APP-E1 might be distinct from the heparin-binding 
region. The computational modelling of the E1 domain also predicted other 
binding pockets that could contribute to PIP binding by APP, with the largest 
around the amino acids residues his151, lys155, gly90 and pro91. The presence of 
a separate PIP-binding pocket may explain why heparin did not block the binding 
of APP to PIP in the protein-lipid overlay assay.  
Although the computational docking models are theoretical, and are not yet 
supported by in vitro binding data, these models can give some indication of the 
affinity of PIPs for APP. The predicted ΔG values for the APP-E1 protein binding 
to IP3 were comparable to that obtained with the PH domain of spectrin binding to 
IP3. The spectrin PH domain binds to IP3 with a Kd of 40 µM, which suggests that 
the affinity of APP-E1 for IP3 may be in a similar range (Hyvonen et al., 1995). 
Importantly, these theoretical data suggest that the affinity of APP for PIP may be 
in a physiologically relevant range.  
To determine the direct mechanism of the interaction of APP-E1 with PIP, the 
computationally predicted binding model will need to be experimentally verified. 
The binding affinities of APP for IP3 could be determined by a direct method such 
as isothermal titration calorimetry (Lemmon et al., 1995). Precise binding sites for 
PIP on APP-E1 can be determined by a number of approaches. Some studies have 
experimentally identified PIP binding sites by X-Ray crystallography (Hyvonen et 
al., 1995). Alternatively, a mutagenesis study could be used to identify the PIP-
binding site, by producing recombinant APPs with the residues that are predicted 
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to be involved in binding to PIPs mutated (Kale et al., 2010). An advantage of this 
approach would be that once a non-PIP binding mutant APP is produced, the 
effect of removing interactions of APP with PIPs could be characterised in cells. 
For example, the effect of non-PIP binding APP expression on APP trafficking 
could be examined. 
Most PIP-binding domains do not bind to a particular PIP with absolute 
specificity, but will bind to a number of PIPs (Kavran et al., 1998). From the data 
in Fig. 3.1 and Fig. 3.3, it is not clear whether APP binds selectively to different 
PIP regioisomers. In the protein-lipid overlay assay, most sAPPα 
immunoreactivity was associated with PI(3)P, PI(4)P and PI(5)P, whereas APP-
E1 immunoreactivity was associated more uniformly with all PIPs (Fig 3.1 and 
3.3). Importantly, the proteins used in this study were not directly comparable, as 
the recombinant sAPPα had a N-terminal 6xHis affinity tag, whereas the 
recombinant APP-E1 had a C-terminal 6xHis affinity tag. Therefore, although it is 
possible that regions of sAPPα outside the E1 domain could modify the binding 
of the APP E1 domain to PIP, this possibility would have to be investigated using 
recombinant proteins expressed in the same expression system with identical 
affinity tags.  
4.2.2 Extracellular PIP is present on the surface of neurons and glia 
Most studies of the function of PIPs have considered roles for PIPs in the 
cytoplasmic leaflets of membranes. This has lead to the commonly held 
assumption that PIPs are only present intracellularly. The data presented in this 
study shows for the first time evidence for the presence of PIP on the outer 
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surface of cells of the central nervous system. Also, this study demonstrates that a 
number of PIP-binding proteins (the PI(4,5)P2 biosensor, PI(3,4,5)P3 biosensor 
and APP-E1) can bind to PIPs on the surface of hippocampal cells in culture. 
These results suggest that PIPs may target proteins to the cell surface, similar to 
the known roles of PIPs in the cytoplasmic leaflet of the plasma membrane (PM; 
Lemmon, 2008). Importantly, these data raise the possibility that many 
extracellular proteins could bind to PIP as a physiological mechanism of targeting 
to the cell surface. If this is the case, it is possible that many extracellular proteins 
may contain PIP-binding domains. 
The presence of PIPs on the surface of cells is perhaps not surprising, as 
phospholipids are known to “flip” from the outer leaflet to the cytoplasmic leaflet, 
and “flop” from the cytoplasmic leaflet to the outer leaflet (van Meer et al., 2008). 
In the PM, the concentration of particular lipids such as phosphatidylserine and 
phosphatidylethanolamine is enriched in the cytosolic leaflet (van Meer et al., 
2008; van Meer, 2011). The asymmetric distribution of lipids in the PM is 
maintained in an ATP-dependent manner by enzymes known as flippases (Daleke, 
2007). The asymmetrical distribution of lipids is a highly dynamic process and is 
known to be altered in processes such as apoptosis and platelet activation (van 
Meer, 2011; Fadok et al., 1992; Bevers et al., 1982).  
Although the majority of studies investigating the function of PIPs have only 
considered intracellular PIPs, a few studies have previously noted the existence of 
PIPs on the surface of cells. Studies of membrane asymmetry in erythrocytes have 
demonstrated that 20% of PI(4,5)P2 is present in the outer leaflet of the PM, but 
no PIP is present (Gascard et al., 1991). The first study to generate antibodies 
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against PIPs noted that anti-PIP antibodies were immunoreactive with the surface 
of live adherent macrophages (Fogler et al., 1987). Recently, some studies have 
demonstrated that some eukaryotic plant pathogens can use extracellular PI(3)P as 
a binding site to gain entry to plant and mammalian cells (Kale et al., 2010; Lu et 
al., 2013). Collectively these studies and the results in this thesis demonstrate that 
PIPs are present on the surface of cells.  
The data in this study suggested that PI(3,4,5)P3 is present on the surface of cells, 
however this was only detected in the presence of APP-E1. Therefore it is 
possible that the levels of cell surface PIPs can be altered. It is also not clear at 
present if PIPs can flip/flop from one leaflet to another. If PIPs could flip from 
one leaflet of the membrane to the other, it is possible that PIP lipid signalling 
could occur in a trans-membrane fashion. However, this prospect has not been 
investigated.  
Interestingly, the PI(4,5)P2 immunoreactivity and the PI(4,5)P2 biosensor data 
(Section 3.2.1) suggested that cell surface PIPs were present in punctate 
microdomains that were smaller than 1 µm in size. This is consistent with other 
studies that report that PIPs segregate into punctate PIP microdomains that are 
less than 1 µm in size in intracellular membranes (van den Bogaart et al., 2011; 
Wang and Richards, 2012). There has been some controversy surrounding 
whether PIP can form microdomains (McLaughlin et al., 2002; McLaughlin and 
Murray, 2005; van Rheenen et al., 2005). It is also not clear whether PIP 
microdomains are distinct from other type of membrane domains, such as lipid 
rafts (Lingwood and Simons, 2010). However, recent evidence suggests that on 
the cytoplasmic leaflet of cell membranes at least, PI(4,5)P2 is not uniformly 
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distributed and may be organised into discrete lateral domains (Golebiewska et 
al., 2008; Golebiewska et al., 2011). A potential mechanism to explain the 
formation of PIP domains is that anionic PIPs may cluster together with cationic 
proteins (van den Bogaart et al., 2011). Further, the clustering of PIPs with 
proteins has been suggested to be important for spatial regulation of processes 
such as synaptic vesicle release and endocytosis (Aoyagi et al., 2005; Khuong et 
al., 2013; Posor et al., 2013). Therefore, the observation in this study that cell-
surface PI(4,5)P2 was present in discrete puncta provides support to the theory 
that PIP can form microdomains, and these domains can spatially segregate 
proteins.  
The APP-E1 recombinant protein that bound to cells was highly localised to the 
PI(4,5)P2 microdomains (Fig 3.14). Previous studies exploring the ability of 
sAPPα to bind to raft fractions of cells have reported that sAPPα binds to cells 
and localises to detergent-resistant membrane fractions (Tikkanen et al., 2002). 
Although the sAPPα cofractionated with markers of caveolae in the detergent-
resistant membrane fractions, immunocytochemical detection of caveolar markers 
showed that sAPPα localised to a novel, non-caveolar type of domain (Tikkanen 
et al., 2002). The data presented in this thesis suggests a possible explanation for 
the observations by Tikkanen et al., (2002), which is that sAPPα localises to 
PI(4,5)P2 rich domains on the cell surface. 
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4.2.3 Mechanism of APP-E1 binding to the cell surface 
The data in this thesis show that APP-E1 can bind to PIP in vitro, and that APP-
E1 localises to PI(4,5)P2 domains on the surface of cells. However, the results did 
not support the hypothesis that PI(4,5)P2 is the only binding site for APP-E1, as 
PI(4,5)P2 was detected on glial cells which APP-E1 did not bind to. Also, the 
binding of APP to the surface of cells could not be reduced by competition with a 
water soluble PI(4,5)P2 analogue. This suggested that there might be another 
binding site for APP on the surface of cells, which has a higher affinity than the 
PIP-binding site. As the binding of PIPs to a protein is commonly a low-affinity 
interaction (Lemmon, 2008), PIPs rarely act alone in membrane targeting 
interactions, but rather act as co-receptors (Di Paolo and De Camilli, 2006; 
Lemmon, 2008; Carlton and Cullen, 2005). Typically, the combination of a PIP-
binding domain and another interaction domain in a protein results in a stronger 
affinity for a particular binding site (Carlton and Cullen, 2005). The data in this 
study suggest that the PIP-binding site could act in combination with another 
component, such as a glycosaminoglycan and/or a receptor.  
Heparin did not block the binding of APP-E1 to PI(4,5)P2 in vitro, which 
suggested that the PIP-binding site is distinct from the heparin-binding site. 
However, heparin was able to block the binding of APP-E1 to cells, which 
provided evidence that the heparin-binding site is involved in binding of APP-E1 
to the cell surface. Importantly, the data did not support the possibility that a 
heparan sulfate proteoglycan was a cell-surface receptor for APP, as heparitinase 
treatment did not affect the binding of APP to cells. This result is consistent with 
a number of other studies, which report that sAPPα binding to cells is 
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heparitinase-insensitive (Hoffmann et al., 1999), or only partially sensitive to 
heparitinase (Ninomiya et al., 1994), or occurs independently of 
glycosaminoglycan synthesis (Reinhard et al., 2013).  
A model to explain the results in this study is presented in Fig. 4.1. In the model, 
the APP E1 domain binds through the heparin-binding site to a high affinity 
receptor that is expressed on neurons. This receptor is present in cell surface 
PI(4,5)P2 microdomains, and APP-E1 interacts with this cell-surface PI(4,5)P2 
through its PIP-binding domain. The PIP-binding site may therefore facilitate 
binding of APP to the receptor by tethering APP to the membrane, or it may play 
another role (discussed in Section 4.2.6). 
Recently, a study was published which supports the conclusion that the APP E1 
domain may bind to a receptor (Reinhard et al., 2013). Reinhard et al. (2013) 
explored the binding of sAPPα, the APP E1 domain and the APP-E2 domain to 
cells. They reported that the E1 domain of APP binds to a high affinity cell-
surface receptor, but this receptor was not a heparan sulfate proteoglycan. 
Interestingly, the E1 domain of APP was necessary for binding to the cell surface, 
and the E2 domain positively modulated this interaction (Reinhard et al., 2013).  
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Figure 4.1. Hypothetical model of the binding of the APP E1 domain to 
the cell surface to explain the data in the study. In this model it is proposed 
that the heparin-binding site in the E1 domain interacts with a receptor 
(X) that is not a heparan sulfate proteoglycan. This receptor is expressed 
on neurons and is present in PI(4,5)P2 microdomains on the cell surface. 
APP also interacts with PI(4,5)P2 on the cell surface through the PIP bind-
ing site, which is distinct from the heparin-binding site. 
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Further, they reported two binding sites for the APP E1 domain on cells, a high-
affinity binding site (Kd = 10 - 80 nM) and a lower affinity-binding site (Kd > 5 
µM), which they suggested could be a lipid (Reinhard et al., 2013). Therefore, the 
low-affinity binding interaction of the APP E1 domain with cells reported by 
Reinhard et al. (2013) could be a result of the PIP-binding domain identified in 
this thesis.  
The data in this study demonstrated that the APP E1 domain is able to bind 
selectively to neuronal cells. Therefore, these data support the presence of a 
specific receptor for APP that is expressed on neurons. Importantly, the presence 
of such a receptor suggests that APP is involved in a cell-surface signalling 
interaction. Many growth factors are known to signal through specific receptors 
(Lemmon and Schlessinger, 2010). Notably, the structure of the APP extracellular 
domain has been likened to a growth factor (Rossjohn et al., 1999; Reinhard et al., 
2013). Many studies have also suggested that APP acts in a trophic capacity 
(Saitoh et al., 1989; Chasseigneaux et al., 2011; Pietrzik et al., 1998; Gakhar-
Koppole et al., 2008; Milward et al., 1992; Jin et al., 1994; Ninomiya et al., 1994; 
Wallace et al., 1997; Caille et al., 2004; Demars et al., 2011; Freude et al., 2011; 
Ohsawa et al., 1999). Therefore, it is likely that the interaction of APP E1 domain 
with the receptor could be involved in the regulation of cellular growth. 
However, the receptor for the APP E1 domain that is expressed on neurons 
remains to be identified. Previous studies have suggested a number of potential 
receptors for APP including β1-integrin, lipoprotein receptor related protein-1 
(LRP1), death receptor 6, p75 neurotrophin receptor and APP itself (Young-
Pearse et al., 2008; Kounnas et al., 1995; Nikolaev et al., 2009; Gralle et al., 
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2009). Of these suggested receptors, LRP1 was reported to bind preferentially to 
KPI-containing isoforms of APP, therefore it is unlikely that LRP1 represents the 
cellular receptor for APP-E1 observed in the experiments this thesis (Kounnas et 
al., 1995). The APP-E1 recombinant protein that was used in this thesis was also 
used by the study that reported that DR6 and p75 neurotrophin receptor were 
receptors for APP. Therefore it is possible that DR6 and p75 neurotrophin 
receptor could be candidate receptors for the binding of APP-E1 to cells observed 
in this study (Nikolaev et al., 2009). Further, APP and β-1 integrin are expressed 
on hippocampal neurons, so these too are possible candidate receptors (Shi and 
Ethell, 2006). The method of detecting cell-bound APP-E1 used in this study 
could easily be applied to compare the distribution of candidate receptors to 
investigate whether any of these receptors are responsible for APP-E1 binding to 
hippocampal neurons. Importantly, identifying the cellular receptor for secreted 
forms of APP will help explain how APP functions. Knowledge of this receptor 
will give understanding of the signalling pathways that are activated by APP, and 
also the types of cells in which APP functions.  
4.2.4  Effect of APP on levels of PIPs  
The results presented in Section 3.3.2 show that the binding of APP-E1 to cells 
increased the level of both PI(4,5)P2 and PI(3,4,5)P3 on the cell surface. This 
increase in PI(4,5)P2 and PI(3,4,5)P3 was localised to neurons but not to glia. As 
APP bound to the cell surface of neurons but not glia, this provides strong 
evidence that APP interacts with PIP on the cell surface of neurons. PIPs are key 
signalling lipids and many cellular signalling pathways such as the PI3K/Akt 
pathway and the Ca2+ pathway involve changes in the level of PIPs (Di Paolo and 
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De Camilli, 2006). Therefore, it is possible that the APP-E1-induced increase in 
the level of cell-surface PIP may influence a signal transduction pathway. 
However, it must be borne in mind that to date the role of cell-surface PIPs in cell 
signalling is unknown. 
In some cellular signalling pathways, such as the PI3K/Akt pathway, signalling is 
mediated through an increase in levels of PI(3,4,5)P3 (Andjelkovic et al., 1997). 
Therefore, the possibility that APP-E1 could activate the PI3K/Akt pathway was 
investigated by assessing the effect of APP-E1 on Akt phosphorylation in primary 
cortical cultures. This experiment did not find an effect of APP-E1 on Akt 
phosphorylation after two hours APP-E1 treatment. Although it is possible that 
APP-E1 could induce a very rapid transient activation of the PI3K pathway, 
which is not observed after two hours, the experimental conditions that were used 
were sufficient to observe an increase in Akt phosphorylation in the positive 
control treatment (insulin). Therefore, the results suggest that the observed 
increase in PIP immunoreactivity on the cell surface does not cause activation of 
the PI3K/Akt pathway by APP-E1.  
A more likely explanation for the increase in the level of cell surface PI(3,4,5)P3 
and the increase in the level of cell surface PI(4,5)P2 is that APP-E1 binding to 
cells sequesters PI(3,4,5)P3 and PI(4,5)P2 on the cell surface. There are reports 
that PI(4,5)P2 binding proteins can induce trans-bilayer redistribution of lipids 
across the membrane (Bucki et al., 2000). Further, PIP-binding proteins have been 
suggested to laterally cluster PIPs in lipid bilayers by binding to them (Gambhir et 
al., 2004; McLaughlin and Murray, 2005). So, it is possible that the presence of a 
PIP-binding protein (APP-E1) stabilises clusters of PIP to some extent, which 
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may explain the increased levels of cell-surface PI(4,5)P2 and PI(3,4,5)P3 that 
were observed in this study. 
A redistribution of PIPs at the cell surface could also occur independently of a 
change in the total level of PIPs. This would be consistent with data from the 
UPLC-measurement of total PIP levels in response to sAPPα treatment (Section 
3.3.1). The results of the UPLC-MS indicated that sAPPα did not affect levels of 
total PIPs. However, as the UPLC-MS approach was unable to measure changes 
in PI(3,4,5)P3, this method was not suitable for detecting the increase in cell-
surface PI(3,4,5)P3 observed using the antibody and biosensor. 
In summary, the observation that APP binding to cells affects the levels of cell-
surface PIP provides strong evidence that APP interacts with PIP on the cell 
surface. These data suggest that APP-E1 increases the level of PIPs on the cell 
surface, which could have a biological consequence. Further investigation is 
required to determine whether the observed effects of APP-E1 on cell surface PIP 
have a resultant effect on cellular physiology.  
4.2.5 Other possible roles for the PIP-binding domain in APP 
The biological role of the PIP-binding domain in APP is not yet clear. However, it 
is not known what roles PIPs play on the cell surface. Many studies of PIPs in an 
intracellular context suggest that PIPs are involved in the targeting of proteins to 
membranes (Lemmon, 2008; Balla, 2005). Therefore, it is quite likely that APP 
binding to PIP is involved in its targeting to the correct cellular location. A study 
has reported that some plant pathogens can use cell surface PIP to gain entry to 
cells (Kale et al., 2010). Therefore, it is possible that sAPPα binding to cell 
surface PIP could result in endocytosis of the sAPPα. The experiments in this 
thesis did not investigate whether sAPPα or APP-E1 was internalised after 
binding to the cell surface, however endocytosis of sAPPα has been previously 
reported to occur (Tikkanen, et al., 2002) 
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Importantly, there are also some studies that suggest PIPs may affect the biology 
of APP. Recently, APP trafficking has been demonstrated to be dependent on 
PI(3)P (Morel, et al., 2013). In addition, it has been known for some time that 
sAPPα and Aβ secretion are reduced by PI3K inhibition (Petanceska et al., 1999). 
Therefore, the E1-PIP-binding domain in APP could also play a role in the 
trafficking and processing of APP. APP could also potentially interact with PIP 
inside the cell, where there is a significant pool of APP (Yamazaki et al., 1996; 
Koo et al., 1996).  
4.2.6 Hypothetical suggestions for roles of the lipid-binding domain in APP 
This study identified a novel PIP-binding domain in the E1 region of APP. 
However, determining the biological role of this domain will require further 
investigation. The data in this study demonstrate that APP binding to PIP alone is 
not sufficient to explain the cell-surface binding of APP as there is at least one 
other binding site on the cell surface. However, APP is able to alter cell surface 
PIPs demonstrating that APP and PIP interact on the cell surface. Therefore, the 
results suggest that the APP PIP-binding domain could elicit another biological 
effect. 
Some speculative suggestions for role of the PIP-binding domain in APP function 
are provided in Fig. 4.2. In the first hypothetical model, PIP binding by APP aids 
the interaction of APP with its receptor by tethering APP to the membrane (Fig. 
4.2A). This kind of co-incidence detection is used by many PIP-binding proteins 
to increase the specificity of binding interactions to particular locations (Carlton 
and Cullen, 2005). The PIP-binding domain could therefore be involved in 
targeting sAPPα to regions of cells where the receptor is present. Alternatively, 
PIP binding could promote a conformational change in APP that allows 
interaction with the receptor (Jackson et al., 2010). Activation of this receptor 
might theoretically elicit a trophic effect of APP.  
Model A. PIP binding by APP aids the interaction of APP with its receptor
Model B. PIP binding by APP results in propagation of signalling
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Figure 4.2. Hypothetical models of biological roles for the APP E1 PIP-binding 
domain. Panel A: The PIP-binding domain may aid the binding of APP to its high-
affinity receptor (receptor X). Targeting APP to PIP microdomains could facilitate 
interactions with a higher affinity receptor present in these PIP domains. Panel B. The 
APP E1 PIP-binding domain may be involved in the propagation of a signalling event. 
In the hypothetical model, APP binding to its high-affinity receptor sequesters PIP on 
the cell surface. This could result in the recruitment of other PIP-binding proteins, 
resulting in signalling. Propagation of PIP signals could occur either laterally (Panel 
3a), or if PIP is able to “flip” from the extracellular leaflet into the intracellular leaflet, 
trans-bilayer signalling could occur (Panel 3b). 
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In the second hypothetical model, APP binds to its receptor, and sequesters cell- 
surface PIP (Fig. 4.2B). This could result in the recruitment of other PIP-binding 
proteins, resulting in signalling. This type of process could be involved in the 
mechanism of activation of the receptor and therefore elicit a trophic effect by 
APP. Importantly, propagation of PIP signals could occur either laterally, or if PIP 
is able to “flip” from the extracellular leaflet into the intracellular leaflet (van 
Meer, 2011), trans-bilayer signalling could occur. Hypothetically, outer leaflet to 
inner leaflet PIP signalling could have important biological implications, for 
example transmission of a signal to stimulate endocytosis, which is known to 
involve the assembly of a number of PIP-binding proteins on the cytosolic side of 
the membrane (Frere et al., 2012).  
Determining the function of the PIP-binding domain in APP will be challenging, 
as the exact function of APP is unclear at this point. However, investigation into 
the function of the PIP-binding domain may also shed light on aspects of the 
physiological roles of APP. To investigate some of the hypothetical models 
above, a possible experimental approach would be to produce cells or animals 
expressing mutant APP with a non-functional PIP-binding domain. This approach 
has been used to convincingly demonstrate that the APP intracellular domain 
controls the trafficking of APP (Perez et al., 1999). Once non-PIP binding APP 
mutants are produced, the effect of the mutations on a number of aspects of APP 
biology could be investigated. Trafficking, expression, processing and effects on 
cellular proliferation could be used as a starting point for further investigation. 
Additionally, if the PIP-binding domain has an unexpected function, this would be 
apparent in the mutant cells and could be characterised.  
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4.3 Final conclusions 
The experiments presented in this thesis demonstrate the existence of a novel PIP-
binding site in the E1 domain of APP. PIP lipids were found to be present on the 
surface of cells, and secreted forms of APP localise to these domains. This study 
increases our understanding of the way APP interacts with the surface of cells, by 
demonstrating APP interacts with PIPs on the cell surface. Also, this study 
increases our understanding of the normal composition of the surface of cells by 
demonstrating the presence of cell surface PIPs. Importantly, many extracellular 
proteins could potentially interact with cell-surface PIPs, which may have broad 
implications for many aspects of biology.  
These data support the possibility that APP could act in a signalling interaction, 
possibly by modulating levels of PIPs, which are lipids that are known to be 
involved in many cellular signalling pathways. The study also provides evidence 
that sAPPα is likely to function as a paracrine factor, and that the E1 domain is 
important in this process. This was demonstrated by the experiments that showed 
the isolated E1 domain could selectively bind to neurons. The PIP-binding 
domain may contribute to this process, but the data also implicate the presence of 
a specific high-affinity receptor for the APP E1 domain. This receptor is only 
expressed on neurons in primary murine hippocampal cultures, and is not likely to 
be a heparan sulfate glycosaminoglycan. Identifying this receptor will provide a 
significant advance for our understanding of how APP functions, by determining 
the direct actions of APP. Understanding of the normal function of APP will 
provide insight into the biochemical processes that are disrupted in AD, and also 
into the normal function of the brain.  
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Appendices 
Appendix I. Materials 
Material  Supplier 
30% Acrylamide/Bis Solution Bio Rad Laboratories Pty. Ltd, 
Gladesville, Australia 
37:4 PI (LM-1502) Avanti Polar Lipids Inc. Alabaster, USA. 
37:4 PI(3,4,5)P3 (LM-1906) Avanti Polar Lipids Inc. Alabaster, USA. 
37:4 PI(3,4)P2 (LM-1903) Avanti Polar Lipids Inc. Alabaster, USA. 
37:4 PI(4,5)P2 (LM-1904) Avanti Polar Lipids Inc. Alabaster, USA. 
37:4 PI(4)P (LM-1900) Avanti Polar Lipids Inc. Alabaster, USA. 
4-(2-Hydroxyethyl)piperazine-1- 
ethanesulfonic acid sodium salt (NA-
HEPES) 
Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI) 
Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
APP N-terminal domain recombinant protein 
corresponding to APP amino acids 18 – 286 
with an C-terminal 6xHis tag (APP-E1)  
ProSci Inc., Poway, USA 
sAPPα* recombinant protein (APP-695 
isoform residues 18-612) with a N-terminal 
6xHis tag 
Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Acetonitrile (Lichrosolv grade) Merck Australia Pty. Ltd, Kilsyth, 
Australia 
AlamarBlue® reagent Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
B27 supplement Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
Bio Rad DC protein assay kit Bio Rad Laboratories Pty. Ltd, 
Gladesville, Australia 
Calcium chloride Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Chloroform  Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
cOmplete ultra protease inhibitor tablets Roche Diagnostics Australia Pty. Ltd. 
Castle Hill, Australia 
Dako mounting medium Dako Australia Pty. Ltd. Campbellfield, 
Australia. 
Deoxyribonuclease-1 Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Dextrose Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
diC8PI(4,5)P2 Echelon Bioscience Inc., Salt Lake City, 
USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Disodium hydrogen phosphate Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Dulbecco’s modified Eagle’s medium 
(DMEM) 
Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
Ethylamine British Drug Houses Ltd., Poole, UK 
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Material  Supplier 
Fatty-acid free bovine serum albumin (BSA) Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Fetal bovine serum (FBS) Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
GlutaMAXTM Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
Glycerol Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Glycine Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Hanks Balanced salt solution (HBSS) Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
Human recombinant basic fibroblast growth 
factor (FGF2) 
Peprotech Inc., Rocky Hill, USA 
Human recombinant epidermal growth factor 
(EGF) 
Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Hybond C Extra nitrocellulose membrane GE Healthcare Pty. Ltd., Rydalmere, 
Australia 
Hydrochloric Acid (37%) Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Igepal CA-630 Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Immobilon chemiluminescent substrate Millipore Australia Pty. Ltd, Kilsyth, 
Australia 
Magnesium chloride  Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Membrane Lipid StripsTM Echelon Bioscience Inc., Salt Lake City, 
USA 
Methanol (HPLC grade) Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Neurobasal medium Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
Nitric Acid Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Non-fat dry milk powder Woolworths Ltd., Bella Vista, Australia. 
Papain Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Paraformaldehyde Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Penicillin/streptomycin Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
PhosStop phosphatase inhibitor tablets Roche Diagnostics Australia Pty. Ltd. 
Castle Hill, Australia 
PI(3,4,5)P3 Biosensor (recombinant GST-
tagged pleckstrin homology domain of 
general receptor for phosphoinositides-1)* 
Echelon Bioscience Inc., Salt Lake City, 
USA 
PI(3)P biosensor (recombinant GST-tagged 
PX domain of p40phox)* 
Echelon Bioscience Inc., Salt Lake City, 
USA 
PI(4,5)P2 biosensor (recombinant GST 
tagged pleckstrin homology domain of 
phospholipase C-δ1)* 
Echelon Bioscience Inc., Salt Lake City, 
USA 
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Material  Supplier 
PI(4)P biosensor (recombinant GST-tagged 
SidC_3C domain)* 
Echelon Bioscience Inc., Salt Lake City, 
USA 
PIP StripsTM 
 
Echelon Bioscience Inc., Salt Lake City, 
USA 
Poly-L-Lysine Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Polyvinylidene fluoride membrane (PVDF) Bio Rad Laboratories Pty. Ltd, 
Gladesville, Australia 
Porcine mucosal heparin Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Sodium chloride Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Sodium deoxycholate Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Sodium phosphate monobasic dihydrate Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
SphingoStripsTM Echelon Bioscience Inc., Salt Lake City, 
USA 
Tris Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Triton X-100 Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Trypan Blue Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
TrypLETM Life Technologies Australia Pty. Ltd., 
Mulgrave, Australia. 
Tween-20 Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
Wortmannin DMSO solution Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
β-Mercaptoethanol Sigma-Aldrich Pty. Ltd., Castle Hill, 
Australia 
* During the course of the study, it was observed that these recombinant proteins are 
unstable, and will loose the ability to bind to PIP over time. For best results, aliquots 
should be flash frozen in liquid nitrogen, stored at -80°C, and only thawed once.  
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Appendix II. Cell culture media, buffers and solutions 
Cell culture media 
Neurobasal plating 
medium 
Neurobasal medium supplemented with 10% v/v FBS, 2 % v/v 
B27 supplement, 1 mM GlutaMAXTM, 100 U mL-1 penicillin and 
100 µg mL-1 streptomycin 
Neurobasal 
maintenance 
medium 
Neurobasal medium supplemented with 2 % v/v B27 
supplement, 1 mM GlutamaxTM, 100 U mL-1 penicillin and 100 
µg mL-1 streptomycin. 
Neurosphere 
proliferation 
medium 
DMEM supplemented with 2% B27, 100 U mL-1 penicillin, 100 
U mL-1 streptomycin, 20 ng mL-1 human FGF2 and human EGF 
20 ng mL-1 
Buffers and solutions 
Phosphate buffered 
saline (PBS) 
154 mM NaCl, 8 mM NaH2PO4, 2 mM Na2HPO4, pH 7.3  
Imaging buffer 125 mM NaCl, 5 mM KCL, 10 mM dextrose, 1 mM MgCl2, 2 
mM CaCl2, 10 mM Na-HEPES, 2% B27 supplement, pH 7.5.  
Tris-buffered saline 
with tween (TBS-
T; protein-lipid 
overlay assay)  
150 mM NaCl, 50 mM Tris-base, pH 7.5, 0.1% Tween-20. 
TBS-T (western 
blotting) 
150 mM NaCl, 25 mM Tris-base, pH 8, 0.2% Tween-20 
SDS-PAGE 
running buffer 
25 mM Tris, 192 mM Glycine, 0.1% SDS 
Laemmli sample 
buffer 
10% β-mercaptoethanol, 2% SDS, 50 mM Tris pH 6.8, 10% 
glycerol 
Cell lysis buffer 150 mM NaCl, 50 mM Tris, 0.5% w/v sodium-deoxycholate, 1% 
v/v Igepal-CA630, 0.1% SDS, pH 7.4 
 
Electroblotting 
buffer 
25 mM Tris, 192 mM Glycine, 20% v/v Ethanol 
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Appendix III. Primary antibodies used in the study 
Antigen 
[clone] 
Type Species Applicati
on 
Dilution Supplier (Catalogue No.) 
6xHis Polyclonal 
(ChIP Grade) 
Rabbit ICC 
PLO 
1:1000 
1:3000 
Abcam Ltd., Cambridge, UK. 
(ab9108) 
APP (a.a.66-
81) 
[22C11] 
Monoclonal 
IgG 
Mouse PLO 1:1000 Millipore Australia Pty. Ltd, 
Kilsyth, Australia. (MAB348) 
APP/Aβ 
(a.a.1-16 of 
Aβ) 
[6E10] 
Monoclonal 
IgG1 
Mouse PLO 
WB 
1:1000 
1:2000 
Covance Pty. Ltd., North 
Ryde, Australia. 
(SIG-39300) 
GAPDH Polyclonal Rabbit WB 1:20,000 Millipore Australia Pty. Ltd, 
Kilsyth, Australia. 
(ABS16) 
GFAP Polyclonal Rabbit ICC 1:1000 Millipore Australia Pty. Ltd, 
Kilsyth, Australia. (AB5804) 
GST 
[GST-R 6G9] 
Monoclonal 
IgG 
Rat ICC 1:500 Sigma-Aldrich Pty. Ltd., 
Castle Hill, Australia. 
(SAB4200055) 
Heparan 
Sulfate [F58-
10E4] epitope 
Monoclonal 
IgM 
Mouse ICC 1:250 Seikagaku Corporation 
Tokyo, Japan. 
(370255) 
MAP2 Polyclonal Rabbit ICC 1:1000 Millipore Australia Pty. Ltd, 
Kilsyth Australia. (AB5622) 
PanAkt 
[C67E7] 
Monoclonal 
IgG 
Rabbit WB 1:1000 
 
Cell Signalling Technology 
Inc. Boston, USA (4691) 
PhosphoAkt-
Ser473 
[D9E] 
Monoclonal 
IgG 
Rabbit WB 1:1000 Cell Signalling Technology 
Inc. Boston, USA (4060) 
PI(3,4,5)P3 Monoclonal 
IgM 
Mouse ICC 1:500 Echelon Bioscience Inc., Salt 
Lake City, USA. (Z-P345) 
PI(3,5)P2 Monoclonal 
IgM 
Mouse ICC 1:500 Echelon Bioscience Inc., Salt 
Lake City, USA. (Z-P035) 
PI(3)P Monoclonal 
IgM 
Mouse ICC 1:500 Echelon Bioscience Inc., Salt 
Lake City, USA. (Z-P003) 
PI(4,5)P2 Monoclonal 
IgM 
Mouse ICC 1:500 Echelon Bioscience Inc., Salt 
Lake City, USA. (Z-P045) 
PI(4)P Monoclonal 
IgM 
Mouse ICC 1:500 Echelon Bioscience Inc., Salt 
Lake City, USA. (Z-P004) 
Abbreviations: PLO – protein-lipid overlay assay, ICC – immunocytochemistry, WB – western blot, 
a.a. – amino acids. Monoclonal antibody clones are indicated in square brackets. Antibody dilutions 
refer to 1 mg mL-1 stocks 
 
  
 236 
Appendix IV. Secondary antibodies used in the study 
 
Antibody Conjugate Application Dilution Supplier (Catalogue No.) 
Goat anti-
mouse IgG 
Alexa-594 ICC 1:1000 Life Technologies Australia 
Pty. Ltd., Mulgrave, 
Australia. (A-11037) 
Goat anti-
mouse IgG 
Alexa-488 ICC 1:1000 Life Technologies Australia 
Pty. Ltd., Mulgrave, 
Australia. (A-11029) 
Goat anti-
mouse IgM 
Alexa-594 ICC 1:1000 Life Technologies Australia 
Pty. Ltd., Mulgrave, 
Australia. (A-21044) 
Goat anti-
rat IgG 
Alexa-594 ICC 1:1000 Life Technologies Australia 
Pty. Ltd., Mulgrave, 
Australia. (A-11007) 
Goat anti 
rabbit IgG 
Alexa-488 ICC 1:1000 Life Technologies Australia 
Pty. Ltd., Mulgrave, 
Australia.(A-11034) 
Goat anti 
rabbit 
HRP PLO 
WB 
1:1000 Dako Australia Pty. Ltd., 
Campbellfield, Australia. 
(P044801-2) 
Goat anti-
mouse 
HRP PLO 
WB 
1:5000 
1:5000 
Dako Australia Pty. Ltd., 
Campbellfield, Australia. 
(P044701-2) 
Abbreviations: HRP - Horse-radish peroxidase. PLO – protein-lipid overlay assay, 
ICC – immunocytochemistry, WB – western blot, Ig – Immunoglobulin, Antibody 
dilutions refer to 1 mg mL-1 stocks. 
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